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The continuing emergence of multidrug-resistant bacteria and the slowing down of the 
discovery and development of novel antibiotics have made antimicrobial resistance an 
ominous threat to human health. As reflected in the World Health Organization’s priority 
pathogens list, this problem is notably more severe in multidrug-resistant Gram-negative 
bacteria. This situation needs to be rectified through alternative approaches, such as the 
revival of 'old' antibiotics and the development of combination therapies.  
This thesis focuses on the combination of the 'old' antibiotics, nitrofurans and vancomycin 
(VAN) with the secondary bile salt sodium deoxycholate (DOC). The synergistic 
interaction of these antibacterials was demonstrated in the in vitro growth inhibition and 
killing of Gram-negative bacteria, including the clinically relevant pathogens such as 
carbapenemase-producing Escherichia coli, Klebsiella pneumoniae, and Acinetobacter 
baumannii. The synergy increased the efficacy and reduced the doses of each of the 
components compared to monotherapy use, with the advantage of mitigating nitrofuran 
mutagenicity.  
Using a transcriptomics approach, underlying mechanisms of the individual and 
combined action of nitrofurans, VAN, and DOC in E. coli were elucidated. The nitrofuran 
antibiotic, furazolidone (FZ), and DOC elicited highly similar gene perturbations 
indicative of iron starvation response, decreased respiration and metabolism, and 
translational stress. VAN, on the other hand, induced extracytoplasmic stress response in 
agreement with its known role in peptidoglycan synthesis inhibition. Through genetic and 
biochemical approaches, Fur (ferric uptake regulator) protein inactivation was confirmed 
 ii 
to be important in the synergy of FZ and DOC and to contribute to the synergy of the 
triple combination. Similarly, the SOS response to DNA damage was shown to be 
essential for the synergy between FZ and VAN and to also contribute to the synergy of 
the triple combination. Taken together, the findings of this thesis strongly suggest the 
presence of multiple interaction points, that leads to the triple synergy, and support the 
proposed mechanism of synergy where the combined effects lead to the amplification of 
damaging effects and suppression of resistance mechanisms. 
Overall, this thesis shows the synergistic triple combination of nitrofurans, DOC, and 
VAN as a promising therapy for Gram-negative infections. Furthermore, this work 
significantly increases the understanding of drug interaction mechanisms that lead to 
synergy, which is hoped to help advance this combination further into the development 
pipeline. Transcriptomics analyses and the follow-up experiments provide key 
fundamental insights into the physiological impact that these three antimicrobials have 
on enterobacterium E. coli and highlight the advantage of combined targets in bacterial 
killing. These findings, in turn, will help design novel antibiotics, mono- or combined 
therapies, against multidrug-resistant bacteria.  
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1.1 Antimicrobial resistance 
Throughout most of human history, what we now know as bacterial infections were 
usually treated with herbal medicines, potions, or extracts. These were often not enough; 
therefore, even uncomplicated bacterial infections often led to death. Since the 
introduction of the first commercially available antibiotic in the 1930s, these drugs have 
significantly improved life and are now an integral part of modern medicine. 
The discovery of penicillin in 1928 heralded the start of the golden age of antibiotics 
(Fleming, 1929). During this time, most of the antibiotics that we know today were 
developed and introduced to the market (Gould, 2016). However, with the decline of new 
antibiotics under development in recent years and the continuing emergence of 
antimicrobial-resistant bacteria, we are at risk of running out of antibiotics. The world is 
facing an antibiotic crisis, where bacterial infections are again a threat. 
Antimicrobial resistance is a phenomenon where bacteria develop mechanisms to resist 
the effects of an antibiotic that was previously effective against them (Munita et al., 2016; 
Peterson et al., 2018). Bacteria can develop mutations or acquire resistance genes through 
horizontal gene transfer, through mechanisms such as antibiotics modification or 
degradation (Wright, 2005), alteration of antibiotic targets (Schaenzer et al., 2020), 
increasing export through efflux pumps (Poole, 2007), and decreasing antibiotic entry by 
decreasing expression of porins (Fernández et al., 2012). The first cases of antimicrobial 
resistance were observed shortly after the introduction of every new antibiotic. For 
example, penicillin was first used to treat Staphylococcus aureus bacteraemia in 1940, 
and a hospital reported its first case of penicillin-resistant S. aureus in 1942 
(Rammelkamp et al., 1942). Back in the 1940s to the 1960s, resistance development was 
not a concern as the discovery of new antibiotics kept pace with the emergence of 
CHAPTER 1 Introduction 
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resistance. However, as we now know today, resistance occurs naturally over time and is 
inevitable; the misuse and overuse of antibiotics and its widespread use in food production 
has dramatically accelerated this process (Ayukekbong et al., 2017; Ma et al., 2021; 
Kirchhelle, 2018). 
The World Health Organization (WHO) has identified the misuse and overuse of 
antibiotics in humans and animals as the main drivers of antimicrobial resistance. The 
Centers for Disease Control and Prevention (CDC) reported that of the 154 million 
antibiotic prescriptions in outpatient settings in the United States from 2010 through 
2011, at least 30% were unnecessary (Fleming-Dutra et al., 2016). The majority of these 
unnecessary antibiotic prescriptions were for upper respiratory tract infections caused by 
viruses. Additionally, prescription of wrong antibiotics, such as the use of excessively 
broad-spectrum instead of narrow-spectrum drugs and prescribing before tests confirm a 
bacterial infection, are the biggest contributors to this problem. Likewise, patients are also 
to blame, with the pressure they put on physicians to prescribe antibiotics and not 
finishing an antibiotic course (Cole, 2014; Fletcher-Lartey et al., 2016; Strumiło et al., 
2016). In some developing countries, antibiotics are even readily accessible from 
pharmacies without a prescription, which makes it easy to self-medicate (Auta et al., 
2019; Ocan et al., 2015). 
Another area that contributes to antimicrobial resistance is the use of antibiotics in food-
producing animals (Landers et al., 2012). Antibiotics are used not just in treating diseases 
but also as prophylactics, feed additives, and growth promoters. Meat production 
accounts for an estimated 73% of the global use of antibiotics (Van Boeckel et al., 2019). 
After years of widespread use in food-producing animals, guidelines and regulations are 
just now being introduced to combat antimicrobial resistance in this area. In 2017, the 
United States introduced new guidelines that made the use of antibiotics for non-
CHAPTER 1 Introduction 
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therapeutic purposes in food-producing animals illegal. As a result, antibiotic use in 
livestock has decreased by 33% (US Food & Drug Administration, 2017). 
Similarly, efforts to combat antimicrobial resistance in the European Union saw more 
than 32% decrease in the overall sales of veterinary antimicrobials between 2011 and 
2017 (European Medicines Agency, 2019). However, a survey found that only 42% of 
countries have limited the use of antibiotics critical for treating humans on animal 
production (World Health Organization et al., 2018). Global trends predict that by 2030, 
the global consumption of all antimicrobials in food animals will increase by 
approximately 50%  (Van Boeckel et al., 2017). 
Today, multidrug-resistant bacteria and superbugs that are resistant to last resort 
antibiotics are continuously emerging. Last resort antibiotics are usually reserved for 
infections where all other common antibiotic options have failed. For instance, 
carbapenem-resistant Enterobacteriaceae are on the "urgent threat list" by the CDC since 
this group of pathogens frequently exhibit resistance to most or all antibiotics (Centers 
for Disease Control and Prevention, 2019). Although these instances are still extreme 
cases, it is predicted to become common unless new antibiotic therapies are discovered. 
An independent review in 2014 estimated that, without appropriate actions, antimicrobial-
resistant infections, which already cause 700,000 deaths each year, could grow to 10 
million deaths coupled with a loss of 100 trillion USD of economic output by 2050 
(O’Neill, 2014). 
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1.2 Antimicrobial resistance in Gram-negative bacteria 
Multidrug-resistant Gram-negative pathogens are an urgent issue in tackling 
antimicrobial resistance. The threat from Gram-negative bacteria is more severe 
compared to that of Gram-positive bacteria due to an additional protective layer, called 
an outer membrane (Breijyeh et al., 2020). This membrane acts as an additional barrier 
inhibiting the entry of both hydrophilic and hydrophobic toxic molecules (Figure 1).  
 
 
Figure 1. The cell wall structure of bacteria  
A) The cell wall of  Gram-negative bacteria is composed of an inner cell membrane and an outer membrane 
with a peptidoglycan layer in-between. B) The cell wall of Gram-positive bacteria does not have an outer 
membrane but has more layers of peptidoglycan compared to Gram-negative bacteria. Created with 
BioRender.com. 
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The outer membrane is an asymmetric lipid bilayer into which transmembrane proteins 
such as porins are embedded. This asymmetric lipid bilayer is composed of an outer 
leaflet primarily made up of lipopolysaccharides (LPS) and an inner leaflet composed of 
phospholipids (Nikaido, 2003). The composition of the outer membrane plays a 
significant role in its selective permeability. Firstly, anionic parts of the LPS allow 
neighbouring LPS molecule to form intermolecular ionic interactions via divalent cations 
(Nikaido, 2003; Nascimento et al., 2014). These cross-bridging interactions result in a 
tight seal and a rigid structure that prevents the entry of molecules and slows down the 
passive diffusion of amphiphilic and hydrophobic molecules (Plésiat et al., 1992). 
Second, the LPS contains saturated fatty acid chains which make the outer membrane 
much less fluid compared to a typical phospholipid bilayer and prevents entry of 
hydrophilic molecules. Instead, hydrophilic molecules must gain access to the cell 
through β-barrel protein channels called porins. These channels are grouped, based on 
selectivity, into specific and "general diffusion" porins and strictly limit the size of 
molecules that can enter the cell (~ 600 Da cut-off) (Vergalli et al., 2020). For example, 
in Escherichia coli, the most abundant outer membrane proteins are the non-specific 
porins OmpC and OmpF, which act as an entryway for small hydrophilic molecules (Choi 
et al., 2019a). Lastly, Gram-negative pathogens express a range of efflux pumps that 
recognise and transport noxious compounds, such as antibiotics and detergents, out of the 
cell (Venter et al., 2015). These properties of the outer membrane are the reasons for 
Gram-negative bacteria's intrinsic resistance to a wide range of antibiotics, including the 
large hydrophilic antibiotic vancomycin (VAN) and bile salts. 
Gram-negative bacteria are common causes of hospitalisations and community-acquired 
infections. ESKAPE pathogens which include four Gram-negative bacteria, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter 
CHAPTER 1 Introduction 
7 
spp., cause most healthcare-associated infections and commonly exhibit multidrug 
resistance. They cause a broad range of diseases which include gastrointestinal illnesses, 
urinary tract infections (UTI), and bloodstream infections. In 2017, WHO released a list 
of priority pathogens, classified into critical, high, and medium priority, that urgently 
need research and development of new antibiotics (World Health Organization, 2017). 
The majority of these pathogens are Gram-negative bacteria including three pathogens 
deemed critical, carbapenem-resistant A. baumannii, P. aeruginosa, and 
Enterobacteriaceae. Carbapenem antibiotics are usually the last line of treatment for 
these multidrug-resistant bacteria, and in the case of carbapenem-resistance, the highly 
toxic polypeptide antibiotic colistin has been reserved as a last resort. However, the 
emergence of colistin resistance genes is now increasingly being reported globally, 
including countries like the US (McGann et al., 2016) and China (Chen et al., 2018; Liu 
et al., 2016). This trend leads to the inability to treat infections, and further demonstrates 
the need for novel antibacterial strategies, especially for Gram-negative pathogens.
CHAPTER 1 Introduction 
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1.3 Strategies to combat antimicrobial resistance 
1.3.1 Novel antibiotics and revival of 'old' antibiotics 
A novel class of antibiotic is defined as having a unique core chemical structure, not a 
derivative of a previous class, and has not been previously used as an antibacterial. The 
golden age of antibiotics saw more than 20 novel classes of antibiotics introduced to the 
market (Coates et al., 2011). Since then, most new antibiotics are analogues or variations 
of these classes, and so are also inhibited by existing resistance mechanisms. In the years 
2000 to 2019, only five first-in-class new drugs were introduced to the market; none of 
which target Gram-negative bacteria (Butler et al., 2017; The Pew Charitable Trusts, 
2019). In the five years from 2014 to 2019, the US Food and Drug Administration (FDA) 
approved only 13 drugs that have antibacterial indications. Of these, none belong to a 
novel class of antibiotics, and none are indicated for WHO critical pathogens. The UK 
Prime Minister-commissioned report on antimicrobial resistance recommends 15 new 
antibiotics, including four that have a truly novel mechanism of action, every decade to 
keep up with the emergence of resistance and meet medical needs (O’Neill, 2015). 
However, as of December 2019, data by The Pew Charitable Trusts lists only 41 
antibiotics under development, and if this is to follow historical trends, only 14% will be 
successful (World Health Organization, 2019a).  
As multidrug resistance continues to emerge, it is apparent that finding novel antibiotics 
is getting harder and that the current clinical pipeline is insufficient to tackle the problem, 
especially for WHO priority pathogens and Gram-negative bacteria (World Health 
Organization, 2019a). This issue is made worse by most pharmaceutical companies 
abandoning the field due to low success rates and unprofitable antibiotic market, with 
many reduced to bankruptcy even after successfully marketing a new antibiotic (Mullard, 
CHAPTER 1 Introduction 
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2019). To fill the gap, scientists are turning to alternatives such as the revival of 'old' 
antibiotics.  
'Old' antibiotics are agents that were developed decades ago and were currently 
abandoned or less favoured due to a variety of reasons, such as toxicity and discovery of 
better alternatives. For example, the 'old' antibiotics, fosfomycin and nitrofurantoin (NIT) 
are again being used to treat uncomplicated UTI due to low prevalence of resistance 
compared to fluoroquinolones and cephalosporins, which suffer from widespread 
resistance (Kranz et al., 2017; Cassir et al., 2014).  
 
1.3.2 Synergistic antibiotic combinations 
Drug synergy is defined as drug combinations having enhanced effects than the simple 
additive effects expected from each drug individually. The increased efficacy imparted 
by the synergy allows the reduction of the effective doses of each drug, which can result 
in the mitigation of off-target toxicities (Tallarida, 2011).  
There are different approaches currently used to assess drug combination synergy. These 
approaches include effect-based strategies, which compare the effects of a drug 
combination directly to their individual effects, and dose-effect based strategies, which 
compare doses of the drug individually and in the combination that give an equivalent 
effect (Foucquier et al., 2015). Examples of effect-based strategies are response 
additivity, highest single agent, and the Bliss Independence model.  
In the response additivity model (Figure 2A), a combination of drugs A and B is 
considered synergistic when the combined effect is greater than the sum of the individual 
effects of A and B. In the highest single-agent approach (Figure 2B), the effect of the 
combination is compared to the individual drug that caused the greatest effect. The 
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combination is synergistic if its effect is higher than the highest single agent, and 
antagonistic otherwise. Lastly, Bliss Independence assumes that drugs that act 
independently follow the law of probability (Bliss, 1939). Therefore, in a combination, 
the effects of individual drug components are independent yet competing events. The 
expected combination effect can be calculated by the equation (EA + EB) – (EA × EB), 
where EA and EB are the effects of drug A and B expressed as a probability (0-1). For 
example, drug A causes 50% inhibition and drug B causes 20% inhibition on their own. 
If the two drugs are additive, then their combined effect will be (0.5 + 0.2) – (0.5 × 0.2) 
= 0.6. Based on this model (Figure 2C), a combination is synergistic if the actual 
combination effect is higher, and antagonistic otherwise.  
 
 
Figure 2. Drug synergy models based on effect-based approaches  
A) Response additivity - the combination is synergistic when the effect of the combination is higher than 
the sum of its individual effects. B) Highest single agent - the combination is synergistic when the combined 
effect is higher than the single agent that caused the biggest effect. C) Bliss independence - the combination 
is synergistic if its effect is higher than the expected additive effect calculated by the equation (EA+EB)-
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Another approach to analysing drug interactions is the dose-effect approach, such as the 
Loewe additivity theory. Loewe additivity assumes that a drug does not interact with itself 
(Loewe, 1953). Therefore, assuming drugs A and B are the same and do not interact, the 
combined effect of 0.5 × minimum inhibitory concentration (MIC) of drug A and 0.5 × 
MIC of drug B is equivalent to the effect of 1 × MIC of either drug A or drug B (Yeh et 
al., 2009). A standard metric used to define drug interactions is the fractional inhibitory 
concentration index (FICI), which uses Loewe additivity as the basis of non-interaction. 
FICI is calculated as follows:  
 












where MICA(com) is the minimum inhibitory concentration (MIC) of drug A when used in 
combination and MICA(alone) is the MIC of drug A when used alone.  
Using this approach, FICI = 1 means no interaction (based on Loewe additivity), FICI < 
1 means synergy, and FICI > 1 means antagonism. However, to avoid misinterpreting 
FICI data that are only slightly above or below the theoretical cutoff of 1, a more 
conservative interpretation is commonly used in drug combination studies. Synergism is 
usually defined as FICI  0.5, indifference as 0.5 < FICI ≤ 4, and antagonism as FICI > 4 
(Odds, 2003). 
FICI determination for drug combinations is commonly determined using a checkerboard 
inhibition assay. For a two-drug combination, a checkerboard assay is typically 
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performed in a multiwell plate with two-fold dilution gradients of the two drugs, as shown 
in Figure 3A. As for a three-drug combination, a three-dimensional checkerboard assay 
is performed, which uses multiple multiwell plates to have three drug gradients, as shown 
in Figure 3C. A graphical illustration, called an isobologram, can complement the FICI 
calculations, where each data point along the line represent the concentrations that give 
the chosen effect (Tallarida, 2011). A combination is considered synergistic when the 
data points are below the additivity line (for a two-drug combination) or additivity plane 
(for a three-drug combination), and antagonistic otherwise (Figure 3B and Figure 3D) 
(Huang et al., 2019).  
The use of synergistic antibiotic combinations is a promising alternative to combat 
antimicrobial resistance. An example is the broad-spectrum antibiotic combination 
trimetophrim-sulfamethoxazole. Trimetophrim and sulfamethoxazole, also known as co-
trimoxazole, target sequential steps in the tetrahydrofolate biosynthesis pathway and 
potentiates each other’s effects leading to synergy (Minato et al., 2018). Advantages of 
using such combinations include enhanced efficacy, improved clearance of pathogens, 
deceleration of resistance development, and reduction of toxicities compared to use of 
each drug individually (Bollenbach, 2015; Yeh et al., 2009). Using new antibiotics in 
synergistic combinations can prolong their life as the enhanced therapeutic effect can 
slow down resistance development (Moellering, 1983). Repurposing of currently 
available antibiotics into combinations is also a less costly and faster way of bringing new 
therapies into clinical use if they are already approved for human use and can speed up 
the development process (Chong et al., 2007). For these reasons, reviving 'old' or 
currently available antibiotics through their use as synergistic combinations is a 
promising source of new antimicrobial therapies. 
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Figure 3. Checkerboard assay and isobologram of drug interactions based on the 
Loewe additivity model  
A, B) Two-drug combinations; C, D) Three-drug combinations. Each data point of the isobologram 
represents the concentrations presented as FIC that give a chosen quantitative effect (e.g. 90% inhibition). 
The combination is synergistic if the data points are below the additivity line or plane connecting FIC 1 on 
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1.4 Nitrofurans 
Nitrofurans are a group of synthetic compounds with a nitrofuran moiety, a nitro group 
attached at the furan C5 position (Figure 4). This 'old' class of broad-spectrum antibiotics 
were clinically introduced in the 1940s to 1950s. They possess antibacterial and some 
antiprotozoal properties, and are currently used as human and veterinary drugs (Vass et 
al., 2008). Furazolidone (FZ) is used to treat enteritis and diarrhoea caused by bacterial 
and protozoal infections, nitrofurantoin (NIT) is used to treat UTI, and nitrofurazone 
(NFZ) is used as a topical agent for burns and wounds. In addition to these commercially 
available nitrofurans, CM4 is a nitrofuran that was identified in a small molecule drug 
screen to possess antibacterial properties (Spagnuolo, J., Jobsis, C. & Rakonjac, J., 
unpublished). 
 
Figure 4. Chemical structures of nitrofurans 
The nitrofuran class of antibiotics have a nitro group attached at the furan C5 position.  
 
The use of nitrofurans had been controversial. Before their prohibition for use in food-
producing animals, nitrofurans were widely used as a feed additive and veterinary 
antibiotic. However, findings of nitrofuran residues in food were concerning as they are 
stable and do not degrade upon standard food preparations (Cooper et al., 2007). Also, 
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nitrofurans are mutagenic, and it is considered that consumption of nitrofuran-
contaminated food presents a health risk since the drug residues can accumulate in tissues 
over time (McCracken et al., 2007; Barbosa et al., 2011). Studies on mice provided 
evidence of nitrofuran intake-related carcinogenicity and toxicity, with symptoms such 
as increased incidence of tumours and seizures (Kari et al., 1989). For these reasons, the 
use of nitrofurans in food-producing animals, except for some topical uses, was banned 
by the FDA in 1991. In 2002, however, the FDA tightened the rules and prohibited the 
use of all nitrofurans in food-producing animals since topical applications also led to 
residues in edible tissues. Currently, many countries, including the European Union, 
Australia, and Japan, prohibit the use of nitrofurans in food production (Vass et al., 2008). 
The exact mechanism of nitrofurans' mutagenicity in mammalian cells is not fully 
understood. It is proposed that the metabolism of nitrofurans leads to unstable active 
metabolites that could interact with DNA (McCalla et al., 1975). The same hypothesis 
has been proposed as the mechanism of nitrofuran cytotoxicity in bacteria. Upon 
activation by bacterial enzymes, active metabolites derived from nitrofurans were 
hypothesised to form adducts with DNA (Wentzell et al., 1980), cause frameshift 
mutations (Obaseiki-Ebor et al., 1986), and interact with proteins and ribosomal RNA 
(rRNA) (McOsker et al., 1994; Yu et al., 1976). NFZ, for example, was shown to directly 
and reversibly inhibit DNA synthesis (Ona et al., 2009) and NIT was reported to cause 
complete inhibition of protein synthesis (McOsker et al., 1994). However, the active 
metabolites that are responsible for these activities remain unknown. 
Despite their controversial history, the nitrofurans are still used today in human 
infections, in part due to their low prevalence of resistance. For example, NIT was 
approved by the FDA in 1953 for the treatment of UTI. Despite decades of use, resistance 
remains relatively rare. In a study conducted in six European countries, out of 775 E. coli 
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isolates collected from female patients with uncomplicated UTI, only 1.2% were resistant 
to NIT (Ny et al., 2019). More importantly, NIT remains effective for some UTIs caused 
by multidrug-resistant Enterobacteriaceae, such as extended-spectrum β-lactamase 
(ESBL)-producing strains (Raja, 2019). Similarly, for FZ, which is used as a component 
of combination therapy for Helicobacter pylori infections, epidemiological data shows 
low prevalence of resistance in Helicobacter isolates (Zamani et al., 2017; Kwon et al., 
2001; Choi et al., 2019b). 
 
 
Figure 5. Type I (oxygen-insensitive) two-electron reduction of nitrofuran 
Type I nitroreductase performs two-electron step-wise reduction to nitroso then a hydroxylamine 
derivative.  
 
Just like many nitroheterocyclic compounds, nitrofurans are prodrugs and must undergo 
activation by specific enzymes. In E. coli, the nitroreductases NfsA and NfsB are known 
to be the primary activation catalysts (Whiteway et al., 1998). Because of this, it is not 
surprising that the main resistance mechanisms are mutations in nfsA and nfsB genes 
(Sandegren et al., 2008; Shanmugam et al., 2016; Whiteway et al., 1998; Mottaghizadeh 
et al., 2019). These enzymes are type I oxygen-insensitive nitroreductases that are 
proposed to catalyse the two-electron reduction of nitrofurans (Figure 5). It has been 
shown that the main product of the aerobic reduction of NIT and NFZ by purified NfsB 
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is a hydroxylamine derivative (Race et al., 2005). The reaction proceeds via two 
consecutive two-electron reductions; the second reduction step happens at a much faster 
rate, which explains why the nitroso intermediate was not observed. In another study, 
NFZ reduction by oxygen-insensitive nitroreductases only detected an open-chain nitrile, 
which was hypothesised to form through rearrangement of the hydroxylamine derivative 
followed by ring-opening (Figure 5) (Peterson et al., 1979). 
Similarly, nifurtimox, an antiprotozoal nitrofuran drug used to treat Chagas disease and 
trypanosomiasis, is also activated by trypanosomal type I oxygen-insensitive 
nitroreductase. This reaction gives a cytotoxic unsaturated open-chain nitrile as the major 
product and a stable saturated open-chain nitrile as a minor product (Bot et al., 2013; Hall 
et al., 2011).  
 
 
Figure 6. Type II (oxygen-sensitive) one-electron reduction of nitrofuran 
Type II nitroreductase performs one-electron reduction to a nitro anion radical, which under aerobic 
conditions, undergoes futile cycling and regenerates back to nitrofuran. 
 
Another type of nitroreductase in E. coli is type II oxygen-sensitive nitroreductase, which 
performs one-electron reduction (Figure 6). Besides NfsA and NfsB, other enzymes 
probably play a role in activating nitrofurans in E. coli since a double knockout of nfsA 
and nfsB genes does not confer full resistance to nitrofurans. In 1979, the presence of 
oxygen-sensitive nitroreductase was reported in E. coli, but the enzyme responsible was 
not identified. This reduction involves a nitro anion free radical, which in the presence of 
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oxygen, oxidises back to a nitrofuran with the concomitant generation of superoxide 
(Peterson et al., 1979). Recent studies by Le et al. (2019) involving nfsA nfsB double-
knockout E. coli mutants selected for increased FZ resistance indicated that a loss of 
function mutation of the gene ahpF leads to increased resistance to FZ. Subsequent 
biochemical studies then demonstrated AhpF to be another nitrofuran-activating enzyme 
with characteristic properties of type II oxygen-sensitive nitroreductase. 
1.5 Sodium deoxycholate 
Bile salts are essential components in lipid digestion, intestinal homeostasis, and 
antimicrobial protection (Begley et al., 2005; Urdaneta et al., 2017). They are produced 
in the liver, stored in the gall bladder, secreted into the small intestines, and recycled via 
the enterohepatic circulation.  
Figure 7 shows a summary of bile salt synthesis and metabolism. Firstly, the primary bile 
salts, cholate and chenodeoxycholate, are produced in the liver from cholesterol. These 
primary bile salts can exist in a conjugated form with glycine or taurine in the liver and 
gall bladder. After food ingestion, the primary bile salts and the conjugated bile salts are 
released into the intestines. Intestinal bacteria then transform these bile salts into 
secondary bile salts by dehydroxylation and deconjugation. Bile salts are facial 
amphiphilic, such that they contain both hydrophilic and hydrophobic faces, and can act 
as an emulsifier and a solubiliser. They are essential in facilitating cholesterol catabolism 
and promoting digestion and absorption of lipids and lipid-soluble nutrients. Bile salts are 
efficiently reabsorbed from the intestinal lumen and recycled back to the liver, and the 
cycle is repeated. In this process, ~95% of the total bile salt pool is recirculated via the 
enterohepatic system, while the rest is excreted in the faeces (Chiang, 2013).  
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Figure 7. Bile salt biosynthesis and metabolism by intestinal bacteria 
Primary bile salts are synthesised from cholesterol and conjugated with taurine and glycine in the liver. In 
the intestines, bacteria transform primary bile salts to secondary bile salts. Majority of bile salts are 
reabsorbed and recycled through the enterohepatic circulation. 
 
Besides their roles in absorption and digestion, bile salts also function as signalling 
molecules that regulate various cellular and molecular processes (Hylemon et al., 2009; 
Beuers, 1997), such as endocrine signalling (Houten et al., 2006), and glucose 
metabolism (Nguyen et al., 2008). Human bile salts also play an essential role in 
maintaining gut microbiota and protection against enteric pathogens. Abnormal bile salt 
patterns, such as reduced bile salt secretion in animals and humans with cirrhosis, usually 
lead to bacterial overgrowth (Fan et al., 2009; Rosenberg et al., 1967; Lorenzo-Zuniga et 
al., 2003; Gunnarsdottir et al., 2003).  
The mechanism of bile salts' antimicrobial activity is not fully understood. They are active 
against S. aureus (Sannasiddappa et al., 2017) and H. pylori (Itoh et al., 1999), with 
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sodium deoxycholate (DOC) being the most potent bile salt. A study also showed that 
more hydrophobic bile salts, such as DOC, are more potent inhibitors of E. coli and 
Enterococcus faecalis growth than hydrophilic bile salts (Sung et al., 1993).  
Being amphiphilic, DOC has detergent properties, which was hypothesised to be 
responsible for its membrane-damaging effects (Begley et al., 2005), including disruption 
of membrane integrity, cell leakage, and proton motive force (PMF) dissipation 
(Sannasiddappa et al., 2017; Kurdi et al., 2006). Besides these effects, it was also 
proposed that the bile salts DOC and sodium cholate can cause protein aggregation 
(Cremers et al., 2014), and induce reactive oxygen species (ROS) production and DNA 
strand breaks (Negretti et al., 2017; Merritt et al., 2009).  
Gram-negative bacteria use several mechanisms to increase tolerance and resistance to 
DOC. Primarily, this intrinsic resistance is attributed to the presence of multiple efflux 
pumps that restrict intracellular DOC accumulation (Gunn, 2000; Lin et al., 2003; Venter 
et al., 2015; Thanassi et al., 1997). Bacteria also tolerate bile salts through other 
mechanisms such as activation of DNA repair, oxidative stress response, and RpoS 
general stress response pathways (Hernández et al., 2012; Prieto et al., 2006; Urdaneta et 
al., 2019).  
DOC is commonly used as a biological detergent, as a component of microbiological 
culture media, and recently as FDA-approved injectable drug to dissolve submental fat 
(Liu et al., 2019). In the context of drug development, DOC can be used as a modifier of 
drugs as it can enhance solubility and absorption of both hydrophilic and hydrophobic 
drugs via chemical conjugation, and formation of micelles and bile salt-stabilised lipid 
bilayer vesicles, called bilosomes (Pavlović et al., 2018; Sun et al., 2010; Stojančević et 
al., 2013; Bowe et al., 1997). For example, bile salts, including DOC, can integrate into 
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lipid bilayers and alter membrane permeability by forming aqueous pores/channels, in 
which hydrophilic molecules can pass (Gordon et al., 1985). 
DOC, on its own, is not a very promising antibacterial agent against Gram-negative 
bacteria due to their intrinsic resistance to this bile salt. However, its natural presence in 
the gut could be advantageous for treating gastrointestinal illnesses. Another approach 
will be to use DOC in a combination that has a synergistic effect, where DOC's efficacy 
against Gram-negative bacteria can be enhanced. 
1.6 Vancomycin 
Vancomycin (VAN) is a glycopeptide antibiotic used to treat most Gram-positive 
infections. It is active against methicillin-resistant S. aureus (MRSA), Clostridioides 
difficile, and Enterococcus spp. VAN is a natural product initially isolated from the soil 
bacterium Amycolatopsis orientalis and was first introduced to the market in 1954. 
Shortly after its introduction, it was overshadowed by other antibiotics, particularly 
methicillin and first-generation cephalosporins that are more efficacious and less toxic 
(Levine, 2006). Widespread use of VAN began in the 1980s as an oral treatment for 
enterocolitis caused by C. difficile (Fekety et al., 1993). It is currently included in the 
WHO list of essential medicines for adults and children as a second-choice treatment for 
C. difficile (World Health Organization, 2019b).  
VAN kills Gram-positive bacteria by inhibiting cell wall biosynthesis (Hammes et al., 
1974). During peptidoglycan synthesis, precursor Lipid II is synthesised inside the cell. 
Lipid II is a disaccharide pentapeptide unit composed of N-acetylglucosamine (GlcNAc) 
and N-acetylmuramic acid (MurNAc), and a pentapeptide containing a terminal D-Ala-
D-Ala chain. Lipid II precursors are translocated across the membrane to the sites of cell 
wall synthesis, where they are incorporated into the growing peptidoglycan through 
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transglycosylation and transpeptidation (Figure 8). During transglycosylation, a Lipid II 
unit is inserted into the growing peptidoglycan chain by the formation of glycosidic 
bonds. This process is followed by transpeptidation, where immature peptidoglycans 
crosslink via the formation of a peptide bond between two Lipid II pentapeptides. 
 
 
Figure 8. Vancomycin inhibition of peptidoglycan synthesis 
VAN binding to D-Ala-D-Ala prevents the crosslinking that occurs during the transpeptidation step of 
peptidoglycan synthesis. Created with BioRender.com based on Figure 1 and review  by Typas et al. (2012). 
 
Outside the cell, VAN binds to the terminal D-Ala-D-Ala (Figure 8), thereby blocking the 
crosslinking between peptidoglycan intermediates that happens during transpeptidation 
(Liu et al., 1994; Nieto et al., 1971; Barna et al., 1984). Additionally, the increased steric 
hindrance around the peptidoglycan precursors indirectly inhibits transglycosylation. The 
result is a weakened cell wall, which leads to cytolysis and cell death. Gram-negative 
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bacteria are naturally resistant to the effects of VAN due to the large size of the drug 
(~1450 Da), which renders it excluded from porins, and due to impenetrability of the 
outer membrane to hydrophilic molecules, unable to reach its target.  
VAN forms a hydrogen-bonded complex with terminal D-Ala-D-Ala. Gram-positive 
bacteria such as Enterococcus develop resistance to VAN by altering D-Ala-D-Ala, for 
instance, to D-Ala-D-Lac or D-Ala-D-Ser, which result in a loss of a hydrogen bond with 
VAN or steric-hindrance-mediated loss of affinity, respectively (Bugg et al., 1991; 
Lebreton et al., 2011; Meziane-Cherif et al., 2012). 
One of the significant adverse effects of VAN is nephrotoxicity. The exact mechanism of 
this toxicity is not fully understood. However, it was proposed that increased ROS and 
oxidative stress are the main culprits (Öktem et al., 2005). There are various risk factors 
associated with VAN-induced nephrotoxicity (Filippone et al., 2017). Some examples are 
high doses, prolonged treatment, history of renal health problems, and concurrent use of 
interacting agents or other nephrotoxic agents (Rybak et al., 1990). In addition, due to its 
poor oral bioavailability, VAN must be administered intravenously. Because of the 
adverse effects and complications with its intravenous administration (Roszell et al., 
2010), VAN is only used as a last line treatment, or for infections where β-lactams cannot 
be used such as in case of allergies or β-lactam resistance (Solensky, 2014; Solensky et 
al., 2000). 
Currently, there are five clinically used glycopeptide antibiotics. VAN was first in its 
class, followed by the natural product teicoplanin, and the semisynthetic drugs telavancin, 
oritavancin, and dalbavancin. Glycopeptides other than VAN all contain lipophilic 
substituents and therefore, have been termed lipoglycopeptides (Zhanel et al., 2010). 
Having lipophilic side-chains and other modifications render these drugs with better 
antimicrobial properties and safety profiles compared to VAN (Crotty et al., 2016). 
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1.7 Synergy between nitrofurans, DOC, and VAN 
1.7.1 Nitrofurans and DOC 
Studies in the Rakonjac laboratory have found synergy between some nitrofurans and 
DOC. Synergy has been observed on Citrobacter gillenii, E. coli O157: H7, and 
Salmonella sv. Typhimurium LT2 (Jobsis, C. & Rakonjac, J., unpublished). Specifically, 
the synergy between FZ and DOC has been demonstrated and characterised in 
enterobacteria (Le et al., 2020). The mechanism of this synergy has not been fully 
elucidated; however, FZ-mediated inhibition of efflux pumps was reported to play a role. 
It was proposed that inhibition of TolC-associated efflux pumps allows DOC to 
accumulate inside the cells and exert its effect together with FZ.  
1.7.2 Nitrofurans and VAN 
Gram-negative bacteria are inherently resistant to VAN. However, in combination with 
nitrofurans, VAN can exert its effect by interacting synergistically. Synergy has been 
observed between NIT and VAN (Zhou et al., 2015) and FZ and VAN (Weerasinghe, 
2017) against E. coli. This synergy suggests that small amounts of VAN can enter Gram-
negative bacteria, which on its own have a negligible effect, but together with nitrofuran 
can impart a synergistic inhibitory effect (Zhou et al., 2015). The mechanism of this 
synergy is currently unknown.
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1.8 The aerobic electron transport chain of E. coli 
The aerobic electron transport chain (ETC) of E. coli couples successive transport of 
electrons from donors to acceptors with the electrogenic translocation of protons from the 
cytoplasm to the periplasmic space (Figure 9). The resulting electrochemical proton 
gradient and electrical potential across the inner membrane is called the proton motive 
force (PMF) (Mitchell, 1961), which can be utilised by energy-requiring processes, such 
as ATP synthesis and antibiotic efflux.  
 
 
Figure 9. The electron transport chain of E. coli 
The electron transport chain consists of membrane-bound proteins that pairs electron transport with the 
electrogenic translocation of proton to the periplasm. The resulting proton gradient and electrical potential 
across the membrane is called the proton motive force which drives ATP synthesis and other processes. 
Created with BioRender.com based on review by Unden et al. (1997). 
 
The E. coli ETC consists of enzymes and complexes localised in the inner membrane: 
dehydrogenases and oxidoreductases that are linked by quinones, as shown in Figure 9. 
The two primary dehydrogenases Nuo (NADH dehydrogenase I), and Ndh (NADH 
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dehydrogenase II) oxidise the electron donor NADH by reducing membrane-associated 
quinones to quinols. The terminal quinol oxidases, cytochromes bo3 (Cyo), bd-I (Cyd), 
and bd-II (App), then re-oxidise the quinol by reducing oxygen to water. These 
dehydrogenases and oxidoreductases have overlapping functions, and their expressions 
are adjusted in response to environmental conditions, such as oxygen availability (Poole 
et al., 2000). For example, the presence of oxygen induces the expression of quinol 
oxidases and represses terminal oxidoreductases of anaerobic ETCs. Cytochrome bd-I, 
which has a high affinity for oxygen, is highly expressed in microaerobic conditions, 
whereas cytochrome bo3, which has a lower affinity, is synthesised maximally in oxygen-
rich conditions (Cotter et al., 1990; Tseng et al., 1996).  
Among these dehydrogenases and oxidoreductases, Nuo and cytochrome bo3 are proton 
pumping, while Ndh is non-proton pumping and does not generate PMF. In contrast, the 
non-proton pumping cytochrome bd-I and bd-II can generate PMF by transmembrane 
charge separation, where oxidation of quinol and reduction of oxygen happens on 
opposite sides of the membrane (Puustinen et al., 1991; Miller et al., 1985).  
1.9 E. coli stress responses to antibiotics 
1.9.1 Oxidative stress response 
E. coli frequently encounter ROS endogenously as a consequence of aerobic metabolism. 
ROS such as superoxide (O2– ) and hydrogen peroxide (H2O2) are inevitable byproducts 
of the reaction of oxygen with univalent electron donors, including flavins, quinones, and 
metal centres involved in the ETC (Messner et al., 1999; González-Flecha et al., 1995). 
These ROS can damage DNA, iron-sulfur (Fe-S) clusters, and protein residues, and can 
lead to cell death (Flint et al., 1993; Jang et al., 2007; Imlay, 2003; Imlay et al., 1988). E. 
coli, therefore, have evolved to have oxidative stress sensing and response mechanisms 
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to increase their survival under aerobic conditions. Basal levels of superoxide dismutases 
and catalases detoxify low amounts of superoxide (2O2- + 2H+  H2O2 + O2) and 
hydrogen peroxide (2H2O2  2H2O + O2) produced by normal metabolic processes. 
However, in the presence of exogenous ROS and agents that increase ROS production 
such as redox-cycling drugs, the basal scavenging enzymes are insufficient, and the 
transcription factors OxyR and SoxRS must tightly regulate the oxidative stress response 
(Farr et al., 1991). 
 
 
Figure 10. Thiol-disulfide switch transcriptional regulation by OxyR 
In the presence of H2O2, the "sensing" cysteine residue of OxyR is oxidised and forms a disulfide bond with 
a neighbouring cysteine. The conformational change results in DNA binding and interaction with RNA 
polymerase that allows induction of the target gene. Oxidised OxyR is reduced by the grxA/gor system, 
with the reduced OxyR able to function as a repressor. Reused with permission from American Society for 
Microbiology Journals: American Society for Microbiology, Journal of Bacteriology. Peroxide-Sensing 
Transcriptional Regulators in Bacteria (Figure 1), (Dubbs et al., 2012), copyright 2012. 
 
OxyR is the primary regulator for H2O2 response (Storz et al., 1992). In the presence of 
H2O2, OxyR's "sensing" cysteine residue is oxidised to a sulfenic acid that rapidly forms 
a disulfide bond with another cysteine (Figure 10). This disulfide bond could also arise 
in a pro-oxidising shift in thiol-disulfide redox status inside the cell (Aslund et al., 1999). 
In both cases, the thiol-disulfide switch of OxyR results in a conformational change in 
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the tetrameric OxyR that alters DNA binding and interaction with RNA polymerase (Choi 
et al., 2001; Zheng et al., 1998; Lee et al., 2004). OxyR can function as a transcriptional 
repressor or activator in its reduced and oxidised states. Oxidised OxyR, as an activator, 
contacts four adjacent major grooves on the DNA, while reduced OxyR, as a repressor, 
contacts two major grooves (Toledano et al., 1994). 
OxyR regulates the transcription of approximately 40 genes with functions that are 
essential for H2O2 detoxification, maintaining the thiol-disulfide redox status, and DNA 
protection from oxidative damage (Seo et al., 2015). Some of these genes are ahpCF 
(alkyl hydroperoxide oxidoreductase), katG (hydroperoxidase I), dps (non-specific DNA-
binding protein), trxABC (thioredoxins), grxAB (glutaredoxins) and sufABCDSE (Fe-S 
cluster assembly system). 
SoxRS is another major regulator of the oxidative stress response, specifically towards 
superoxide (Greenberg et al., 1990; Li et al., 1994). SoxR and SoxS constitute a two-
stage regulatory system, where the activation of SoxR induces the transcription of soxS, 
which in turn regulates the transcription of genes involved in superoxide stress response 
(Figure 11A) (Li et al., 1994). SoxR is a homodimeric transcription factor which is 
activated via the oxidation of its [2Fe-2S] clusters (Gaudu et al., 1997; Ding et al., 1996). 
The mechanism of activation of SoxR is not fully understood. Whether superoxide itself 
oxidises and activates SoxR is debated since redox-cycling drugs can induce SoxR-
regulated genes even in the absence of superoxide during anaerobic conditions (Privalle 
et al., 1988; Gu et al., 2011). However, redox-cycling drugs alone cannot fully account 
for SoxR activation, since SoxRS regulon members can be activated in superoxide 
dismutase mutants in the absence of redox-cycling drugs (Liochev et al., 1999). The 
SoxRS regulon includes sodA, encoding superoxide dismutase for superoxide 
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detoxification, acrAB, encoding a multidrug efflux pumps, and yggX for protection of Fe-
S proteins against oxidative damage (Pomposiello et al., 2003).  
 
 
Figure 11. Transcription activation of SoxS-MarA-Rob regulon 
A) Two-stage regulation of SoxRS regulon. SoxR activation induces transcription of soxS. SoxS in turn, 
induces transcription of its regulon members. B) MarR binds to two sites in the promoter region and inhibits 
transcription of its operon. Under inducing conditions, such as the presence of phenolic compounds, MarR 
is deactivated, and the promoter region is freed, allowing mar operon transcription. C) The DNA binding 
protein Rob is constitutively expressed in E. coli and present in a non-binding sequestered form under 
normal conditions. Presence of an inducing signal, such as bile salts, activates Rob, which can then bind 
DNA and influence transcription of its regulon members. Created with BioRender.com. Adapted from 
Figure 1 by Duval et al. (2013) under CC BY-SA 4.0. 
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1.9.2 SoxS-MarA-Rob regulon 
SoxS, MarA, and Rob are global regulators responsible for adaptive mechanisms for 
different stress stimuli, such as antibiotics, oxidative, and chemical stresses (Duval et al., 
2013). They are homologous transcription factors of the AraC family of proteins that have 
overlapping regulons. As discussed before, SoxS is a regulator of genes involved in 
oxidative stress, and oxidised SoxR activates its transcription.  
The mar (multiple antibiotic resistance) operon consists of marRAB. The transcriptional 
regulation by MarA is shown in Figure 11B. MarR represses the transcription of its 
operon by binding to two specific sites, sites I and II, within the operator/promoter regions 
in marO (Martin et al., 1995). In the presence of certain compounds such as phenolic 
chemicals (Cohen et al., 1993), MarR is deactivated, allowing MarA to activate the 
transcription by binding to a 20-bp region (marbox) in the promoter of the operon (Martin 
et al., 1996).  
Unlike MarA and SoxS, which are synthesised in the presence of stimuli,  Rob is a DNA-
binding protein that is constitutively expressed in the cell (Skarstad et al., 1993). Rob is 
regulated post-translationally through a "sequestration-dispersal" mechanism shown in 
Figure 11C (Griffith et al., 2009). In the absence of a stimulus, Rob is unable to bind the 
promoter of its regulated genes. This inactive form was proposed to be due to the C-
terminal domain-mediated sequestration of Rob that blocks the N-terminal domain 
required for Rob-DNA binding (Kwon et al., 2000). In the presence of an inducer, Rob 
becomes dispersed which exposes the N-terminal domain and allowing DNA binding. 
Unconjugated bile salts, decanoate (Rosenberg et al., 2003), and dipyridyl (Rosner et al., 
2002) are some of the compounds that can induce Rob activation. 
Although different mechanisms regulate SoxS, MarA, and Rob, they are also known to 
regulate each other's transcription. SoxS, MarA, and Rob can activate the mar operon 
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(Miller et al., 1994; Chubiz et al., 2012), and MarA and SoxS can repress Rob (McMurry 
et al., 2010; Michán et al., 2002). Activation of the SoxS-MarA-Rob regulon influences 
the transcription of genes involved in multiple resistance mechanisms, which include 
preventing the accumulation of antibiotics by increasing expression of efflux pumps 
(acrAB) and decreasing outer membrane permeability by decreasing expression of porins 
(ompF)  (Chubiz et al., 2011; Duval et al., 2013). 
 
1.9.3 SOS response 
DNA damage in E. coli activates the SOS response pathways that are regulated by the 
action of LexA repressor. Under normal conditions, LexA binds to a 16-bp sequence, 
called the SOS box, usually located near or inside the RNA polymerase binding site in 
the promoter region of its target genes (Zhang et al., 2010). The binding of LexA to the 
SOS box, therefore, represses the transcription of its regulon members (Figure 12) (Erill 
et al., 2003).  
The primary inducing signal for SOS response is the accumulation of single-stranded 
DNA (ssDNA) (Salles et al., 1984). Sensing of this signal is provided by protein RecA, 
which binds ssDNA and forms a nucleoprotein filament that promotes the autoproteolytic 
cleavage of LexA (Menetski et al., 1985; Craig et al., 1981; Little, 1984). This event 
lowers the levels of LexA and derepresses the transcription of genes involved in the SOS 
response. Besides regulating recA and its own transcription, LexA also regulates more 
than 50 genes involved in DNA repair, DNA damage tolerance, and induction of delayed 
cell division (Fernández de Henestrosa et al., 2000; Lewis et al., 1994; Walker, 1984). 
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Figure 12. SOS response induction 
LexA is the transcriptional repressor of SOS genes. When ssDNA accumulates due to DNA damage, RecA 
binds ssDNA and forms a nucleoprotein filament that stimulates LexA self-cleavage, which consequently 
derepresses transcription of SOS genes. Created with BioRender.com based on Figure 1 and review by 
Maslowska et al. (2019). 
 
The SOS response allows for high fidelity DNA repair to take place first before low 
fidelity DNA tolerance pathways that have mutagenic potential. The first sets of genes to 
be induced are the nucleotide excision and homologous recombination genes (uvrABCD, 
recA,  ruvAB) to repair the lesions (Moolenaar et al., 2000). However, for lesions that are 
not easily repaired, activation of the mutagenic DNA damage tolerance pathways, such 
as translesion synthesis performed by the polymerases PolIII (polB), polIV (dinB), and 
PolV (umuCD), are essential to bypass the DNA damage and advance the replication fork. 
During SOS induction, sulA gene is also induced, which causes DNA damage checkpoint 
by inhibiting cell division and allow time for DNA repair (Trusca et al., 1998).
CHAPTER 1 Introduction 
33 
1.9.4 Iron starvation response 
Iron is an essential element in many biological processes, including cellular respiration, 
and energy metabolism. It is also a component of heme and Fe-S clusters, which are 
indispensable cofactors of enzymes with fundamental functions in these processes. 
However, despite the vital roles of iron in cells, it can also be toxic due to its ability to 
catalyse ROS production under aerobic conditions (Touati, 2000). Therefore, to achieve 
iron homeostasis, E. coli must balance the uptake of iron from its environment and 
manage the levels of cellular iron. In E. coli, the transcription factor Fur is the principal 
regulator of iron homeostasis (Troxell et al., 2013).  
Fur (Ferric Uptake Regulator) is a DNA-binding protein which uses ferrous ion (Fe2+) as 
a corepressor and functions as a transcriptional repressor of genes in its regulon (Figure 
13A). At high Fe2+ concentrations, Fur and Fe2+ form a homodimer that binds to 19-bp 
DNA sequences (Fur boxes) usually located in the promoter of its regulated genes, thus 
repressing their transcription (Bagg et al., 1987; Baichoo et al., 2002). In contrast, at low 
Fe2+ concentrations, the Fur-Fe2+ complex does not form, clearing the promoter region of 
the regulated genes, and allowing their transcription (Figure 13A). In addition to its role 
as a repressor, Fur's role as a direct and indirect activator has also been demonstrated in 
E. coli and other bacteria (Nandal et al., 2010; Troxell et al., 2013).  
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Figure 13. Iron-dependent transcriptional regulation by Fur 
A) Fur regulates the transcription of its regulon by acting as a repressor with iron as its corepressor. In iron 
replete conditions, Fur-Fe binds to the furbox in the promoter region and prevents the transcription of the 
gene, while in iron limiting condition, Fur is inactive and does not bind the furbox. B) Fur can also act as 
an anti-repressor by preventing binding of another repressor. An example is the iron storage gene ftnA, 
which is repressed by H-NS. Binding of Fur-Fe to the promoter region of ftnA prevents repression by H-
NS. C) RyhB sRNA, whose transcription is regulated by Fur, mediates post-transcriptional regulation of 
iron-utilising genes. During iron limiting conditions, ryhB transcription is induced. RyhB sRNA then pairs 
with its target mRNA and thereby prevents translation and facilitates degradation. Created with 
BioRender.com. Adapted from  Figure 2 by Troxell et al. (2013) under CC BY 3.0. 
 
During iron starvation, Fur-regulated genes are derepressed to activate pathways for iron 
import. Fe2+ are directly imported, while the insoluble ferric ion (Fe3+) are imported as 
ferri-siderophore complexes. Another response to iron starvation is the down-regulation 
of genes relating to iron storage and non-essential iron-containing proteins (Seo et al., 
2014; McHugh et al., 2003). ftnA, an iron storage gene, is downregulated during iron 
CHAPTER 1 Introduction 
35 
limiting conditions with Fur acting as an anti-repressor by displacing the ftnA repressor, 
H-NS (Figure 13B) (Nandal et al., 2010). Similarly, Fur can indirectly regulate the 
expression of iron-utilising proteins through small RNA (sRNA) RyhB (Figure 13C). 
RyhB, which is expressed under iron limiting conditions, pairs with its target mRNA with 
the help of chaperone Hfq, resulting in transcription termination of the growing mRNA 
or block of the translation (Massé et al., 2002). In addition, RyhB recruits RNAse E, 
which then degrades the target mRNA (Massé et al., 2003). All of these mechanisms 
result in reduced RyhB target mRNA and gene product. The RyhB-dependent mechanism 
was found to regulate at least 56 genes in E. coli including fumA (fumarate hydratase), 
sodB (Fe-containing superoxide dismutase), sdh (succinate dehydrogenase), isc (Fe-S 
cluster synthesis), nuo (NADH dehydrogenase), frd (fumarate reductase), and acnA 
(aconitase A) (Desnoyers et al., 2009; Massé et al., 2002; Massé et al., 2005). 
Iron homeostasis pathways and oxidative stress response are interconnected. Iron 
starvation could be a product of a highly oxidative environment, and an oxidative 
environment could be a result of the iron starvation response (Cornelis et al., 2011). 
Increased iron assimilation as a result of iron homeostasis perturbations could lead to 
increased iron levels that can enhance the Fenton reaction (Fe2++ H2O2 → 
Fe3+ + HO• + OH-) and lead to the production of ROS, such as the highly DNA-
damaging hydroxyl radical (Imlay et al., 1988). Similarly, increased ROS can result in 
iron limitation by oxidising Fe2+ to Fe3+ again via the Fenton reaction (Nunoshiba et al., 
1999). Therefore, the oxidative response and iron starvation response pathways are highly 
connected as evidenced by Fur regulation of the oxidative stress response genes soxRS 
(superoxide response) and sodA (Mn-containing superoxide dismutase) (Niederhoffer et 
al., 1990).  
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1.9.5 Extracytoplasmic stress response 
Comprising of the inner membrane, periplasmic space, and the outer membrane, the E. 
coli envelope is the interface between the intracellular and extracellular environment. It 
functions as a barrier against noxious chemicals and is also the site of essential processes 
such as respiration, nutrient transport, efflux, and adhesion (Silhavy et al., 2010). Being 
the first barrier to the external environment, it is usually the first target of external stresses 
and must be able to tolerate changing conditions. E. coli have at least five 
extracytoplasmic stress response pathways that quickly sense a disruption in envelope 
homeostasis and repair any associated damage: Cpx, Bae, Rcs, Psp, and σE (Mitchell et 
al., 2019). These response pathways have independent and overlapping induction signals 
and regulon members. 
Cpx and Bae are classical two-component regulatory systems that rely on an inner 
membrane sensor (CpxA and BaeS) and a response regulator (CpxR and BaeR) (Raivio 
et al., 1997; Raffa et al., 2002). In the presence of a specific signal, the sensor histidine 
kinase autophosphorylates and transfers a phosphoryl group to the receiver domain of the 
response regulator (Figure 14AB). The response regulator becomes active and can bind 
DNA and regulate the expression of its regulon. One of the best-charactersised roles of 
the Cpx response is in sensing and responding to stress due to misfolded envelope 
proteins, with at least 50 regulon members, some encoding chaperones and proteases 
involved in protein folding and degradation (Pogliano et al., 1997; Price et al., 2009). 
Other signals known to activate the Cpx response include alkaline pH (Danese et al., 
1998), adhesion (Otto et al., 2002), and high osmolarity (Jubelin et al., 2005). Bae, on the 
other hand, only have eight confirmed genes in its regulon: its operon (baeSR), multidrug 
efflux pumps (mdtABC, mdtD, and acrD), and a periplasmic protein (spy) (Raffa et al., 
2002; Baranova et al., 2002; Leblanc et al., 2011). 
CHAPTER 1 Introduction 
37 
 
Figure 14. E. coli extracytoplasmic stress response systems 
A, B) CpxRA and BaeRS two-component system- Inducing signals lead to the autophosphorylation of 
sensor CpxA or BaeS. Transfer of the phosphoryl group to the regulator CpxR or BaeR results in its 
activation, which allows it to bind DNA and regulate transcription of its target genes. C) Rcs phosphorelay 
system- Under inducing conditions, sensor protein RcsC autophosphorylates, then phosphorylates RcsD. 
RcsD, in turn, phosphorylates RcsB, leading to its activation and induction of its target genes. D) Psp phage 
shock protein system- Under inducing conditions, PspB and PspC interact with PspA, which releases PspF. 
PspF can then interact with RNA polymerase to induce transcription of its operon E)  Alternative sigma 
factor σE-dependent pathway- Misfolded outer membrane proteins bind and activate protease DegS.  DegS, 
then cleaves RseA, freeing σE, which can then interact with RNA polymerase to regulate expression of its 
target genes. Created with BioRender.com. Adapted by permission from Springer Nature: Springer Nature, 
Nature Reviews Microbiology. Envelope stress responses: balancing damage repair and toxicity 
(Figure 1), (Mitchell et al., 2019), copyright 2019. 
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The Rcs phosphorelay system is also a two-component system, albeit more complex, with 
an intermediary protein RcsD between the sensor histidine kinase RcsC and the response 
regulator RcsB (Figure 14C) (Majdalani et al., 2005). Initially determined as a regulator 
of colanic acid capsule synthesis (Gottesman et al., 1985), the Rcs system is also activated 
by cell envelope stresses including exposure to β-lactam antibiotics (Laubacher et al., 
2008), damage to periplasmic peptidoglycan (Callewaert et al., 2009), modification of 
peptidoglycan (Evans et al., 2013), and defects in lipoprotein sorting (Tao et al., 2012).   
The last two systems are Psp and σE. Psp (phage shock response) is primarily induced by 
stresses that damage the inner membrane and disrupt the PMF (Jovanovic et al., 2006). 
Under inducing conditions, inner membrane proteins PspB and PspC bind PspA to free 
PspF, which is normally bound by PspA (Figure 14D) (Flores-Kim et al., 2016). PspF 
can then induce the σ54-dependent transcription of the psp operon (Wigneshweraraj et al., 
2008). The Psp proteins function in repairing damage to the inner membrane and 
maintaining the PMF (Kobayashi et al., 2007; Jovanovic et al., 2006). Lastly, σE (sigma 
E) is an alternative sigma factor-dependent pathway that responds to misfolding of outer 
membrane proteins and stresses that ultimately lead to disruptions in outer membrane 
protein assembly, such as defects in LPS biosynthesis (Mecsas et al., 1993; Lima et al., 
2013; Klein et al., 2016). Inner membrane protein RseA normally sequesters σE 
(Campbell et al., 2003). However, under inducing conditions such as the presence of 
unfolded outer membrane proteins, the protease DegS is activated and degrades RseA.  
σE is then able to interact with RNA polymerase and regulate gene expression (Figure 
14D) (Ades et al., 1999).  
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1.10 Rationale and objectives of the study 
Antimicrobial resistance that renders existing antimicrobial therapies ineffective poses a 
significant threat to public health with an enormous social and economic burden globally. 
The issue is notably more severe concerning the Gram-negative bacterial pathogens than 
their Gram-positive counterparts since the former group is inherently resistant to many 
antimicrobial agents due to a highly impermeable outer membrane and a range of 
powerful efflux pumps (Breijyeh et al., 2020). This problem is reflected in the WHO's 
list of priority pathogens that urgently need research and development of new antibiotics 
(World Health Organization, 2017). As multidrug resistance continues to emerge and 
spread globally, and with the current clinical development pipeline insufficient to keep 
pace (World Health Organization, 2019a), this problem needs to be rectified through 
alternative strategies, such as the revival of 'old' drugs by employing them in novel 
synergistic antibacterial combinations.  
Previous studies in the Rakonjac lab focused on secretin channels have found secretin 
gate mutants  that are ‘leaky’ to DOC and large antibiotics including Van (Spagnuolo et 
al., 2010; Khanum, 2015). In a small molecule screen to find secretin gate-opening 
molecules that could sensitise E. coli to DOC or large antibiotics, synergy with nitrofuran 
was instead accidentally found. Studies have then shifted on pairwise synergies between 
the 'old' antibiotic nitrofurans and DOC or VAN applied to Gram-negative pathogens as 
an alternative strategy to tackle antimicrobial resistance. However, high concentrations 
of DOC and VAN in the two-drug combinations, even after the dose reduction imparted 
by the synergy, preclude the use of these combinations as viable treatment options for 
Gram-negative bacterial infections. To further improve the combination, it was 
hypothesised that the combination of the three antibacterials, nitrofurans, DOC, and 
VAN, if synergistic, will further enhance the efficacy and lower the individual doses, 
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which can mitigate adverse effects. Therefore, the focus of this research was to establish 
the combination of nitrofurans, DOC, and VAN as a potential therapy for Gram-negative 
bacterial infections.  
The aims of this study were 1) to determine whether nitrofurans, DOC, and VAN are 
synergistic in Gram-negative pathogens by characterising the in vitro interaction in terms 
of growth inhibition and bacterial killing. To develop this combination into a potential 
therapy, understanding the mechanism of synergy is essential. The gap in the knowledge 
of the individual drugs’ mechanisms of action in Gram-negative bacteria, however, 
impedes the understanding of the mechanistic bases of their synergistic interaction. 
Henceforth, the study also sought 2) to first determine the individual mechanisms of 
action of the antibacterials, followed by the 3) mechanism of synergy, by investigating 
the genome-wide transcriptional responses of the model Gram-negative bacterium E. coli 
to each of the antibacterials individually and in combination. Biochemical, physiological, 
and genetic approaches were subsequently combined to identify the roles of some key 
pathways hypothesised to be involved in the action and synergy of FZ, DOC, and VAN, 
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2.1 Antibiotics 
FZ, NIT, NFZ, and VAN were purchased from Goldbio (St. Louis, MO, USA). DOC was 
a kind gift from New Zealand Pharmaceuticals (Palmerston North, NZ). Dalbavancin and 
oritavancin were purchased from MuseChem (Fairfield, NJ, USA). Ox gall bile salts 
powder (Cat No. B3883) was purchased from SigmaAldrich (St. Louis, MO, USA).  
2.2 Bacterial strains and growth conditions 
All bacterial strains used in this study are described in Table 1. All strains were grown in 
trypticase soy broth at 37 °C with shaking at 200 rpm (rotations per minute), except for 
E. coli K12 laboratory strains which were grown in 2xYT medium. For Staphylococcus, 
Streptococcus, and Pasteurella strains, the growth medium was further supplemented 
with 5% sheep blood. For the preparation of exponential phase cells, fresh overnight 
culture was 100-fold diluted and incubated to reach the optical density at 600 nm (OD600) 
of 0.1–0.3. Unless otherwise stated, the cation-adjusted Mueller-Hinton (MH) II broth 
(Becton-Dickinson, USA) was used in the susceptibility testing, checkerboard, and time-
kill assays. Since nitrofuran stocks were prepared in dimethyl sulfoxide (DMSO), DMSO 
concentrations in the following assays were fixed to 1% or 0.1%, as stated. 
The introduction of the kanR gene deletion mutations into the E. coli K12 strain K1508 
from the corresponding Keio collection E. coli K12 knock-out strains (Baba et al., 2006) 
was performed using phage P1 transduction, as previously described (Thomason et al., 
2007). To eliminate potential polar effects on downstream genes in the operon, the FLP 
recombinase recognition target (FRT)-flanked kanR cassette was removed using FLP-
mediated recombination using plasmid pCP20 (FLP+,  λ ci857+, λ pR Repts, AmpR, CmR) 
(Cherepanov, 1995). 
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Table 1. Bacterial strains used in the study 
Strains Genotype/Description Source 
E. coli ATCC 25922 Antibiotic susceptibility 
reference/quality control strain 
ATCC® 25922; NCTC 
12241; NZRM 916 
E. coli ERL034336 O157, human isolate Dr Anne Midwinter, 
School of Veterinary 
Science, Massey 
University, Palmerston 
North, New Zealand 
E. coli UPEC P191 Isolate from a feline urinary tract 
infection 
New Zealand Veterinary 
Pathology (NZVP) 
diagnostic labs, 
Palmerston North, New 
Zealand 
E. coli NZRM 4402 Plasmid-mediated AmpC β-
lactamase-producing (CMY-2) 
NZRM 4402 
E. coli NZRM 4364 Carbapenemase (IMP-4) producing. 
Human isolate from hospital 
outbreak (Melbourne, Australia) 
NZRM 4364 
E. coli NZRM 4457 NDM-1 metallo-β-lactamase-
producing, nitrofuran-resistant 
ARL09/232 (Williamson 
et al., 2012); NZRM 4457 
(Olivera et al., 2020) 
E. coli NZRM 4524 Verotoxin-producing E. coli (VTEC). 




Isolate from a municipal sewage 
processing (water purification) plant, 
Palmerston North, New Zealand 
(Le et al., 2020) 
Klebsiella pneumoniae 
PMR001 
Isolate from a municipal sewage 
processing (water purification) plant, 
Palmerston North, New Zealand 












OXA-181 carbapenemase-producing NZRM 4498 
Salmonella enterica sv. 
Typhimurium LT2 
Type strain ATCC® 43971 
Salmonella enterica  
NZRM 4533 





Type strain ATCC® 13313; NCTC 
4837; NZRM 1015 
Acinetobacter lwoffi 
NZRM 1218 
Knee wound isolate (NZ)  NZRM 1218 
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Acinetobacter 
baumannii NZRM 3697 




baumannii NZRM 4408 




Isolate from a feline oral cavity NZRM 959 
Staphylococcus aureus 
NZRM 3478 
Methicillin-resistant. Human wound 




Human wound isolate. Erythromycin 
(ermA) resistant 






methicillin-resistant. Human isolate 
(NZ) 
 NZRM 4548 
Staphylococcus aureus 
NZRM 4549 







reference/quality control strain 




Exotoxin positive control GAS 91/367; NZRM 
4366 
E. coli K12 laboratory 
strains 
Genotype/Description Source 
BW25113 rrnB3 lacZ4787 hsdR514  
(araBAD)567 (rhaBAD)568 rph-1 
Keio collection 
(Baba et al., 2006) 
kanR removed 
K2578 BW25113 ΔappB 
K2579 BW25113 ΔcyoB 
K2580 BW25113 ΔcydB 
K2581 BW25113 Δfur 
K2582 BW25113 Δndh 
K2583 BW25113 ΔnuoM 
K1508 MC4100 [F− araD− Δlac U169 relA1 
spoT1 thiA rpsL (StrR)] ΔlamB106 
(Spagnuolo et al., 2010) 
K2588 K1508 ΔappB 
This study 
K2589 K1508 ΔcyoB 
K2590 K1508 Δfur 
K2591 K1508 Δndh 
K2592 K2508 ΔnuoM 
K2600 K1508 ΔcydB 
K2605 K1508 ΔrecA 
NZRM, The New Zealand Reference Culture Collection: Medical Section 
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2.3 Susceptibility testing 
The broth microdilution assay for antimicrobial susceptibility was performed according 
to the Clinical and Laboratory Standards Institute (CLSI) guidelines (Clinical and 
Laboratory Standards Institute, 2015) in a 384-well plate format. Each well contained 5 
× 105 colony forming units (CFU)/mL in exponentially-growing phase, 1% DMSO, and 
the test antibacterial in a total volume of 50 μL. Each treatment was performed in 
triplicate. The plate was incubated at 37 ºC for 18 h for enterobacteria and 
Staphylococcus, and 24 h for Acinetobacter and Streptococcus as recommended by the 
CLSI guidelines (Clinical and Laboratory Standards Institute, 2015). The OD600 was 
measured to assess growth inhibition. The MIC is defined as the concentration that 
inhibits at least 90 % of growth at the endpoint (Campbell, 2011). 
The CLSI guidelines were also followed for determining MIC using the agar dilution 
method. Briefly, 2xYT agar plates containing two-fold dilutions of test antibacterials 
were prepared. Onto these agar plates, 10 L of exponentially-growing bacterial 
inoculum (1 × 106 CFU/mL) were spotted in triplicate, such that each spot contains 104 
CFU. The plates were incubated at 37 C for 18 h before scoring, and the MIC was 
determined as the lowest concentration of antimicrobial agent that completely inhibits 
growth, disregarding a single colony or a faint haze caused by the inoculum.  
2.4 Checkerboard assay 
The synergy between the test antibacterials was examined using growth inhibition three-
dimensional checkerboard microdilution assay in 384-well plates according to the CLSI 
guidelines (Clinical and Laboratory Standards Institute, 2015). Two-fold dilutions with a 
concentration range of 2 × MIC to 0.06 × MIC of the antibacterials and exponential-phase 
bacteria were prepared in BBL™ cation-adjusted MH II broth (Becton-Dickinson, 
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Sparks, MD, USA). Each well contained 5 × 105 CFU/mL, 1% DMSO, and the 
antibacterials in a total volume of 50 μL. Each plate was incubated at 37 ºC for the 
required time according to CLSI guidelines, and the OD600 was measured to quantify 
growth (Campbell, 2011). Each combination of concentrations was performed in 
triplicate and the mean growth inhibition was used to determine MIC values, which 
correspond to concentrations of combinations that result in at least 90% of growth 
inhibition. Fractional inhibitory concentration index (FICI) was calculated using the 











where MICnitrofuran(com), MICDOC(com), and MICVAN(com) is the MIC of nitrofuran, DOC, and 
VAN when used in combination and MICnitrofuran(alone), MICDOC(alone), and MICVAN(alone) is 
the MIC when used alone. Using the lowest FICI, the interactions were interpreted as 
synergistic if FICI ≤ 0.5; indifferent if 0.5 < FICI  ≤ 4.0 and antagonistic if FICI > 4.0 
(Odds, 2003). 
2.5 Time-kill assay 
Exponentially-growing bacterial cultures were prepared at 5 × 105 CFU/mL and treated 
with individual antibacterial agents (FZ, DOC, VAN) or combinations thereof at specified 
concentrations in a final volume of 10 mL. The cultures treated with 1% DMSO were 
included as vehicle controls. Each treatment was performed in triplicate. The bacterial 
cultures were incubated at 37 C with shaking at 200 rpm. At time points 0, 2, 4, 6, 8, and 
24 h, 500 L was sampled from each culture and centrifuged at 10,000 ×g for 1 min. The 
pellet was then resuspended in 100 L of the maximum recovery diluent (0.1% peptone, 
0.85% sodium chloride (NaCl), and 10-fold serial dilutions were drop-plated (10 L) on 
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2xYT agar.  Plates were incubated at 37 C overnight before counting colonies. The limit 
of detection is 60 CFU/mL or 1.78 log10 CFU/mL. The synergy of the combination was 
defined as   2log10 decrease in the cell count (CFU/mL) compared to the most potent 
single drug at 24 h.  
2.6 MTT assay for cellular viability 
Human embryonic kidney 293T (HEK293T) cells were grown in Gibco® Dulbecco’s 
Modified Eagle Medium (Thermo Fisher Scientific, USA) supplemented with 10% fetal 
bovine serum (Moregate Biotech, New Zealand) at 37 °C in a 5% CO2 atmosphere. 
HEK293T cells were first seeded into a 384-well plate at 1000 cells per well and 
incubated for 24 h. Two-fold serial dilutions of the test antibacterial(s) were then added 
into the cell culture, followed by 48 h incubation. Each treatment was prepared in 
triplicate, and the cultures without test antibacterials were included as negative controls. 
After incubation, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, 
Thermo Fisher Scientific, USA) was added at a final concentration of 0.5 mg/mL, and the 
plate was incubated at 37 °C for 2 h. The purple formazan crystals resulting from the 
MTT reduction were solubilised using SDS-HCl solution (10% w/v sodium dodecyl 
sulfate (SDS), 10 mM hydrochloric acid). After overnight incubation at 37 °C, the 
absorbance of the samples at 570 nm was recorded. Percentage inhibition were calculated, 
and a dose-response curve was fitted using the drc (v3.0-1) R package (Ritz et al., 2016). 
From the fitted curves, 20%, 50%, and 90% inhibitory concentrations (IC20, IC50, IC90), 
were then determined. The interaction of the antimicrobial agents was assessed using the 
FICI equation above, substituting inhibitory concentration (IC20, IC50, IC90) values for 
MIC. 
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2.7 IC50 (half-maximal (50%) inhibitory concentration) 
determination for transcriptome study 
The IC50 determination was performed in 384 well plates using exponentially-growing E. 
coli K1508 and two-fold drug dilutions prepared in 2xYT medium. Each well contained 
a starting inoculum of approximately 1 × 106 CFU/mL, 1% DMSO, and test 
antibacterial(s), in a final volume of 50 μL. Negative control (vehicle only-1% DMSO) 
and media-only control (blank) were included. The plate was incubated at 37 oC for 24 h, 
and OD600 was read using MultiskanTM GO Microplate Spectrophotometer. The % 









The r package drc v. 3.0-1 (Ritz et al., 2016) was used to plot the concentration-response 
(% inhibition) curves fitted with the four-parameter log-logistic model to determine the 
IC50. 
2.8 Total RNA extraction 
Exponentially-growing cultures of the E. coli strain K1508 at 5 × 107 CFU/mL were 
treated with antibacterial(s) in a final volume of 25 mL. The DMSO concentration for all 
treatments were fixed at 0.1%. After incubation at  37 °C with shaking at 200 rpm for 1 
h, the cultures were then harvested by centrifugation at 5000 ×g for 10 min, and the 
resulting pellet was subjected to phenol (pH 4.45)-chloroform RNA extraction, as 
follows:  
The pellet was resuspended in 1 mL of resuspension buffer (20 mM sodium acetate 
(NaOAc) pH 5.5, 1 mM ethylenediaminetetraacetic acid (EDTA), 1% SDS) and 
CHAPTER 2 Materials and methods 
49 
transferred to a 1.5 mL microtube containing an equal volume of phenol: chloroform (1:1) 
and 0.2 g of 425-600 m acid-washed beads (Sigma-Aldrich). The samples were vortexed 
at top speed for 90 sec to lyse the cells. The phases were then separated by centrifugation 
(5 min, 3000 ×g, 4 ºC), and the aqueous phase was transferred to a 1.5 mL microtube 
containing an equal volume of phenol: chloroform (1:1). The aqueous phase was 
separated again and was washed a final time by chloroform extraction.  The RNA was 
then precipitated by adding to the aqueous phase 1/10 volume of 3 M NaOAc pH 7.0 and 
2.5 volumes of ethanol. The tube was mixed by inversion and allowed to precipitate at -
80 ºC overnight. The precipitated RNA was collected by centrifugation (30 min, 13000 
×g, 4 ºC), and the pellet was dissolved in diethylpyrocarbonate (DEPC)-treated water. 
The extracted RNA samples were subjected to DNase digest using RNase-free DNase I 
(Roche Applied Science) according to the manufacturer's instructions. The RNA was 
recovered using the phenol-chloroform-based method as described above (2× phenol: 
chloroform, 1× chloroform extractions, and ethanol precipitation), followed by being 
dissolved and stored in Tris-EDTA buffer pH 8.  
RNA quantification and quality analysis were performed using Qubit RNA BR Assay 
(Life Technologies, Thermo Fisher Inc.) and LabChip GX nucleic acid analyzer (Caliper 
Life Sciences, PerkinElmer), respectively.  
2.9 RNA sequencing  
The RNA samples were sent to Novogene Co., Ltd. (Beijing, China) for library 
preparation and sequencing. Using 3 μg total RNA per sample, rRNA was first depleted 
from the total RNA using the Ribo-Zero™ magnetic kit (Illumina) following the 
manufacturer’s protocol. A total of 50 ng of the rRNA-depleted RNA per sample were 
used to construct cDNA libraries using NEBNext® Ultra™ Directional Library Prep Kit 
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for Illumina® (New England Biolabs, USA). The resulting complementary DNA (cDNA) 
libraries were quality checked using Agilent 2100 Bioanalyzer, then quantified using 
quantitative PCR (qPCR). The libraries were subsequently subjected to 150-bp paired-
end sequencing on the Illumina HiSeq 2500 platform, producing approximately 20 
million paired-end reads for each library.  
2.10 RNA-seq data analysis 
The raw sequencing data were filtered by Novogene using their in-house Perl scripts, 
which included removing adapters, removing reads containing N > 10%, and removing 
reads containing low-quality base (Qscore  5) which is over 50% of the total base.  
Prior to analysing the data, the quality of the reads was checked using FastQC v0.11.7-5 
(Andrews, 2010). The RNA sequencing reads (Appendix B, Supplementary files 6-13) 
were mapped against the E. coli K1508 genome (Appendix B, Supplementary file 1) using 
HISAT2 v2.1.0 (Kim et al., 2015). The resulting mapping files in SAM format were 
sorted and converted to BAM format using SAMtools v1.7 (Li et al., 2009).  The number 
of reads that mapped to a gene was then counted using featureCounts v1.6.0 (Liao et al., 
2013). 
To explore variability between and within treatment groups, a principal component 
analysis was performed using the plotPCA function of DESeq2 (v1.26.0) R package 
(Love et al., 2014) on the regularised log-transformed normalised counts for all the genes 
of all the samples. The PCA was then visualised graphically using ggplot2 v3.3.0 
(Wickham, 2016). 
Differential expression analysis was performed using DESeq2 (Appendix B, 
Supplementary file 3). For genes with low counts or high variability, log2 fold change 
(log2FC) estimates will be higher and are not representative of gene expressions. To have 
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a better representation of gene rankings by effect size, log2FC were shrunk using the 
apeglm shrinkage estimator v1.8.0 (Zhu et al., 2018). Differentially expressed genes 
(DEG) were defined as genes with an adjusted p-value [multiple test adjustment using the 
Benjamini-Hochberg method (Benjamini et al., 1995)] of less than 0.01, and shrunken 
fold changes greater than 1.5 (|log2FC| > 0.58). 
Gene Ontology (GO) term analysis was performed on the DEGs using PANTHER 15.0 
(Protein ANalysis THrough Evolutionary Relationships) (Mi et al., 2018). The statistical 
overrepresentation test was performed using the Fisher’s Exact test with Benjamini-
Hochberg false discovery rate (FDR) multiple test correction. The significantly 
overrepresented GO terms were selected using an FDR cutoff of 0.05.  
K means clustering was performed on regularised-log transformed normalised counts. A 
priori, a model-based optimal K number was determined according to Bayesian 
Information Criterion using the Mclust function of the mclust (v5.4.6) R package 
(Scrucca et al., 2016). The K means clustering was visualised as a heatmap generated 
using the pheatmap (v1.01.12) R package (Kolde, 2019).  
2.11 Metal concentration analysis by ICP-MS 
Antibiotic-treated E. coli cultures in a total volume of 80 mL were prepared the same way 
as the RNA samples described above. After antibiotic treatment, samples were collected 
and prepared for inductively coupled plasma mass spectrometry (ICP-MS), as previously 
described (Williams et al., 2019). Briefly, cells were harvested by centrifugation (5000 
×g, 10 min), then washed twice with 25 mL phosphate buffered saline (PBS) containing 
0.5 mM EDTA, then twice with PBS. All samples were adjusted to a cell number of 2 × 
109 CFU based on their OD600 values. Washed cell pellets were then digested with 500 
µL of 70% (wt/vol) nitric acid (≥99.999% trace metals basis) at 80 °C overnight. Each 
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sample was diluted 1:20 in Milli-Q H2O (18.2 MΩ), giving a final acid matrix of 3.5%. 
The samples were then sent to The University of Waikato Mass Spectrometry Facility for 
analysis of metal content by ICP-MS on an Agilent 8900 system. 
2.12 Oxygen consumption  
E. coli K1508 was cultured in 2xYT and cells at OD600 of 0.3 were treated with FZ, 
VAN, and DOC, alone and in combination at 37 °C for 1 h. Cells were then diluted in air-
saturated 2xYT to OD600 of 0.2, and dissolved oxygen was measured in a closed chamber 
with constant stirring using a Clark-type oxygen electrode (Rank Brothers Ltd.) linked to 
a chart recorder (Vernier LabQuest Mini). The electrode was calibrated using air-
saturated 2xYT medium (~220 nmol/mL) and sodium dithionite (0 nmol/mL). 
2.13 Mutagenicity assay 
Exponentially-growing E. coli K1508 at 1 ×107 CFU/mL were treated with FZ, VAN, and 
DOC, alone and in combination in a final volume of 10 mL in 2xYT medium. The cultures 
were incubated at 37 °C with shaking at 200 rpm for 24 h. The cultures were then 
centrifuged at 5000 ×g for 10 min and resuspended in maximum recovery diluent (0.1% 
peptone, 0.85% NaCl). Serial dilutions were made and plated in triplicate onto 2xYT agar 
containing 100 µg/mL rifampicin to select for rifampicin-resistant colonies, and on non-
selective 2xYT agar to count the total number of colonies. The plates were scored after 
24 h incubation at 37 °C. The mutation frequency was calculated by dividing the number 
of rifampicin-positive colonies by the total number of colonies from 9-11 biological 
replicates. 
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2.14 Ethidium bromide accumulation and efflux  
The ethidium bromide accumulation assay was performed as previously described 
(Viveiros et al., 2008). Briefly, E. coli K1508 cultured in 2xYT was centrifuged at 5000 
×g for 10 min and resuspended in MOPS media (Neidhardt et al., 1974) supplemented 
with 0.4% glucose and 0.1% casamino acids (MOPS-G-CA). Cells at OD600 of 0.3 were 
then dispensed in triplicate into a black 96-well plate containing FZ, VAN, and DOC 
alone and in combination, and 0.125 µg/mL ethidium bromide. Fluorescence (544/590 
nm) was monitored at 37 °C every 2 min for 1 h using the FluoStar Galaxy fluorescence 
microplate reader (BMG Labtech). Carbonyl cyanide m-chlorophenylhydrazine (CCCP) 
at 5 µg/mL was used as a positive control. 
For the efflux assay, E. coli K1508 cells were first loaded with ethidium bromide by 
incubating with 5 µg/mL ethidium bromide and 5 µg/mL CCCP at 37 °C with shaking at 
200 rpm for 1 h. The bacteria were then centrifuged (5000 ×g, 10 min), washed with PBS, 
and resuspended in MOPS-G-CA. Cells were dispensed in triplicate into a 96-well plate 
containing FZ, DOC, and VAN alone and in combination, and the fluorescence monitored 
as described above. 
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3.1 Introduction 
Studies in our laboratory have identified pairwise synergies between nitrofurans and DOC 
or VAN against E. coli in a small-molecule screen. The synergy enhanced the efficacy 
and lowered inhibitory concentrations of the individual components. The combinations, 
therefore, have the potential of expanding the use of normally Gram-positive-only 
antibacterials, VAN and DOC, to Gram-negative bacteria. To further improve the 
combination in terms of efficacy and dose reduction to mitigate adverse effects,  the three-
way interaction of nitrofurans, VAN, and DOC was investigated. Since all these 
antibacterials are currently approved for clinical use in human indications, repurposing 
them will have the advantage of already having established toxicity studies which can 
accelerate the development timeline for this therapy.  
This chapter demonstrates the in vitro synergy between nitrofurans, VAN, and DOC in 
the growth inhibition and killing of a range of clinical Gram-negative pathogenic isolates, 
including multidrug-resistant and carbapenemase-producing bacteria for which new 
therapies are urgently needed (World Health Organization, 2017). To explore the 
possibility of using the combination in treating WHO priority Gram-positive pathogens 
(e.g. MRSA), the interaction of these three antimicrobials was also evaluated in Gram-
positive bacteria. Additionally, it was investigated whether the same synergistic effect 
can be achieved with other glycopeptides instead of VAN or a combination of bile salts 
instead of DOC. Lastly, the in vitro interaction of the antibacterials against mammalian 
cells was investigated. 
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3.2 Results 
3.2.1 Susceptibility testing 
The interaction of nitrofuran, VAN, and DOC was assessed on a range of lab strains and 
clinical isolates selected from the New Zealand Reference Culture Collection (NZRM) 
held by the Institute of Enviromental Science and Research (ESR, New Zealand). A range 
of clinically relevant multidrug resistant strains, specifically those that are listed as 
priority pathogens by WHO (World Health Organization, 2017), were tested. These 
included enterobacteria and Acinetobacter baumannii harbouring carbapenem genes (A. 
baumannii NZRM 4408, E. coli NZRM 4364, K. pneumoniae NZRM 4412 and NZRM 
4498) and -lactam resistance genes (E. coli NZRM 4402 and NZRM 4457, K. 
pneumoniae NZRM 4387), and MRSA (NZRM 3478, NZRM 4548, NZRM 4549).  The 
susceptibility of the strains were first determined according to the CLSI guidelines and 
the MIC for nitrofurans, DOC, and VAN are summarised in Table 2.  
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Table 2. Minimum inhibitory concentrations  
Strain MIC (µg/mL) 
Gram-negative FZ DOC VAN NIT NFZ CM4 
E. coli ATCC 25922 1.25 80000 500 16 8 16 
E. coli NZRM K1508 1.25 >80000 250 16 8 4 
E. coli ERL034336 1.25 80000 250 16 8 32 
E. coli UPEC P191 1.25 80000 250 16 8 16 
E. coli NZRM 4364 0.25 >80000 125 NT NT NT 
E. coli NZRM 4402 0.625 40000 500 NT NT NT 
E. coli NZRM 4457 >128 80000 250 128 64 >128 
E. coli NZRM 4524 1.25 80000 500 NT NT NT 
C. gillenii PMR001 5 80000 500 16 16 32 
K. pneumoniae PMR001 1.25 80000 1000 64 32 >64 
K. pneumoniae NZRM 4387 2.5 80000 2000 NT NT NT 
K. pneumoniae NZRM 4412 32 80000 2000 >128 128 >128 
K. pneumoniae NZRM 4498 16 >80000 2000 >128 64 >128 
S. enterica sv. Typhimurium LT2 2.5 40000 500 16 8 16 
S. enterica  NZRM 4533 2 80000 1000 32 8 8 
S. dysenteriae NZRM 1015 4 >80000 250 8 8 4 
A. lwoffi NZRM 1218 16 40000 62.5 NT NT NT 
A. baumannii NZRM 3697 32 80000 125 NT NT NT 
A. baumannii NZRM 4408 >128 80000 250 >128 32 >128 
P. dagmatis NZRM 959 2 1250 31.25 4 4 16 
Gram-positive FZ DOC VAN NIT NFZ CM4 
S. aureus NZRM 3478 4 312.50 2 NT NT NT 
S. aureus NZRM 4315 2 625 1 NT NT NT 
S. aureus NZRM 4548 2 625 1 NT NT NT 
S. aureus NZRM 4549 2 625 1 NT NT NT 
S. pyogenes NZRM 4366 16 156.25 0.78 NT NT NT 
S. pneumoniae NZRM 2764 2 625 0.78 NT NT NT 
MIC, minimum inhibitory concentration; FZ, furazolidone; DOC, sodium deoxycholate; VAN, 
vancomycin; NIT, nitrofurantoin; NFZ, nitrofurazone; NT, not tested. 
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3.2.2 Nitrofurans, VAN, and DOC synergy against Gram-negative 
pathogens 
Growth-inhibition checkerboard assays were performed to evaluate the synergy between 
nitrofurans, VAN, and DOC against a range of Gram-negative bacteria. As a proof of 
concept that the nitrofurans, as an antibiotic class, is synergistic with VAN and DOC, the 
antibacterial effect of the combinations of these two agents with either of the four 
nitrofurans (FZ, NIT, NFZ, and CM4) was evaluated in a checkerboard assay against the 
reference strain E. coli ATCC 25922. All four nitrofurans were found to be synergistic 
with DOC and VAN, with FICIs ranging from 0.11 to 0.15 (Appendix A, Figure A- 1). 
Among the nitrofurans included in this study, FZ is the most potent against the strains 
tested (Table 2). Therefore, FZ was chosen as a representative of the nitrofurans in the 
expanded strain profiling by checkerboard and time-kill assays. The FICIs for the two-
drug and three-drug combinations of FZ, VAN, and DOC are listed in Table 3. For some 
of the strains, where the MIC could not be determined, the FICI was calculated using the 
highest tested concentration. In this case, the actual FICI would be lower than the 
calculated value, and for some strains, it may not be possible to classify an interaction 
when the calculated FICI is bordering between synergistic and indifferent, such as in E. 
coli NZRM 4457. 
FZ, VAN, and DOC combination was synergistic against 15 strains, indifferent against 
four strains (S. enterica sv. Typhimurium LT2, K. pneumoniae PMR001, K. pneumoniae 
NZRM 4412, and P. dagmatis NZRM 959), and unable to be classified as synergistic or 
indifferent against one strain (E. coli NZRM 4457). Of importance is the synergy of the 
combination against some of the WHO critical priority pathogens, carbapenemase-
producing E. coli NZRM 4364 and A. baumannii NZRM 4408, and ESBL-producing K. 





 Table 3. Minimum inhibitory concentrations and fractional inhibitory concentration indices for the most synergistic two-drug and 
three-drug combinations of FZ, VAN, and DOC against Gram-negative strains identified in a checkerboard assay 
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*, MIC is higher than the highest tested concentration which was used to calculate the FICI, therefore actual FICI is lower than calculated value; Values in bold indicate 
synergy (FICI ≤ 0.5); a, fold dose reduction compared to MIC when used  alone are shown in brackets; FZ, furazolidone; DOC, sodium deoxycholate; VAN, 
vancomycin; FICI, fractional inhibitory concentration index. 
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To further investigate the interaction between FZ, VAN, and DOC in terms of bacterial 
killing, time-kill assays were performed on some representative pathogens for which the 
triple combination showed growth inhibition synergy in the checkerboard assay. The 
strains were exposed to sub-inhibitory concentrations of FZ, VAN, and DOC or two-drug 
and three-drug combinations of these concentrations over a time course of 24 h. The time-
kill analysis for E. coli ATCC 25922, S. dysenteriae NZRM 1015, C. gillenii PMR001, 
and A. baumannii NZRM 3697 are shown in Figure 15. Combination of subinhibitory 
concentrations of FZ, VAN, and DOC resulted in > 2log10 reduction in viable cell count 
after 24-h exposure in comparison with the most active single drug, demonstrating the 
synergy in the bacterial killing of the three-drug combination in these strains. In these 
four examples, the triple combination led to the extinction of the challenged bacterial 
population at the end of the assay (a.k.a. below the limit of detection), that was not 
achieved by single drugs or double combinations at the same concentrations.  
Time-kill assay for the three multidrug-resistant pathogens, E. coli NZRM 4364, A. 
baumannii NZRM 4408, and K. pneumoniae NZRM 4387 was performed and shown in 
Figure 16. Interestingly, bactericidal synergy was still retained against these strains, 
though the effect was less profound than against the drug-sensitive strains (Figure 15)
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Figure 15. Time-kill analysis of FZ, VAN, and DOC combinations in killing (A) E. 
coli ATCC 25922, (B) S. dysenteriae NZRM 1015, (C) C. gillenii PMR001, and (D) A. 
baumannii NZRM 3697.  
The data is presented as mean ± standard error of the mean (SEM) of three independent measurements. The 






























FZ 0.156255 μg/mL + VAN 62.5 μg/mL
VAN 62.5 μg/mL + DOC 2500 μg/mL
FZ 0.15625 μg/mL + DOC 2500 μg/mL



























FZ 0.625 μg/mL + VAN 31.25 μg/mL
VAN 31.25 μg/mL + DOC 2500 μg/mL
FZ 0.625 μg/mL + DOC 2500 μg/mL




























FZ 0.625 μg/mL + VAN 62.5 μg/mL
VAN 62.5 μg/mL + DOC 5000 μg/mL
FZ 0.625 μg/mL + DOC 5000 μg/mL
FZ 0.625 μg/mL + VAN 62.5 μg/mL + DOC 5000 μg/mL


























FZ 4 μg/mL + VAN 62.5 μg/mL
VAN 62.5 μg/mL + DOC 2500 μg/mL
FZ 4 μg/mL + DOC 2500 μg/mL
FZ 4 μg/mL + VAN 62.5 μg/mL + DOC 2500 μg/mL
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Figure 16. Time-kill analysis of FZ, VAN, and DOC combinations in killing 
carbapenemase-producing (A) E. coli NZRM 4364 and (B) A. baumannii NZRM 
4408, and (C) multidrug-resistant ESBL-producing K. pneumoniae NZRM 4387.  
The data is presented as mean ± standard error of the mean (SEM) of three independent measurements. The 































FZ 4 μg/mL + VAN 62.5 μg/mL
VAN 62.5 μg/mL + DOC 2500 μg/mL
FZ 4 μg/mL + DOC 2500 μg/mL



























FZ 1.25 μg/mL + VAN 125 μg/mL
VAN 125 μg/mL + DOC 2500 μg/mL
FZ 1.25 μg/mL + DOC 2500 μg/mL




























FZ 0.03125 μg/mL + VAN 62.5 μg/mL
VAN 62.5 μg/mL + DOC 2500 μg/mL
FZ 0.03125 μg/mL + DOC 2500 μg/mL
FZ 0.03125 μg/mL + VAN 62.5 μg/mL + DOC 2500 μg/mL
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3.2.3 Indifferent interaction of FZ, DOC, and VAN against Gram-
positive bacteria 
VAN is not the first choice for the treatment of Gram-positive infections due to its adverse 
effects (Bruniera et al., 2015). Using VAN in a combination will allow lowering the 
effective dose of VAN, thus reducing or preventing its adverse effects. The interaction 
between FZ, VAN, and DOC against some important Gram-positive pathogens such as 
Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes was 
investigated using checkerboard assay. In the six Gram-positive strains tested, all two-
drug and three-drug combinations of FZ, VAN, and DOC were classified as indifferent, 
with FICIs ranging from 0.53 to 1.05 (Table 4). The MICs of at least two out of these 






 Table 4. Minimum inhibitory concentrations and fractional inhibitory concentration indices for the most synergistic two-drug and three-
drug combinations of FZ, VAN, and DOC against Gram-positive pathogens identified in a checkerboard assay 
a, fold dose reduction compared to MIC when used  alone are shown in brackets; FZ, furazolidone; DOC, sodium deoxycholate; VAN, vancomycin; FICI, fractional 
inhibitory concentration index. 
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3.2.4 Interactions of bile salts mixture with FZ and VAN against E. 
coli 
To explore whether a natural bile combination present in the human gut can aid treatment 
of gastrointestinal illness caused by enterobacteria in combination with FZ and VAN, the 
interaction of these two antibacterials with a bile salts mixture that is similar in 
composition to that in the human gut was investigated. Ox gall powder from Sigma-
Aldrich (Cat No. B3883) was reported to have bile salt ratios closest to human bile (Hu 
et al., 2018) and was therefore used in this study. The content of DOC in the ox gall 
powder, according to Hu et al. (2018) is 0.09% (wt/wt) or 2.09 mmol/kg. 
The MIC of the ox gall powder for the E. coli strain ATCC 25922 was found to be 200 
mg/mL, a much higher value than that of DOC (80 mg/mL). Checkerboard assay was 
performed to investigate interactions between FZ, VAN, and ox gall bile salts (Appendix 
A, Figure A- 2). In the two-way combinations of the ox gall bile salts with FZ or VAN, 
the FICI were both 1.02, indicating indifferent interaction in the double combinations. 
Three-way combination of ox gall bile salts, VAN, and FZ led to a modest decrease in 
the FICI (0.63), yet this value corresponds to an indifferent interaction. 
 
3.2.5 Interactions of lipoglycopeptides with FZ and DOC against E. 
coli 
Dalbavancin and oritavancin are two modified versions of VAN that have been reported 
to possess higher efficacy against Gram-positive bacteria and better safety profile than 
VAN (Crotty et al., 2016).  Given that they share the same mechanism of action with 
VAN, it was hypothesised that dalbavancin and oritavancin were also synergistic with FZ 
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and DOC in inhibiting Gram-negative pathogens. The highest achievable concentration 
of dalbavancin and oritavancin, due to limited solubility in media, is 200 μg/mL. This 
concentration was too low to inhibit the growth of E. coli ATCC 25922. The combination 
of 200 µg/mL dalbavancin or oritavancin with FZ (0.04 µg/mL) and DOC (625 µg/mL), 
resulted in the lowest FICI of <1.04, indicating indifferent interactions (Appendix A, 
Figure A- 3).  
 
3.2.6 In vitro cytotoxicity of FZ, VAN, and DOC combination is 
indifferent  
One advantage of repurposing drugs FZ, VAN, and DOC as a combination is that they 
are approved for clinical use in some form of human indication. This means that safety 
and toxicity studies have already been determined in a clinical setting. In this section, the 
cytotoxicity of the antibiotics and their combinations against HEK293T cell line was 
assessed. The purpose of this was not to investigate the toxicity of each of the drugs but 
rather to investigate the interaction of the drugs in terms of toxicity. 
The HEK293T cell line was treated with FZ, VAN and DOC alone and in combination 
for 48 h before performing a colourimetric MTT assay to measure cellular viability. The 
individual drug concentration-response curves for HEK293T cell line after 48 h of 
treatment are shown in Figure 17. The R package drc (Ritz et al., 2016) was used to fit a 
four-parameter log curve to identify the inhibitory concentration at different effects (20%, 
50%, and 90% inhibition). Up to 5000 g/mL of VAN was tested; however, this 
concentration did not achieve 90% HEK293T inhibition, hence the IC90 could not be 
determined (Figure 17B). For the subsequent FICI calculations at 90% inhibition, the 
highest tested VAN concentration, 5000 g/mL, was used as proxy to estimate the FICI. 
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IC20 = 2.7 ± 0.4 g/mL 
IC50 = 4.7  0.3g/mL 
IC90 = 11.6 ± 2.4 g/mL 
B 
 
IC20 = 918 ± 28 g/mL 
IC50 = 2853 ± 304 g/mL 
IC90 > 5000 g/mL 
                                             C 
 
IC20 = 30.1 ± 4.8 g/mL 
IC50 = 52.7 ± 3.1 g/mL 
IC90 = 94.4 ± 18.1 g/mL 
Figure 17. Concentration-response curves of FZ, VAN, and DOC on HEK293T 
The inhibitory concentrations (20%, 50%, and 90%) showing mean ± standard error of three biological 
replicates were determined from the curves fitted using non-linear regression models. 
 
Next, we investigated the interaction of FZ, VAN, and DOC in terms of cytotoxic effect. 
Cells were incubated with combinations of drugs at fixed ratios of the IC50 of FZ, VAN, 
and DOC, and the number of viable cells after treatment was estimated using MTT assay. 
At low and high toxicity effects (20%-90%), the FICI’s for the two-drug and three-drug 
combinations of FZ, VAN, and DOC ranged from 0.56 to 1.78, indicating indifferent 
interactions (Table 5).  
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Table 5. Concentrations (g/mL) that resulted in 20%, 50%, or 90% inhibition in 
HEK293T and the calculated FICI.  
 












FZ 2.70    
VAN  918   
DOC   30.10  
FZ+DOC 0.75  8.43 0.56 
FZ+VAN 1.36 827  1.4 
VAN+DOC  371 6.85 0.63 













FZ 4.70    
VAN  2853   
DOC   52.70  
FZ+DOC 2.35  26.35 1 
FZ+VAN 4.18 2539  1.78 
VAN+DOC  1170 21.61 0.82 













FZ 11.60    
VAN  >5000   
DOC   94.40  
FZ+DOC 4.47  50.07 0.92 
FZ+VAN 5.88 3566  <1.22 
VAN+DOC  2568 47.43 1.02 
FZ+VAN+DOC 2.82 1712 31.62 <0.92 
FZ, furazolidone; VAN, vancomycin; DOC, sodium deoxycholate; FICI, fractional inhibitory concentration 
index
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3.3 Discussion  
Novel effective therapies are urgently needed for Gram-negative bacteria, in particular, 
carbapenemase-producing A. baumannii and Enterobacteriaceae that top the list of WHO 
priority pathogens for which development of novel therapies is urgent. With the 
conventional approach of small molecule antibiotic development unable to keep pace 
with the continuing emergence and spread of multidrug resistance, alternative strategies 
are necessary to expand the therapeutic space. Synergistic combinations of currently 
available antibiotics show promise due to their enhanced activity with the advantage of 
improved clearance of pathogens, slowed-down resistance development, and decreased 
toxicity (Bollenbach, 2015).  
VAN and DOC, on their own, are not effective against Gram-negative bacteria, as 
evidenced by their high MICs. Due to the relative impermeability of the outer membrane, 
large antibiotics such as VAN are not able to reach their targets in Gram-negative bacteria 
(Hammes et al., 1974; Nieto et al., 1971). These bacteria have also evolved to be highly 
resistant to bile salts, including DOC (Gunn, 2000; Raphael et al., 2005; Paul et al., 2014). 
As shown in this study, a Gram-negative-active agent, nitrofuran, somehow undermines 
tolerance of these bacteria to VAN and DOC, thereby allowing the use of these 
antimicrobials to be expanded beyond Gram-positive bacteria.  
Because of the synergistic interaction, effective doses of individual drugs in the 
combinations have been significantly reduced. For example, in the reference strain E. coli 
ATCC 25922, the concentrations in the most synergistic triple combination are 16-fold, 
32-fold and 50-fold lower for FZ, DOC, and VAN, respectively, compared to 
monotherapy. This reduction is especially significant for drugs that have adverse effects, 
such as VAN and nitrofurans. The massive decline in the use of these drugs after their 
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introduction to the market is due to their toxicity. Adverse reactions of VAN, including 
nephrotoxicity and ototoxicity (Filippone et al., 2017; Forouzesh et al., 2009), are partly 
the reasons why this antibiotic is considered a last resort treatment for Gram-positive 
infections. Similarly, nitrofuran use has been controversial due to its mutagenicity (Vass 
et al., 2008). Harnessing of the synergy and using these antibiotics in a combination at 
low concentrations will allow the revival of these ‘old’ drugs due to the reduction or 
elimination of adverse effects.  
Since lipoglycopeptide antibiotics dalbavancin and oritavancin have better safety profiles 
than VAN, their use can be expanded beyond Gram-positive bacteria by employing them 
in the triple combination instead of VAN (Section 3.2.5). The combination of these 
lipoglycopeptides with FZ and DOC was tested, and it was found that at the highest 
soluble concentration in liquid media, dalbavancin and oritavancin are not inhibitory to 
E. coli. The FICI’s of these lipoglycopeptides could not be calculated because insolubility 
precluded determination of their MIC for E. coli. Using maximal soluble concentrations 
as proxies, checkerboard analyses showed at least indifferent interaction with FZ and 
DOC; synergistic interaction, however, cannot be excluded.  
Bile salts are present in the intestines. FZ is used to treat bacterial diarrhoea, and VAN is 
already available as an oral tablet to treat C. difficile diarrhoea and S. aureus enterocolitis. 
The combination, therefore, has a potential application in treating gastrointestinal 
illnesses. Because of its size and hydrophilicity, VAN is poorly absorbed in the 
gastrointestinal tract (Rao et al., 2011). This property is an advantage when treating 
localised gastrointestinal infections. VAN can be administered as a low dose of 500 
mg/day (125 mg qid) or as a high dose of >2000 mg/day (250mg or 500mg qid). A study 
has found that faecal concentrations of VAN, although affected by many factors, are 
generally proportional to the administered dosage. For 250 mg qid, faecal levels were 
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generally above 2000 mg/L, and for 500 qid, faecal concentrations are >4000 mg/L 
(Gonzales et al., 2010). In all cases, the poor absorption of VAN, as evidenced by high 
faecal concentrations, proves that the in vitro combination concentration against Gram-
negative bacteria that were identified in this study can be achieved in vivo by oral 
administration of VAN. The combination can, therefore, extend the use of VAN in 
gastrointestinal infections caused by Gram-negative bacteria.  
Bile salts are present along the gastrointestinal tract. To take advantage of the bile salts’ 
antibacterial activities in treating gastrointestinal infections, the combination of FZ, 
VAN, and a human-gut-like in vitro bile mixture (ox gall) was tested against E. coli, and 
it was found that this combination interacts indifferently (Section 3.2.4). These findings 
infer that components other than DOC  (e.g. other bile salts) of ox gall powder have 
antibacterial properties, which act only additively with FZ and/or VAN, and that the DOC 
content of ox gall powder is not sufficient to result in synergy. An important 
consideration, however, is that bile salts are deconjugated and dehydroxylated along the 
gastrointestinal tract after they are released from the gall bladder (Urdaneta et al., 2017). 
For that reason, ox gall powder may not be a suitable human bile model due to 
underrepresentation of DOC in comparison to the human intestines, where bile salt 
transformations lead to a higher DOC concentration. Notwithstanding this caveat, it can 
be concluded from the ox gall experiment that for treating gastrointestinal infections, 
DOC would need to be supplemented together with FZ and VAN to achieve the 
synergistic effect of the triple therapy. 
Another potential application of the combination is in topical applications, such as 
ointments and wound dressings. DOC is known to have hydrogel-forming capabilities, 
with many studies reporting the synthesis of different DOC-containing hydrogels with 
different properties (Valenta et al., 1999; McNeel et al., 2015; Guo et al., 2018). This 
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feature can be used to develop the combination as a hydrogel type ointment with DOC 
acting as the carrier system and as an antimicrobial. The FDA recently approved 
Kybella® (deoxycholic acid active ingredient) as a cosmetic injection for the reduction 
of submental fat. The maximum recommended single dose of Kybella® is 100 mg using 
10 mg/mL injections. Since the 10 mg/mL injections are considered safe, the most 
synergistic combination concentration of DOC (e.g. 2500 µg/mL in E. coli reference 
strain ATCC 25922) required to inhibit Gram-negative pathogens in vitro, can also be 
considered safe for topical use. The topical administration of VAN has also been explored 
in the past. VAN powder has been used topically to lower the rate of surgical site 
infections (Mallela et al., 2017). Additionally, its use in dressings has been tested in 
chronic wounds caused by Gram-positive infections such as MRSA and has been shown 
to reduce the bacterial load and achieve healing (Albaugh et al., 2013; Saif et al., 2019). 
The FZ, VAN, and DOC combination can be developed as a topical treatment for 
infections caused by both Gram-positive and Gram-negative pathogens.  
In addition to testing the combination in Gram-negative pathogens, we also investigated 
the drug interaction in Gram-positive bacteria that cause skin and soft tissue infections 
such as S. aureus and S. pyogenes (Section 3.2.3). Although the three molecules are not 
synergistic against Gram-positive pathogens, the individual MICs of DOC and VAN are 
very low in comparison to those for Gram-negatives (Table 4). The combination therapy 
effective against Gram-negatives will therefore contain at least two molecules at 
concentrations above the Gram-positive MIC and will therefore inhibit these latter 
organisms. The combination therapy could, therefore, be considered an alternative 
therapeutic option for the WHO priority pathogens such as MRSA. Besides these Gram-
positive bacteria, some Gram-negative pathogens, such as enterobacteria, can also cause 
skin and soft tissue infections, albeit at lower rates compared to Gram-positive pathogens 
CHAPTER 3 In vitro characterisation of nitrofurans, VAN,  
and DOC synergy against Gram-negative pathogens 
75 
(Moet et al., 2007). This study, showing indifference in Gram-positive bacteria and 
synergy against Gram-negative bacteria, provides evidence for the potential of the 
combination as a broad-spectrum treatment for Gram-negative and Gram-positive skin 
and wound infections.  
Lastly, the interaction of FZ, VAN, and DOC against HEK293T cell line was 
investigated. A crucial part of drug development is the characterisation of drug safety. To 
assess the balance between safety and efficacy, a therapeutic index, which is the ratio of 
toxic dose and effective dose, can be calculated. The FZ, VAN, and DOC combination 
has a synergistic efficacy (Section 3.2.1, Table 3) against Gram-negative pathogens and 
indifferent cytotoxicity (Section 3.2.6, Table 5). Therefore, using these in vitro findings, 
it is expected that the therapeutic index will increase when the drugs are used in 
combination compared to monotherapy. Although in vitro toxicity experiments can be a 
good alternative during early drug development, in vitro results does not always translate 
in vivo (McKim, 2010). For example, DOC’s IC50 against HEK293T cell line in this study 
is around 50 µg/mL, which is consistent with other in vitro cytotoxic effect studies of 
DOC and deoxycholic acid on cell lines (Wang et al., 2011; Gupta et al., 2009). In 
contrast, Kybella® whose active ingredient is deoxycholic acid is approved by the Food 
and Drug Administration for a maximum dose of 10 mg in 10 mg/mL subcutaneous 
injections, which is 200 the IC50 in the cell line model. Therefore, in this regard, the 
effect of the combination will still need to be assessed using in vivo animal models. 
As part of developing the combination as a clinical treatment, it is crucial to study the 
mechanism of synergy. Understanding how the drugs interact will explain why the 
combination is not synergistic in some Gram-negative strains. The mechanism of synergy 
between FZ and DOC was proposed to be mediated by inhibition of efflux pumps by FZ, 
which allows DOC to accumulate inside the cell (Le et al., 2020). In this study, we have 
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shown the lack of synergy between FZ, VAN, and DOC in Gram-positive bacteria, which 
further demonstrates that the presence of an outer membrane as a barrier to DOC and 
VAN is part of the mechanism of synergy in Gram-negative bacteria.   
In summary, this chapter presented the synergistic combination of FZ, VAN, and DOC 
against Gram-negative pathogens. The synergistic interaction allows the use of 
antimicrobials, such as VAN and DOC, that would otherwise be ineffective against Gram-
negative pathogens. Also, potential applications of the combinations were discussed such 
as treatment for gastrointestinal infections caused by enterobacteria, with the advantage 
of preventing antibiotic-associated C. difficile diarrhoea, and as a broad-spectrum topical 
treatment for skin and wound infections. Further work needs to be done, which includes 
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4.1 Introduction 
The previous chapter presented the synergistic interaction of nitrofurans, DOC, and VAN 
as a basis for combination therapy against susceptible Gram-negative pathogens. Their 
synergy in vitro has been characterised; however, the mechanism of synergy or how these 
antibacterials interact with each other to elicit a synergistic effect is currently unknown. 
To add to the problem, the exact mechanism of action of the two individual components, 
nitrofurans and DOC, are not fully understood. Nitrofurans and DOC have been reported 
to have variable effects on Gram-negative bacteria, depending on concentration. These 
include DNA damage (Ona et al., 2009; Merritt et al., 2009), protein aggregation 
(Cremers et al., 2014), and membrane damage (Begley et al., 2005). It is unclear, 
however, whether these effects are results of the direct attack on their targets (i.e. DNA, 
protein, membrane) or downstream effects upon interaction with their unknown target(s). 
In contrast, VAN’s mechanism of action and target in Gram-positive bacteria are well-
characterised, but its effects against Gram-negative bacteria are currently unknown. 
Several studies have challenged the existing notion that VAN, being a large hydrophilic 
molecule, cannot diffuse across the outer membrane nor be transported through porins of 
Gram-negative bacteria. Zhou et al. (2015) have proposed that small amounts of VAN 
can enter E. coli, which makes it possible for VAN to be synergistic with NIT (Zhou et 
al., 2015). Additionally, E. coli tolC and acrAB null mutants were reported to be more 
resistant to VAN, suggesting the possibility that VAN can penetrate the outer membrane 
through the AcrAB-TolC efflux pump complex (Krishnamoorthy et al., 2013; Weeks et 
al., 2010).  
In this study, a transcriptomics approach was employed to understand the mechanisms of 
action and synergy of the nitrofuran FZ, DOC, and VAN against a well-characterised 
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model Gram-negative bacterium, E. coli K12. This chapter presents the transcriptional 
responses of E. coli to these three antibacterials alone and in combination, and discusses 
the possible mechanistic bases of their synergy.   
4.2 E. coli K12 strain K1508 
E. coli K12 strain K1508 used in this study was derived from strain MC4100, but with a 
lamB (maltose outer membrane channel) deletion (Misra et al., 1988). Strain MC4100 is 
a commonly used K12 lineage in many genetic experiments, with a fully sequenced and 
annotated genome (Laehnemann et al., 2014). Based on similarities in genotypes and 
close genealogy, MC4100 genome could be used as the reference for this transcriptomics 
study, with only the lamB deletion to take into account. However, the MC4100 strain was 
constructed more than 40 years ago (Casadaban, 1976), and variations in stocks of K12 
strains between different laboratories are common. Henceforth, E. coli K1508 genome 
was analysed by sequencing in order to generate the sequence reference for the 
transcriptome study. Sequencing was carried out using 250-bp paired-end sequencing on 
the Illumina MiSeq platform, and variations between the MC4100 genome and K1508 
were detected using Pilon v1.23 (Walker et al., 2014). The MC4100 genome sequence 
and annotation (NCBI GenBank Accession: HG738867) were then modified based on the 
detected variants (Appendix A, Table A- 1), and the resulting genome and annotation 
(Appendix B, Supplementary file 1 and 2) were used as the reference for the study.  
E. coli K1508, like MC4100, harbours relA1 and spoT1 mutations. These two genes 
encode enzymes that regulate the levels of the alarmones guanosine 5′, 3′-
(bis)diphosphate (ppGpp) and guanosine 5′-triphosphate, 3′-diphosphate (pppGpp) 
involved in regulating the stringent response (Condon et al., 1995). RelA is a (p)ppGpp 
synthase, and SpoT is a bifunctional ppGpp synthase/hydrolase. The relA1 allele contains 
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an IS2 insertion in the relA gene that disrupts RelA (p)ppGpp-synthase activity (Metzger 
et al., 1989). As a consequence, E. coli strains containing this relA1 mutation display 
lower basal levels of (p)ppGpp than wild-type and do not accumulate (p)ppGpp in 
response to amino acid starvation (Lagosky et al., 1980). The spoT1 allele, on the other 
hand, contains missense mutations in the portion of the open reading frame (ORF) 
encoding the synthase domain and an in-frame insertion of six nucleotides, resulting in 
extra two amino acids in the hydrolase domain of the SpoT protein (Spira et al., 2008). 
This SpoT variant (spoT1), therefore has a disrupted SpoT (p)ppGpp-hydrolase activity 
and strains containing this spoT1 allele display elevated basal levels of (p)ppGpp 
compared to wildtype (Laffler et al., 1974). Together, however, these two alleles 
compensate for each other’s effect on (p)ppGpp levels, which was proposed to be the 
reason for strains evolving to have both alleles in their genome. Even with the 
counteracting effects of relA1 and spoT1 on (p)ppGpp levels, the more predominant effect 
is a higher basal level of (p)ppGpp compared to wildtype. Given that (p)ppGpp stimulates 
expression of the rpoS gene (Gentry et al., 1993; Kvint et al., 2000), the strains containing 
these two mutations contain higher levels of RpoS (Spira et al., 2008), the transcriptional 
regulator for general stress response, that is upregulated at the entry into the stationary 
phase of growth. Strains containing relA1 and spoT1 alleles, including K1508, are 
therefore considered to be a ‘relaxed’ strain (i.e. does not respond to amino acid starvation 
by initiating a stringent response) with increased stress resistance due to increased RpoS 
levels. 
Preliminary work to screen for the synergy between FZ, DOC, and VAN was performed 
using the rich growth medium 2xYT (instead of the standard MH broth). Stronger synergy 
has been identified in E. coli strain K1508 in 2xYT, with FICI of 0.13, instead of an FICI 
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of 0.5 in MH broth (Appendix A, Figure A- 4). For these reasons, this medium was chosen 
for the following transcriptomics study. 
4.3 Experimental design 
To determine drug concentrations to be used in the transcriptomics study, a concentration-
response (% inhibition) curve was plotted to identify the IC50 of the antibacterials on E. 
coli K1508. For the combination, the concentrations that gave the lowest FICI (most 
synergistic combination) in a checkerboard assay using 2xYT medium were first 
determined, then fixed-ratio dilutions of these concentrations were used to plot a 
concentration-response curve.  
A sublethal concentration (IC50) and a short incubation time were chosen to prevent the 
transcriptome profile being overwhelmed by stochastic expression of cell death genes. 
Cell death can lead to transcriptomic changes unrelated to the drug perturbations, and 
thereby confound the mechanism of action studies. The short incubation time also 
ascertains that the amino acid source in the medium is not exhausted, to avoid amino acid 
starvation, which strain K1508 cannot properly respond to. In addition, since gene 
expression is profoundly affected by growth (Klumpp et al., 2009), a time point when the 
treated samples were in exponential phase and were growing at a similar rate as the 
control was chosen for the transcriptome analysis in order to prevent differentially 
expressed genes arising from the difference in the growth phase of treated and untreated 
(control) samples. It was experimentally determined that these conditions are fulfilled one 
hour after drug addition (data not shown).  
The study has three main objectives: to investigate the (i) mechanism of action of FZ, 
DOC, and VAN individually, (ii) mechanism of the synergy of the combination of FZ, 
DOC, and VAN, and (iii) differences in effect on E. coli physiology when a drug is 
CHAPTER 4 Characterising the mechanism of action and synergy  
of FZ, VAN, and DOC against E. coli using transcriptomics 
 82 
applied individually vs in combination. The design consisted of eight treatments with four 
biological replicates each, totalling 32 samples. The treatments were control (vehicle 
only; 0.1% DMSO), IC50 concentrations of FZ, DOC, and VAN individually, the triple 
combination of FZ, DOC, and VAN that gave 50% inhibition, and the single drug controls 
for the combination (i.e. same concentrations used in the combination). The 
concentrations used and names of the analysed samples are summarised in Table 6.  
Analyses corresponding to the three objectives stated above were as follows: (i) Gene 
expression profiles of cultures exposed to single antibacterials (FZ, DOC, VAN) were 
first compared against the no-antibacterials control, and gene ontology (GO) term 
enrichment analysis was performed on the differentially expressed genes (DEGs; adj p < 
0.01, FC > 1.5) to identify perturbed pathways; (ii) The DEGs of the triple combination 
treatment (FZ+DOC+VAN) were analysed for enriched GO terms and compared with the 
results of the controls containing individual antibacterials at concentrations applied in 
combination (FZ 3d, DOC 3d, VAN 3d); (iii) Lastly, gene expression profiles for each of 
the individual antibacterials and the triple combination at IC50 (FZ, DOC, VAN, 
FZ+DOC+VAN) were compared to determine DEGs and pathways that are differentially 
expressed in the single antibacterials compared to the combination but have the same 
overall effect on bacterial growth.
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Table 6. Drug concentrations used in the transcriptomics study  
    Concentration (μg/mL) 
  Sample name Treatment FZ DOC VAN 









 FZ FZ IC50 1.9 0 0 
DOC DOC IC50 0 5000 0 







IC50 0.117 1875 7.5 
 FZ 3d FZ 3-drug control 0.117 0 0 
 DOC 3d DOC 3-drug control 0 1875 0 
 VAN 3d VAN 3-drug control 0 0 7.5 
FZ, furazolidone; DOC, sodium deoxycholate; VAN, vancomycin; IC50, 50% inhibitory concentration.
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4.4 Pre- and post-sequencing quality control 
The purified total RNA samples were analysed by electrophoresis to determine RNA 
quality before sequencing. There were two major bands expected for 23s and 16s rRNA 
at 2.9 kb and 1.5 kb, respectively, and fast-migrating bands (< 200 nt) corresponding to 
5s rRNA and tRNA. The samples showed no signs of genomic DNA or protein 
contamination, normally visible as bands running above the 23s rRNA band.  All the 
samples (Figure 18) appeared to be intact and had RNA integrity number higher than 9, 
according to LabChip® GX nucleic acid analyser (PerkinElmer). 
 
 
Figure 18. Integrity of the purified total RNA samples 
The qualities of the total RNA samples were analysed by gel electrophoresis in the LabChip GX nucleic 
acid analyser. All samples had an RNA integrity number higher than 9. Bands from top to bottom indicate 
23s rRNA, 16s rRNA, 5s rRNA, and tRNA. 
 
A principal component analysis (PCA) was performed to assess the overall similarity 
between the samples. PCA is a technique for dimensionality reduction or summarisation 
of the patterns of variation in the data. Before performing the PCA, a regularised log-
transformation was applied to the normalised counts to reduce the effects of few highly 
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within-group replicates clustered together, showing low variation between replicates. In 
terms of between-group variability, FZ, DOC, and FZ+DOC+VAN showed clear 
separation from the other groups, while VAN, FZ 3d, DOC 3d, and VAN 3d overlapped 
with the control. 
 
 
Figure 19. Principal component analysis 
PCA plot showing variation and clustering within and between treatment groups.  The axes show two 
principal components that explain the greatest proportion (73% and 8%) of variation in regularised log-
transformed normalised counts for all genes.  
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4.5 Results 
4.5.1 Transcriptional response to individual antibacterials  
FZ, DOC, and VAN applied individually at IC50 resulted in 1212, 1968, and 17 DEGs 
relative to the control, respectively (list of all DEGs is available in Appendix B, 
Supplementary file 4). Figure 20 shows these genome-wide expression changes of E. coli 
exposed to FZ, DOC, or VAN visualised as volcano plots to identify specific genes with 
large expression level differences and statistical significance. These plots show 
differences in RNA counts between antibacterial-containing cultures and no-antibacterial 
control as shrunken log2 fold changes (log2FCs) against the adjusted (adj) p values (see 
Chapter 2, Section 2.10); the red dots indicate DEGs. VAN treatment resulted in only 17 
DEGs. This small number of DEGs explains the overlap with the control in the PCA 
(Figure 19), that is based on expression levels of the vast majority of genes that are very 
similar in these two treatments.  
For FZ-treated samples, fhuF (ferric iron reductase), sodA (superoxide dismutase), and 
dinI (DNA damage inducible protein I) were among the most upregulated, while glp 
regulon genes (involved in glycerol and glycerol-3-phosphate catabolism) and nanC 
(encoding an outer membrane channel protein) were among the most down-regulated. For 
DOC-treated samples, the most upregulated gene is grxA (glutaredoxin) and among the 
most upregulated are the translation-related genes leuV, aspV, valW, proM, serT, and 
glyY. 
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Figure 20. Genome-wide expression changes in response to individual antibacterials 
(A) FZ, (B) DOC, or (C) VAN at the respective IC50 concentrations (compared to control). The scatter plots 
display the shrunken log2FCs and the adjusted p values. Red dots represent significantly differentially 
expressed genes (adjusted p < 0.01, |log2FC| > 0.58) relative to control, with numerical annotations to 
indicate the number of differentially expressed genes. The ten most upregulated, downregulated, and 
statistically significant genes are labelled in each plot. 
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The sets of differentially up- (log2FC > 0.58) and downregulated genes (log2FC < 0.58) 
for FZ and DOC treatments were also separately analysed for significantly enriched GO 
term annotations (Appendix B, Supplementary file 5). In FZ-treated samples, the second 
most enriched GO term for upregulated genes is SOS response, the canonical response to 
severe DNA damage. GO terms associated with ribosome assembly, iron uptake, and 
translation are significantly enriched in both FZ and DOC upregulated genes  (Figure 
21A). On the other hand, cellular respiration, carbohydrate transport, and tricarboxylic 
acid (TCA) cycle are enriched in the downregulated genes (Figure 21B).  
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Figure 21. Gene ontology term enrichment analysis of FZ and DOC DEGs  
Significantly overrepresented (FDR < 0.05) biological process GO terms in FZ and DOC (A) upregulated 
and (B) downregulated DEGs (adj p < 0.01, |log2FC | > 0.58) using PANTHER GO overrepresentation test. 
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4.5.2 Transcriptional response to FZ, DOC, and VAN combination 
FZ+DOC+VAN combination resulted in 1384 DEGs, while FZ 3d, DOC 3d, and VAN 
3d alone at the same concentration resulted in 3, 119, and 1 DEGs, respectively (list of 
all DEGs is available in Appendix B, Supplementary file 4). Figure 22 shows the volcano 
plots for FZ+DOC+VAN and its 3-drug controls. The low numbers of DEGs in FZ 3d, 
VAN 3d, and DOC 3d alone explains their overlap with the control samples, as shown in 
the PCA (Figure 19).  
 
 
Figure 22. Genome-wide expression changes in response to triple FZ+DOC+VAN 
combination 
The scatter plots display the shrunken log2FCs and the adjusted p values (Benjamini-Hochberg). Red dots 
represent significantly differentially expressed genes (adj p < 0.01, |log2FC| > 0.58) relative to control, with 
numerical annotations to indicate the number of differentially expressed genes. The ten most upregulated, 
downregulated, and statistically significant genes are labelled in each plot. 
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As presented in the volcano plots (Figure 22), the synergy of the combination was 
evidenced by the number of DEGs in the combination being more than the sum of DEGs 
when each antibacterial was applied alone at the same absolute concentrations (FZ 3d, 
DOC 3d, or VAN 3d). Physiologically, the synergy is reflected by the growth-inhibitory 
effect of FZ+DOC+VAN combination and the lack thereof in FZ 3d, DOC 3d or VAN 
3d cultures. The most upregulated genes in the cultures containing FZ+DOC+VAN 
combination were serT  (serine tRNA) and valW (valine tRNA), whereas the most 
downregulated were nanC and genes belonging to the glp regulon The only DEGs for FZ 
3d were lpp (major outer membrane lipoprotein), dinQ (uncharacterised protein whose 
expression is DNA damage-inducible), and hupB (DNA-binding protein), while the only 
DEG for VAN 3d was eda, a gene encoding a multifunctional aldolase enzyme. Lastly, 
the majority (~80%) of DOC 3d DEGs fall within those seen for the combination (Figure 






Figure 23. Overlap of DEGs between FZ+DOC+VAN IC50 combination and single 
antibacterials at the same concentrations used in the combination 
Venn diagrams show the numbers of (A) upregulated and (B) downregulated DEGs in response to 
FZ+DOC+VAN treatment and the 3-drug controls.  
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4.5.3 Comparison of differentially expressed gene clusters in the 
presence of combination and single antibacterials at IC50 
To analyse in more detail the physiological proceses affected by combination and single 
antibacterials at IC50, all DEGs were subjected to K means clustering analyses using the 
identified optimal K number (K=7), and the resulting clusters were subjected to GO term 
enrichment analysis. The heatmap and GO terms enriched in each cluster are shown in 
Figure 24.  
As shown in the heatmap, the combination resulted in the same pattern of regulation of 
gene clusters as cultures containing only FZ or DOC. For example, the FZ+DOC+VAN 
combination upregulated genes involved in ribosome assembly, translation (Cluster 2), 
and amino acid transport (Cluster 4), and downregulated genes encoding enzymes of TCA 
cycle (Cluster 7) and those encoding proteins involved in carbohydrate transport (Cluster 
3), similar to cultures containing only FZ or DOC.  
An important difference between the FZ and triple combination is that the former 
upregulated SOS response genes (Cluster 5) indicative of DNA damage and the latter 
failed to induce these responses, reflecting a significantly decreased DNA damage in the 
presence of triple combination. It is noticeable, however, that the changes in expression 
of some of the gene clusters (e.g. Cluster 3, 4, and 6) are not as pronounced in the presence 
of the triple combination compared to the single-antibacterials cultures.  
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Figure 24. Heatmap of DEG clusters and GO term enrichment.  
K means clustering was performed on the regularised log-transformed normalised counts of all the DEGs 
in FZ, DOC, VAN, and FZ+DOC+VAN. The model-based optimal number of K (K=7) was determined a 
priori. The colours in the map represent row-scaled expression levels: blue indicates the lowest expression, 
white indicates intermediate expression, and red indicates the highest expression. Each cluster was 
subjected to PANTHER biological process GO term overrepresentation test and the tops 5 enriched GO 
terms are shown along with their false discovery rates (FDR). 
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4.5.4 Extracytoplasmic stress response to VAN treatment 
GO term enrichment analysis of all the 17 DEGs detected in the cultures exposed to VAN 
at IC50 (Table 7) resulted in no overrepresented GO terms. Perturbed pathways were 
therefore identified based on the transcriptional master regulators of all the DEGs. Most 
of the DEGs were found to belong to one or more stress response regulons, most 
frequently Rcs (11 genes), followed by S (3), Cpx (2), and Lrp (2), with only one gene 
each belonging to Bae and 32. Of the induced pathways, three (Rcs, Cpx and Bae) 
respond to envelope stresses. Upregulation of these pathways is in agreement with the 
VAN target in Gram-positive bacteria, peptidoglycan synthesis (Hammes et al., 1974), 
known to induce cell envelope stress (Jordan et al., 2008). 
 
Table 7. Significantly differentially expressed genes in response to VAN treatment 


















Periplasmic chaperone Spy 
Uncharacterised periplasmic protein YcfJ 
Osmotically-inducible lipoprotein B 
Inner membrane protein YaiY 
Glycine tRNA 
Biofilm dependent modulation protein 
Uncharacterised protein YpeC 
Uncharacterised protein YaaX 
Uncharacterised protein YgaC 
Regulator of capsular synthesis 
Uncharacterised protein YpfG 
Heat shock protein HslJ 
Uncharacterised protein YmgD 
Inhibitor of vertebrate lysozyme 





































aND, regulators not determined 
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4.5.5 SOS response to FZ treatment 
FZ upregulated the SOS response and DNA repair genes as shown in Figure 25. These 
genes are part of the LexA regulon which responds to DNA damage (Fernández de 
Henestrosa et al., 2000; Lewis et al., 1994; Walker, 1984). Some of these genes encode 
proteins that function in nucleotide excision repair (uvr, ruv), homologous recombination 
(rec), translesion synthesis (umuC, umuD, dinB, polB), and delayed cell division (sulA); 
the upregulation of which are indicative of the induction of the SOS response of E. coli. 
 
 
Figure 25. Differential expression of genes involved in SOS response 
The heatmaps show the log2FC of the  DEGs in cultures containing a single antibacterial (FZ or DOC), and 
the triple combination (FZ+DOC+VAN). Significant genes have adjusted p < 0.01. 
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4.5.6 Iron starvation responses 
FZ and DOC induced the iron starvation response. Upregulated genes were enriched in 
Fe2+ uptake and siderophore-dependent Fe3+ uptake, such as feo for Fe2+ uptake, ent for 
enterobactin synthesis and export, exbB, exbD, tonB, fhu, fep, and fec for ferri-siderophore 
complex uptake (Figure 26A). Fe-S cluster biogenesis genes, isc and suf (Figure 26B) 
were also upregulated, indicating an increased need for Fe-S cluster biogenesis and repair.  
Another response to iron starvation is down-regulation of genes relating to iron storage 
and non-essential iron-containing proteins. FZ and DOC downregulated the iron storage 
genes ftnA and bfr. Additionally, ryhB expression was upregulated, and RyhB sRNA-
mediated inhibition of iron-utilising proteins could explain the down-regulation of sodB 
(Fe-containing superoxide dismutase), and the respiratory genes nuo, frd, sdh, hyb, and 
cyd (Desnoyers et al., 2009; Massé et al., 2002; Massé et al., 2005).  
Upregulation of iron uptake genes, Fe-S cluster biogenesis genes, oxidative stress genes, 
and downregulation of genes encoding non-essential iron-containing proteins and iron 
storage, all point to the Fur inactivation induced by FZ and DOC. Interestingly, this effect 
is less pronounced in FZ+DOC+VAN, with most of the iron import DEGs of FZ- and 
DOC-containing cultures not statistically significant in the combination, albeit also 
upregulated (Figure 26). 
CHAPTER 4 Characterising the mechanism of action and synergy  
of FZ, VAN, and DOC against E. coli using transcriptomics 
97 
 
Figure 26. Differential expression of genes involved in iron import and iron-sulfur 
cluster assembly 
The heatmaps show the log2FC of the DEGs in cultures containing a single antibacterial (FZ or DOC), and 
the triple combination (FZ+DOC+VAN). Significant genes have adjusted p < 0.01. 
CHAPTER 4 Characterising the mechanism of action and synergy  
of FZ, VAN, and DOC against E. coli using transcriptomics 
 98 
4.5.7 FZ and DOC upregulation of protein synthesis 
FZ, DOC, and the triple combination FZ+DOC+VAN upregulated a shared set of genes 
enriched for those encoding ribosome proteins and enzymes involved in protein synthesis 
(Figure 27). The rps and rpl genes encoding ribosomal small and large subunit proteins 
and translation-related genes were upregulated. The ribosomal/translational machinery 
requires both an abundance of amino acids and ATP. It is, therefore expected that 
increased cellular ATP is needed to increase ribosomal gene transcription, and subsequent 
increase in ribosomes for translation (Schneider et al., 2002; Gaal et al., 1997). For these 
reasons, it is not surprising that RNA polymerase (rpoABC), and amino acid transport 
genes were also upregulated, in agreement with the abundance of amino acids needed by 
the upregulated production of translational machinery. 
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Figure 27. Upregulation of genes encoding protein synthesis machinery 
The heatmaps show the log2FC of the DEGs in cultures containing a single antibacterial (FZ or DOC), and 
the triple combination (FZ+DOC+VAN). Significant genes have adj p < 0.01. 
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4.5.8 Downregulation of the electron transport chain and central 
carbon metabolism 
FZ and DOC both downregulated genes involved in the central carbon metabolic 
pathways such as glycolysis, pentose phosphate pathway, and TCA cycle, as shown in 
Figure 28. Additionally, these two antibacterials, when applied individually, also resulted 
in the downregulation of genes encoding dehydrogenase and oxidoreductase genes of the 
ETC/respiratory chains (Figure 28). Some of the genes encoding NADH dehydrogenase 
I (nuoABCDEFGHIJKLMN), glycerol-3-phosphate dehydrogenase (glpABC), formate 
dehydrogenase (fdnGHI), hydrogenase I (hyaABC), and hydrogenase II (hybABC) were 
downregulated. Similarly, quinol oxidase bd-I (cydAB), periplasmic nitrate reductase 
(napFDAGHBC), nitrate reductase (nrfABCDEFG), nitrate reductase A (narGHJI), 
DMSO reductase (dmsABC), TMAO reductase (torACD), fumarate reductase (frdABCD), 
and quinol oxidase bd-II (appBC) were downregulated. Most of these genes encode 
proteins from the DMSO reductase family of molybdoenzymes: Nitrate, TMAO, DMSO 
reductases, and formate dehydrogenase. Downregulations of these molybdoenzyme genes 
could then explain the lowered expression of genes involved in molybdate uptake 
(modABC) and molybdopterin cofactor synthesis (moa, mob, moc, mog), which suggest 
a decreased need for molybdenum. Interestingly, the triple combination 
(FZ+DOC+VAN) caused changes of the same direction as FZ and DOC alone, however, 
these were less pronounced (mostly not statistically significant).  
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Figure 28. Downregulation of  the central carbon metabolism and electron 
transport chain 
The heatmaps show the log2FC of the  DEGs in containing a single antibacterial (FZ or DOC), and the 
triple combination (FZ+DOC+VAN). Significant genes have adjusted p < 0.01. 
CHAPTER 4 Characterising the mechanism of action and synergy  
of FZ, VAN, and DOC against E. coli using transcriptomics 
 102
4.5.9 Oxidative stress 
FZ and DOC treatment resulted in changes in the expression of genes of the OxyR and 
SoxRS regulons, indicative of oxidative stress (Figure 29). SoxS-regulated sodA, which 
is involved in eliminating superoxide, was upregulated in both FZ and DOC. In the FZ-
treated samples, the usual OxyR-regulated genes that protect the cell from H2O2 toxicity 
such as ahpCF were not differentially expressed. In addition, the expression of katG, a 
catalase that eliminates H2O2 via degradation to water and oxygen, and dps, a protector 
of DNA to the effects of oxidative stress (Choi et al., 2000), were downregulated. Unlike 
FZ, DOC upregulated OxyR-regulated genes ahpC, ahpF, katG, dps, grxA and trxC 
indicative of H2O2 stress.   
 
4.5.10 Antibiotic-induced resistance mechanisms 
FZ and DOC, besides inducing stress related to their antibacterial effect, also induce 
transcriptional responses that favour increased resistance by increasing the capacity for 
expulsion of antibacterials out of the cells. Multiple antibiotic resistance (mar) genes 
marA and marB, of which the former is a master regulator of large number of genes 
involved in increased antibiotic resistance, were overexpressed in all three cultures. 
Among the efflux pumps, acrA and acrB were upregulated in the presence of DOC, by 
more than two-fold (Figure 29).  AcrAB, along with TolC, makes up a key multidrug 
efflux pump and an essential mechanism for resistance to multiple antibiotics (Okusu et 
al., 1996; Nikaido et al., 2008). Besides upregulation of the efflux pumps, E. coli also 
responds to antibiotic stress by altering the expression of outer membrane porins, such as 
OmpF and OmpC. FZ downregulated both ompC (~1.6-fold) and ompF (~3.3-fold), while 
DOC downregulated ompF by more than 2-fold.  
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Figure 29. Differential expression of genes involved in oxidative stress and 
antibiotic-induced resistance mechanisms  
The heatmaps show the log2FC of the  DEGs in cultures containing a single antibacterial (FZ or DOC), and 
the triple combination (FZ+DOC+VAN). Significant genes have adj p < 0.01. 
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4.6 Discussion 
The synergistic combination of nitrofurans, DOC, and VAN was shown in Chapter 3 to 
be a promising approach to tackle antimicrobial resistance. However, the underlying 
mechanism for their synergy was unknown. Although the interactions between drugs 
cannot always be inferred or predicted from the individual components’ mechanisms of 
action (Ankomah et al., 2013), knowledge of these individual modes of action can help 
with understanding the mechanistic basis of synergy.  
 In Gram-positive bacteria, VAN binds to its target D-Ala-D-Ala of Lipid II and inhibits 
the peptidoglycan synthesis (Liu et al., 1994; Hammes et al., 1974). Gene expression 
analyses of E. coli treated with the peptidoglycan synthesis inhibitors, such as β-lactam 
antibiotics (Laubacher et al., 2008) and colicin M (Kamenšek et al., 2013), showed 
upregulation of the Rcs-regulated genes, including the set of DEGs in Table 7. 
Furthermore, the transcriptomic response of an E. coli strain with a compromised outer 
membrane to VAN also showed differential expression of Rcs pathway genes (O’Rourke 
et al., 2020). In another study, growth of E. coli at low temperatures was found to increase 
susceptibility to VAN. This increased susceptibility can be suppressed by heterologous 
expression of Enterococcus VAN resistance cluster (vanHBX), suggesting a mechanism 
of action through inhibition of peptidoglycan synthesis, same as in Gram-positive bacteria 
(Stokes et al., 2016). Results from this study, along with the abovementioned published 
findings, support the notion that VAN can enter E. coli, and exert the same peptidoglycan 
synthesis inhibition that induces envelope stress and activates the Rcs pathway.  
Based on all the findings presented in this study, FZ and DOC seem to have highly 
correlated target pathways that result in almost the same transcriptional perturbations in 
the same biological processes. Computational approaches to explore drug combination 
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network interactions suggest that drugs that target functionally related pathways or have 
directly connected targets are more likely to lead to a synergistic effect.  (Wang et al., 
2012; Zou et al., 2012; Chen et al., 2016). FZ+DOC+VAN affected the same pathways 
as did FZ and DOC when applied alone; production of ribosome components and 
translation were induced, while the central carbon metabolism and carbohydrate 
transport/uptake were downregulated. FZ and DOC monotherapy also affected iron 
uptake and respiratory chain/ETC genes, but the combination’s effects on these pathways 
were less pronounced. Of importance is the lack of SOS induction in the combination, 
which indicates the absence of major DNA damage. This could be attributed to the 
significantly reduced dose of FZ in the combination or another mechanism that suppresses 
FZ-induced DNA damage. Since increased frequency of mutation results in higher 
frequency of resistance, and DNA damage in eukaryotic (host) cells is known to lead to 
oncogenesis (Hiraku et al., 2004; Olive et al., 1977), this finding highlights the advantage 
of using the combination over FZ or another nitrofuran alone, in terms of mitigating 
mutagenicity in bacterial cells or DNA damage to the eukaryotic cells. 
Based on the transcriptomics data presented in this chapter, target pathways that are either 
affected or induced in response to FZ, DOC, and VAN in E. coli can be traced, and their 
interactions leading to synergy can be proposed (Figure 30). FZ and DOC both resulted 
in the upregulation of genes encoding iron uptake systems and downregulation of those 
encoding iron storage and iron-utilising proteins (Section 4.5.6). These results are 
indicative of iron limiting conditions or inactivation of the transcriptional regulator Fur 
caused by the presence of FZ or DOC. The induction of iron uptake mechanisms in 
response to DOC is consistent with a microarray study by Hamner et al. (2013), where 
bile salt treatment of enteropathogenic E. coli in vitro resulted in increased expression of 
iron acquisition genes. The authors have proposed that bile acted as a signal for the iron-
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restricted host intestinal environment. It still remains to be elucidated, however, whether 
bile salt physiologically causes iron imbalance in vitro, to which E. coli responds 
appropriately, or if it is instead (or in addition) a signal activating the iron uptake 
response, notwithstanding the iron starvation. Similarly, these findings are consistent with 
a microarray study by Fu et al. (2007) of FZ-treated Shigella flexneri, which showed an 
upregulation of iron uptake genes. Currently, the mechanism by which FZ disturbs the 
iron homeostasis remains unknown. 
The iron-sparing mechanisms that are induced by Fur inactivation or iron limitation also 
result in the downregulation of iron-containing proteins such as respiratory enzymes 
(Massé et al., 2005). Both FZ and DOC downregulated genes encoding ETC proteins 
including NADH dehydrogenase I (encoded by multiple nuo genes) and cytochrome bd-
I (encoded by multiple cyd genes) (Figure 28). NADH dehydrogenase I (containing FeS 
centres) and cytochrome bd-I ubiquinol oxidase (containing FeS centres and 
cytochromes) are two primary proton-translocating complexes of the ETC, and therefore, 
generators of PMF.  Downregulation of the nuo and cyd genes by both FZ and DOC could 
lead to the dissipation of PMF which powers multiple multidrug efflux pumps. Another 
cause for reduction of the number of proton-transferring complexes could be the failure 
to assemble Fe-S clusters (centres) within NADH dehydrogenase I, ultimately caused by 
potential inactivation of Fur. Low Fur leads to the switch from the Isc to Suf machinery 
for Fe-S cluster biogenesis (Mettert et al., 2014; Lee et al., 2008). The Suf system was 
reported to be insufficient for maturation of multi-Fe-S-complex-containing Nuo protein, 
the key component of NADH dehydrogenase I, whose further depletion in this way likely 
leads to diminished PMF (Ezraty et al., 2013). Given that PMF is directly or indirectly 
required for the function of efflux pumps, low PMF is conducive for the accumulation of 
DOC and FZ inside the cells by preventing their efflux. These findings support a previous  
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Figure 30. Proposed interaction of FZ, DOC, and VAN that leads to synergy  
FZ and DOC upregulated iron uptake and downregulated iron-utilising respiratory chain, indicative of Fur 
inactivation. Downregulation of genes involved in the electron transport chain likely leads to the 
diminishing of the proton motive force that powers efflux pumps, which in turn, could lead to the inhibition 
of efflux and accumulation of FZ and DOC inside the cells. Moreover, transcriptomic data by O’Rourke et 
al. (2020) showed that VAN downregulates SOS response genes. This effect would contribute to synergy, 
as the failure to repair major lesions caused by DNA-damaging effects of FZ and DOC would indeed result 
in bacterial death. Lastly, FZ and DOC downregulated the central carbon metabolism, an effect commonly 
observed in bacteriostatic antibiotics. Red, blue, and green indicate effects specific to FZ, DOC and VAN, 
respectively, whereas purple indicates effects that are common to FZ and DOC. Black lines indicate known 
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study in which the deletion of tolC resulted in the loss of synergistic interaction between 
FZ and DOC, suggesting the importance of efflux in the synergistic interaction (Le et al., 
2020).  
Another effect observed in both FZ- and DOC-containing cultures is oxidative stress 
(Section 4.5.9). If these drugs disrupt Fur protein leading to its loss of 
function/inactivation, the labile Fe2+ iron pool will be in excess, and Fe2+ can catalyse the 
Fenton reaction and produce ROS that causes oxidative stress and DNA damage leading 
to the SOS response (Imlay et al., 1988). In this study, FZ treatment only showed 
induction of superoxide response genes, while DOC showed induction of both superoxide 
and hydrogen peroxide stress responses (Figure 29). An important fact to consider is that 
the lack of change in the expression of ahpCF and the downregulation of dps and katG in 
FZ-treated E. coli does not necessarily mean that there is no H2O2 stress. The observed 
downregulation of katG and dps could be a downstream result of another FZ effect such 
as iron starvation. For example, KatG is a protein that uses heme as a cofactor, and under 
iron starvation, heme synthesis and utilisation could be limited. Additionally, since OxyR 
activation is known to be H2O2 concentration-dependent (González-Flecha et al., 1997; 
Seaver et al., 2001), it is possible that the H2O2 concentration at the sample collection 
timepoint is still below the concentration needed to activate OxyR. Another possibility is 
that FZ only results in the production of low levels of H2O2 that is quickly detoxified by 
basal H2O2 scavenging enzymes, hence there is no need to activate the OxyR regulon. In 
Shigella flexneri, however, FZ was shown to upregulate the expression of ahpC and ahpF, 
which indicates the presence of H2O2 stress (Fu et al., 2007).  
In terms of DNA damage, as predicted, FZ treatment led to the induction of the SOS 
response (Section 4.5.5), consistent with the DNA-damaging effects of nitrofurans that 
have been reported extensively. FZ and NIT were shown to cause filamentation in 
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Salmonella due to inhibition of cell division that occurs during SOS response (Chadfield 
et al., 2004). The DNA damage has been speculated to be caused by the reactive 
byproducts and intermediates of nitrofuran reduction. For example, superoxide, produced 
during Type II nitroreduction (Chapter 1, Figure 6), can readily transform to DNA-
damaging hydroxyl radical (Imlay et al., 1988), and hydroxylamine derivatives, produced 
during Type I nitroreduction (Chapter 1, Figure 5), are reported to cause DNA damage 
and mutagenicity (Stolarski et al., 1987; Sakano et al., 2004; Yamamoto et al., 1993). 
α,β-unsaturated nitriles can also be formed (Hall et al., 2011), and these derivatives have 
the same Michael acceptor property as α,β-unsaturated carbonyls, which are known 
inducers of DNA damage and mutagenesis (Janzowski et al., 2003; Eder et al., 1993; 
Eder et al., 1990).  
DOC, on the other hand, only resulted in significant differential expression of a few genes 
involved in DNA repair (Section 4.5.5, Figure 25): Only four genes, recX, ruvC, recQ, 
and dinF were upregulated by more than 1.5-fold (log2FC > 0.58), while lexA, cho (uvrC 
homologue), and dinI were statistically significant (adj p < 0.01), but were only 
differentially expressed by less than 1.5-fold. ROS generation and DNA damage have 
been reported to be induced by bile salts in bacteria such as Campylobacter (Negretti et 
al., 2017) and Salmonella (Walawalkar et al., 2016). Using reporter genes, DOC was also 
found to induce dinD, a gene associated with DNA damage, in E. coli (Bernstein et al., 
1999). It is, therefore, not surprising that Salmonella and Campylobacter DNA repair 
mutants (e.g. recBCD, addAB) are more sensitive to DOC in comparison to the wildtype 
parents (Prieto et al., 2006; Gourley et al., 2017). The absence of the upregulation of most 
genes involved in SOS response and DNA repair during the first 60 min of exposure to 
DOC, may be due to premature sampling, if the effect of DOC is secondary and requires 
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longer incubation time. Alternatively, the concentration of DOC may have been too low 
to induce the required level of DNA damage for an SOS response.  
FZ and DOC both downregulated the central carbon metabolic pathways (Section 4.5.8, 
Figure 28). This effect could be a result of the drop in the proton-pumping ETC 
complexes. Due to less energy demand and lower NADH use, the central carbon 
metabolism could be downregulated through metabolite feedback mechanisms. This 
effect is commonly observed in bacteriostatic antimicrobials, which inhibit growth by 
reducing cellular metabolism. FZ and DOC at inhibitory concentrations are bactericidal. 
The concentrations used in this study are subinhibitory, and since the exact modes of 
action of these two antibacterials are not fully understood, bacteriostatic action at these 
concentrations cannot be ruled out. A microarray study of bacteriostatic translation 
inhibitors kasugamycin and puromycin in E. coli showed downregulation of genes of the 
glycolytic, pentose phosphate pathway, and TCA cycle (Sabina et al., 2003). Also, 
chlortetracycline, which is another bacteriostatic translation inhibitor, showed 
downregulation of similar metabolic proteins in an E. coli proteome study (Lin et al., 
2014). 
FZ and DOC also resulted in the upregulation of genes encoding ribosomal proteins and 
other components of translation machinery (Section 4.5.7). Since samples were collected 
at a time point when the growth rate of treated samples is similar, if not lower, than that 
of the untreated samples, the upregulation of ribosomal and translation genes in the 
treated samples cannot be attributed to increased growth rate. A similar effect has been 
reported by Mathieu et al. (2016) in E. coli treated with sublethal concentrations of 
antibiotics (ampicillin, norfloxacin, and gentamicin). These antibiotics have different 
mechanisms of action; however at sublethal concentrations (
1
2
 MIC), they elicited the 
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same increase in ribosomal and translational capacity and increased energy production, 
all while growth rates were identical to the untreated samples. The authors have proposed 
that, at sublethal concentrations, the antibiotics trigger a response in E. coli whereby it 
maintains growth, along with cell repair and maintenance as long as sufficient nutrients 
are present (Mathieu et al., 2016). This hypothesis could explain the increased expression 
of ribosome and translation genes at sublethal FZ and DOC concentrations used here. 
Similar to the abovementioned report, at the time point of sample collection, the 
antibacterial-containing cultures had an almost identical growth rate as no-antibacterial 
controls, showing that the cells were keeping up with rapid growth all while dealing with 
stress and damage induced by the antibiotics. 
This effect is also commonly observed in cultures with protein synthesis inhibitors and 
acts as a counteracting mechanism to the reduced translational activity, enabling the cells 
to keep the pace of protein synthesis at low levels of translation inhibition (O’Rourke et 
al., 2020; Sabina et al., 2003; Lin et al., 2014; Dennis, 1976). Reactive intermediates of 
nitrofurans have been reported to bind ribosomal protein subunits and rRNA non-
specifically; this interaction was proposed to cause translation inhibition (McOsker et al., 
1994; Yu et al., 1976). DOC, on the other hand, was demonstrated to be able to aggregate 
proteins (89 total); 23  of which were ribosomal and other translation machinery proteins 
(Cremers et al., 2014). FZ and DOC have also been reported to result in the production 
of ROS, which are major sources of damage to macromolecules, primarily nucleic acids 
(Liu et al., 2012). ROS have been shown to damage rRNA and inhibit the ribosome during 
protein synthesis (Willi et al., 2018). Additionally, Zhong et al. (2015) reported a 
reduction of tRNA levels during oxidative stress that resulted in the deceleration of 
translation. In conclusion, direct FZ and DOC effects on ribosomal and translation 
proteins via aggregation, together with effect on rRNA via ROS, result in translational 
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stress, to which E. coli responds by increasing the expression of translation and rRNA 
synthesis genes, as observed in FZ and DOC treatment.  
The synergy between FZ and DOC is apparent in their correlated transcriptional 
responses. One way in which synergy can arise is if one drug inhibits the resistance 
mechanism(s) of the other, such as in the case of β-lactams and β-lactamase inhibitors 
(Kobayashi et al., 1989). Cultures containing DOC alone and the FZ+DOC+VAN 
combination both upregulated the expression of efflux pump component genes, acrA and 
acrB (Figure 29). Although in this study upregulation of acrA and acrB by FZ was not 
statistically significant, upregulation of these genes by FZ has been reported previously 
(Fu et al., 2007). Upregulation of efflux pumps will prevent the accumulation of these 
antibacterials inside the cells. In this instance, synergy could arise through the combined 
effect of FZ and DOC in diminishing the PMF, in turn, de-energising the efflux pumps 
and preventing drug efflux. This mechanism allows the accumulation of drugs inside the 
cell and exertion of their effects on their targets. 
This study only uncovered 17 genes that are affected significantly by VAN. Therefore, it 
is difficult to draw conclusions on the possible sources of synergy from VAN effects. 
DOC is known to disrupt the outer membrane (Begley et al., 2005) and even integrate 
into membranes and form aqueous channels in which hydrophilic molecules can pass 
(Gordon et al., 1985). It is possible that membrane disruption by DOC allows more VAN 
to enter and exert its effect. Using the transcriptomics data by O’Rourke et al. (2020), 
who investigated the transcriptional response of an E. coli strain with a compromised 
outer membrane to various antibiotics including VAN, another pathway affected by VAN 
was revealed. Biological process GO term enrichment of significantly downregulated 
genes (FDR < 0.01, log2FC < 0) using PANTHER showed SOS response to be 
overrepresented. The SOS response genes downregulated by VAN in the O’Rourke et al. 
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dataset are umuC, umuD, uvrB, uvrC, uvrD, recN, dinB, dinG, polB, cho, and sulA. 
Downregulation of these genes could then explain the synergy between NIT and VAN 
reported by Zhou et al. (2015), who hypothesised that VAN must increase DNA-
damaging effects when combined with DNA-damaging agents (NIT or trimethoprim), 
thereby eliciting a synergistic effect. If VAN exerts the same inhibition of SOS/DNA 
repair in wildtype E. coli, this effect would contribute to the triple synergy through 
amplification of the FZ and DOC DNA-damaging effects.  
In summary, this chapter searched for the possible mechanistic bases of the synergy 
between FZ, DOC, and VAN using a transcriptomics approach. The transcriptional 
responses shed light on the modes of action of FZ and DOC, whose primary targets are 
most likely multiple. In the absence of a single target, it was impossible to precisely 
determine which are the target effects and which are the downstream responses for these 
two antibacterials. Nonetheless, by analysing the highly correlated perturbed pathways of 
FZ and DOC, in combination with VAN effects, it was possible, based on identified 
changes in gene expression, to formulate hypotheses on the mechanisms involved in the 
suppression of resistance and amplification of damaging effects. Some of these will be 
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5.1 Introduction 
Chapter 4 presented the transcriptomic response of E. coli to single antibacterials (FZ, 
DOC, or VAN) and their triple combination. Results showed the lack of SOS response 
induction in the combination despite strong induction in cultures containing FZ alone, 
highlighting the advantage of synergistic interactions in mitigating adverse effects. The 
transcriptional responses also indicated a role of the Fur regulon in the FZ and DOC 
action, which could be contributing to the synergy of the combination. FZ and DOC 
caused gene expression changes consistent with the inactivation of Fur, mimicking a 
reversal of Fur's transcriptional repression of iron uptake genes that occurs during iron 
limitation. This activity is expected to have downstream effects on iron-rich proteins, such 
as TCA cycle and transmembrane redox enzyme complexes of the ETC (Massé et al., 
2005), and could therefore explain the downregulation of some ETC genes after FZ and 
DOC treatment.  
The ETC produces PMF that drives ATP synthesis (Maloney et al., 1974) and is utilised 
by energy-requiring processes such as solute transport (Paulsen et al., 1996; Mitchell, 
1976). The PMF consists of two components: the electric potential (ΔΨ) arising from the 
charge separation across the membrane, and the transmembrane proton gradient (ΔpH). 
Disruption of the PMF could occur through inhibition of specific membrane-associated 
ETC proteins, which could lead to membrane depolarisation (Hards et al., 2015). Also, 
some membrane-damaging agents, which are usually lipophilic, can disrupt multiple 
targets through interaction with the membrane, resulting in the loss of membrane 
integrity, inhibition of membrane proteins, and dissipation of the PMF (Feng et al., 2015; 
Sikkema et al., 1995; Straus et al., 2006). Downregulation of ETC genes (Chapter 4), 
combined with the reported membrane-damaging effects of VAN and DOC, could lead 
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to the disruption of the PMF, and subsequently the inhibition of the PMF-dependent 
efflux pumps (Paulsen et al., 1996), which play a significant role in antibiotic resistance. 
Another affected pathway that could be contributing to the synergy is the DNA damage-
DNA repair pathway. Intermediates or byproducts of nitrofuran activation are DNA-
damaging and induce the SOS response (Ona et al., 2009; Mitosch et al., 2019). Although 
no DNA damage response was found in DOC-treated E. coli in this study, DOC and other 
bile salts have been reported to cause DNA damage and induce the SOS response in E. 
coli and other bacteria (Prieto et al., 2006; Merritt et al., 2009), at concentrations and 
under growth conditions that are different from those used in Chapter 4. Moreover, as 
shown in Chapter 4 and reported previously, both of these agents result in the production 
of ROS that cause oxidative DNA damage (Prieto et al., 2006; Negretti et al., 2017). 
VAN, on the other hand, has been shown not to induce SOS response in S. aureus (Plata 
et al., 2013). However, it is generally accepted that bactericidal antibiotics, such as VAN, 
ultimately generate ROS that can damage DNA and lead to cell death (Kohanski et al., 
2007). O’Rourke et al. (2020) transcriptomics dataset showed that VAN treatment of 
outer membrane-compromised E. coli downregulated genes involved in the SOS 
response. This effect, if proven, could explain the synergy between nitrofuran and VAN, 
reported in this study and by Zhou et al. (2015). 
This chapter aims to validate the findings of the transcriptomic analysis and explore 
potential pathways involved in synergy. Firstly, the role of the Fur protein and the ETC 
enzymes in the action and synergy of FZ, DOC, and VAN, along with possible 
downstream effects on efflux, were investigated through the use of gene deletion mutants 
and biochemical approaches. Next, since the combination did not show induction of SOS 
response genes, the mutagenicity of the monotherapies and combination were determined 
CHAPTER 5 Investigating pathways involved in  
the action and synergy of FZ, DOC, and VAN 
 118 
to confirm that the significantly decreased dose of FZ in the combination lowers mutation 
frequency in E. coli. Lastly, the role of the SOS response in the synergy was investigated.  
5.2 Results 
5.2.1 Fur plays a role in the synergy of FZ and DOC 
The transcriptomic analyses showed gene expression changes consistent with the 
inactivation of Fur protein after FZ and DOC treatment. A fur deletion mutant was 
constructed in strain K1508 to investigate the involvement of Fur protein in the action of 
FZ and DOC. Since Fur is the transcriptional repressor of iron uptake genes, fur mutant 
accumulates iron inside the cells and can be used to investigate the effects of increased 
iron levels in antibiotic susceptibility. The MIC of FZ, DOC, and VAN were determined 
in E. coli K1508 (wildtype for fur) and derived fur mutant using broth microdilution 
method, and it was found that the deletion of fur increased susceptibility to FZ by 2-fold, 
while DOC and VAN MICs were unchanged (Table 8). These results were further 
confirmed in the Keio collection strain E. coli BW25113, whose fur deletion mutant also 
showed decreased MIC (2-fold) of FZ.  
 
Table 8. Minimum inhibitory concentrations of fur mutants using broth 
microdilution  
  MIC (g/mL)  
 FZ DOC VAN 
K1508 2.5 >80000 250 
K1508 fur 1.25 >80000 250 
BW25113 2 >80000 250 
BW25113 fur 1 >80000 250 
MIC, minimum inhibitory concentration; FZ, furazolidone; DOC, sodium deoxycholate; VAN, 
vancomycin 
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Interestingly, the effect of fur deletion on VAN susceptibility has already been assayed 
on agar, and this deletion was shown to increase susceptibility to VAN (Liu et al., 2010). 
This contradiction to the present results could be attributed to the different methods used 
to determine susceptibility (in liquid vs on solid medium). Therefore, MIC determination 
was also performed using the agar dilution method (Clinical and Laboratory Standards 
Institute, 2015). High concentrations of DOC, however, precluded MIC determination 
using this method, since they result in self-induced gelation that interferes with 
solidification of agar. Similar to the broth method, fur deletion increased FZ 
susceptibility, but the difference was more pronounced (4-fold; K1508 MIC was 1 g/mL 
and K1508 fur 0.25 g/mL). Moreover, fur mutant showed a 2-fold increase in 
susceptibility to VAN (K1508 MIC was 250 g/mL and K1508 fur is 125 g/mL), in 
agreement with the Liu et al. (2010) study. Lastly, since DOC solubility level in media is 
preventing MIC determination, any effects of fur deletion on DOC susceptibility cannot 
be ruled out. 
The transcriptional analysis of FZ- and DOC-treated E. coli resembled Fur inactivation 
(Chapter 4, Section 4.5.6). This Fur inactivation could be contributing to the effect of FZ 
and DOC on E. coli through the increase of Fe2+ that could lead to oxidative stress by 
potentiating the Fenton reaction (Imlay, 2003). In addition, it could also result in the 
downregulation of PMF-generating enzymes (Seo et al., 2014), leading to the inhibition 
of PMF-dependent efflux. For these reasons, it was hypothesised that the combined action 
of FZ and DOC, which results in the inactivation of Fur, is a possible source of the 
synergy of FZ and DOC that was previously reported (Le et al., 2020). Furthermore, since 
deletion of fur increased susceptibility to VAN on solid media, it is possible that the 
inactivation of Fur by FZ and DOC increases susceptibility to VAN effects, and 
contributes to the triple-drug combination synergy. If these scenarios were true, 
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disruption of Fur would make this combined activity on Fur inactivation redundant, thus 
increasing the interaction index (FICI) in the fur deletion mutant relative to that in the 
fur+ parent strain. 
To validate this model, checkerboard assay was performed on K1508 and its fur mutant. 
Deletion of fur in K1508 caused a shift from the synergistic interaction between FZ and 
DOC in the wildtype (FICI < 0.09) to indifferent interaction (FICI < 0.63), as shown in 
Figure 31A. These results were also confirmed in the E. coli strain BW25113 (Figure 




Figure 31. FZ-DOC interactions in the absence of Fur 
The isobolograms of FZ and DOC interaction in growth inhibition of A) K1508 and B) BW25113 strains 
and derived fur mutants. Each data point corresponds to the fractional inhibitory concentrations (FICs; 
ratios of the MIC in combination vs. alone). 
 
A triple combination checkerboard assay was performed for K1508 and derived fur 
mutant to investigate whether Fur also plays a role in the triple combination synergy. 
Only a slight increase in the FICI of FZ+DOC+VAN was measured in the fur mutant 
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in synergy (Appendix A, Figure A- 5A). Taken together, these findings support the 
hypothesis that Fur is an interacting point for the synergy between FZ and DOC. In terms 
of the triple combination synergy, however, the action on Fur is contributing to the 
synergy, but other major sources are likely, given that deletion of fur still results in a 
synergistic interaction, albeit less profound. 
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5.2.2 Intracellular metal homeostasis is affected by FZ and DOC 
Since FZ and DOC resulted in dysregulation of iron homeostasis, the effect of the 
antibacterials and their combination (at the same concentrations used in the 
transcriptomics study in Chapter 4) on intracellular iron levels was investigated using 
ICP-MS analysis. Given that regulation of multiple metal homeostases in bacteria is 
interconnected (Chandrangsu et al., 2017), the levels of other essential metals, including 
magnesium, zinc, nickel, manganese, and copper were also measured.  
The intracellular levels were measured for the higher-abundance metals, magnesium, 
iron, and zinc (Figure 32A) and lower-abundance metals nickel, manganese, and copper 
(Figure 32B). FZ treatment resulted in a 1.8-fold decrease in iron (p<0.001) and a 3-fold 
increase in manganese levels (p<0.001). DOC, on the other hand, resulted in a more than 
9-fold decrease in magnesium (p<0.001), a 1.6-fold decrease in iron (p<0.05), an almost 
2-fold decrease in manganese (p<0.001), and a 2.5-fold increase in copper levels 
(p<0.05). Lastly, the triple combination’s effect on the levels of these metals is the same 
as DOC, indicating DOC’s effect to be the most predominant in the combination. The 
fold changes caused by the combination, however, are much more pronounced than those 
by DOC, such as the 18-fold decrease in magnesium (p<0.001), a 1.9-fold decrease in 
iron (p<0.001), an almost 5-fold decrease in manganese (p<0.001), and a 6.5-fold increase 
in copper (p<0.001).  
There was no significant change in the total intracellular zinc and nickel levels in the 
presence of any of the single antibacterials or combination, as compared to the no-
antibacterials control; while VAN treatment resulted in no significant change in the total 
intracellular levels of any of the metals that were analysed in this study. Taken together, 
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FZ and DOC, besides affecting iron homeostasis, also result in the dysregulation of other 
essential metals, including manganese, magnesium, and copper.  
 
 
Figure 32. Intracellular metal levels after treatment with FZ, DOC, and VAN and 
the triple combination 
Intracellular metal concentrations were measured using ICP-MS in K1508 cells exposed to IC50 doses of 
FZ, DOC and VAN alone and FZ+DOC+VAN combination for 1 h. Data show the mean of 3 biological 
replicates) ± standard error of the mean. Statistical significance (Student’s t-test of treatment vs control) is 
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5.2.3 The electron transport chain  
The transcriptomic analysis (Chapter 4) showed downregulation of some ETC genes. This 
could be a result of the Fur inactivation, which induces an iron-sparing mechanism 
mediated by the sRNA RyhB, and is known to regulate the ETC genes cyd (cytochrome 
bd-I) and nuo (NADH dehydrogenase I) (Massé et al., 2005). In addition, downregulation 
of the central carbon metabolism can explain the downregulation of these genes through 
a feedback mechanism for less energy demand. It cannot be ruled out, however, that a 
separate pathway that leads to the downregulation of these genes are affected by FZ and 
DOC. Nevertheless, these findings prompted the investigation of the role of the ETC in 
the action of FZ, VAN, and DOC. 
 
Table 9. Minimum inhibitory concentrations of electron transport chain mutants 
 MIC (g/mL) using broth 
microdilution 
MIC (g/mL) using agar 
dilution 
 FZ DOC VAN FZ DOC VAN 
K1508 2.5 >80000 250 1 ND 250 
K1508 appB 2.5 >80000 250 1 ND 250 
K1508 cyoB 2.5 >80000 250 1 ND 250 
K1508 cydB 2.5 >80000 250 1 ND <31.25 
K1508 ndh 2.5 >80000 250 1 ND 500 
K1508 nuoM 2.5 >80000 250 1 ND 250 
MIC, minimum inhibitory concentration; FZ, furazolidone; DOC, sodium deoxycholate; VAN, 
vancomycin; ND, not determined 
 
To investigate the involvement of each of the major aerobic ETC enzymes, deletion 
mutants (appB - cytochrome bd-II, cyoB - cytochrome bo3, cydB - cytochrome bd-I, 
ndh -NADH dehydrogenase II, nuoM - NADH dehydrogenase I) were constructed by 
P1 transduction. The MIC of FZ, DOC, and VAN in each of the mutants were determined 
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using broth microdilution and agar dilution methods, as shown in Table 9. Using broth 
microdilution, there was no change in the MIC of the knockouts compared to wildtype, 
while using agar dilution, increased susceptibility and resistance to VAN was observed 
in cydB and ndh mutants, respectively.  
Although the MIC of FZ in the knockout mutants remained unchanged using the agar 
dilution method, a slightly increased survival of cyoB and ndh mutants can be observed 
on agar containing ½  MIC concentration (0.5 g/mL) of FZ (Figure 33). Interestingly, 
cyoB and ndh are the only ETC genes that were upregulated by FZ and DOC in the 
transcriptomics study, while the rest were downregulated (Chapter 4, Figure 28). 
 
 
Figure 33. Survival of electron transport chain deletion mutants at sub-MIC FZ 
Logarithmically growing E. coli K1508 wildtype, ΔappB (cytochrome bd-II), ΔcyoB (cytochrome bo3), 
cydB (cytochrome bd-I), ndh (NADH dehydrogenase II), and, nuoM (NADH dehydrogenase I) were 
ten-fold serially diluted and spotted onto 2xYT plates containing 0.5 g/mL FZ (1/2  MIC), and incubated 
overnight at 37 ºC overnight. The experiment was conducted three times, and a representative result is 
shown.  
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The possibility that the ETC genes play a role in the synergy of FZ and DOC was also 
investigated using checkerboard assays. There was no change in FZ and DOC FICI for 
appB and cyoB mutants compared to the wildtype parent strain K1508, while the FICIs 
for cydB, ndh, and nuoM increased slightly, but are still considered synergistic (Table 
10). To confirm these results, checkerboard assay was also performed on deletion mutants 
of the Keio collection strain BW25113, and it was found that only ndh deletion resulted 
in a decrease in synergistic interaction between FZ and DOC (Table 10).  
 
Table 10. Fractional inhibitory concentration index for FZ-DOC interactions in 
electron transport chain mutants 
 FICI FZ-DOC   FICI FZ-DOC 
K1508 <0.09  BW25113 <0.5 
K1508 appB <0.09  BW25113 appB <0.5 
K1508 cyoB <0.09  BW25113 cyoB <0.5 
K1508 cydB <0.16  BW25113 cydB <0.5 
K1508 ndh <0.28  BW25113 ndh <0.63 
K1508 nuoM <0.16  BW25113 nuoM <0.5 
FICI FZ-DOC, lowest fractional inhibitory concentration index from furazolidone and sodium 
deoxycholate interaction assessed using checkerboard assay. 
 
5.2.4 FZ and DOC decelerates E. coli aerobic ETC 
Downregulation of genes encoding ETC enzymes prompted the assessment of 
physiological changes at the level of cellular respiration, induced by FZ, DOC, or VAN 
(at the same concentrations as those used in Chapter 4). Oxygen is the major electron 
acceptor of the E. coli aerobic ETC (Ingledew et al., 1984). Therefore, to investigate the 
overall effect of the antibiotics on aerobic respiration, the rates of oxygen consumption 
were measured using a Clark-type oxygen electrode (Figure 34).  
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Exposure to FZ and DOC for 1 h significantly decreased the oxygen consumption rate, 
causing a 1.6-fold (p<0.001) and 1.7-fold (p<0.001) decrease, respectively, in comparison 
to the no-antibacterial control. VAN, on the other hand, only caused a slight decrease 
(~1.15-fold) compared to the untreated control, but this change was still considered 
statistically significant (p<0.05). Similarly, the FZ+DOC+VAN combination decreased 
oxygen consumption by ~1.7-fold (p<0.001). In the single-antibacterial cultures where 
concentrations of each antibacterial were lowered to the same absolute concentration as 
in the combination (FZ 3d, DOC 3d, or VAN 3d), only DOC 3d resulted in a significant 
decrease in oxygen consumption compared to the no-antibiotic control. These findings 
are in agreement with the downregulation of aerobic ETC genes by FZ, DOC, and the 
FZ+DOC+VAN combination observed in Chapter 4 (Section 4.5.8). 
 
 
Figure 34. Oxygen consumption rate in antibacterial-containing cultures 
Oxygen consumption by K1508 cultures was measured with a Clark-type closed-chamber oxygen electrode 
during exposure to FZ, DOC, and VAN alone and in combination. The cells were pre-treated with the drugs 
for 1 h, then oxygen consumption was measured for up to 5 min. Data show the mean of 3 replicates ± 
standard error of the mean. Statistical significance (Student’s t-test of treatment vs control) is indicated by 
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5.2.5 Possible efflux inhibitory activity of FZ and DOC 
Downregulation of ETC genes, supported by the lowered oxygen consumption rates, 
indicate diminished PMF and possibly lower ATP concentration due to diminished 
activity of ATP synthase. These changes may, in turn, affect the PMF-dependent efflux 
pumps. Given that, at a minimum, DOC resistance is majorly reliant on efflux pumps 
(Thanassi et al., 1997), one possible synergy mechanism could be through decreased rate 
of expulsion. If FZ and VAN do result in the inhibition of efflux, this activity could be a 
source of the synergistic interaction.  
To investigate whether FZ, DOC, VAN, or triple combination inhibit efflux pumps, 
ethidium bromide accumulation and efflux assays were performed. Ethidium bromide is 
a DNA-intercalating agent that fluoresces when bound to DNA (Olmsted et al., 1977), 
and is also an efflux pump substrate. Therefore, drug effects on efflux can be investigated 
by monitoring accumulation or extrusion of ethidium bromide using fluorometry. In these 
assays, carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was used as a positive 
control. CCCP is a protonophore that dissipates the proton gradient across the inner 
membrane, leading to a drop in PMF. By majorly compromising PMF, CCCP uncouples 
oxidative phosphorylation (ATP synthesis) from ETC, leading to a drop in oxidative 
phosphorylation and ATP production, as well as inhibition of efflux pumps (Heytler, 
1963; Kasianowicz et al., 1984).  
Firstly, the highest ethidium bromide concentration (0.125 g/mL) that does not result in 
accumulation in untreated cells was identified experimentally. Figure 35A shows the 
ethidium bromide accumulation during treatment with FZ, DOC, and VAN 
monotherapies and combination. As expected, CCCP increased the accumulation of 
ethidium bromide. Similarly, all cultures containing DOC (DOC, FZ+DOC+VAN, DOC 
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3d) and cultures containing VAN also increased ethidium bromide accumulation starting 
at 10 min and 20 min time points, respectively. Lastly, FZ did not result in any observable 





Figure 35. Effect of FZ, DOC, and VAN ethidium bromide accumulation  
A) 0.125 g/mL ethidium bromide and antibiotics were added to E. coli K1508 and the fluorescence was 
monitored at 37 ºC for 1 h. B) E. coli K1508 were first treated with the antibiotics for 1 hr then 0.125 g/mL 
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To check whether a prolonged exposure to antibacterials (or CCCP) will have a more 
pronounced effect on efflux, especially for FZ, cultures were pre-treated with the drugs 
for 1 h before the addition of ethidium bromide. In Figure 35B, almost immediate 
accumulation of ethidium bromide fluorescence was observed in the presence of CCCP, 
VAN, and DOC, but still, no changes were observed in the presence of FZ. 
To confirm the results obtained above on the accumulation of ethidium bromide, an efflux 
assay was also performed. Initially, cells were subjected to conditions that promote 
significant ethidium bromide accumulation over a period of 1 h: incubation with 5 g/mL 
ethidium bromide and 5 g/mL CCCP in 2xYT at 37 C. After this ethidium bromide-
loading step, the cells were washed, then resuspended in medium containing the test 
antibacterials with or without 0.4% glucose, which is commonly used to re-energise 
efflux pumps (Paixão et al., 2009). As shown in Figure 36A, efflux takes place readily in 
the presence of glucose at 37 C, an activity that is inhibited in the presence of CCCP and 
to a lesser extent in cultures containing DOC (DOC, FZ+DOC+VAN, and DOC 3d). In 
the absence of glucose, the same results were obtained, except a slight delay in the 
decrease of ethidium bromide fluorescence was observed in the presence of FZ (indicated 
by an arrow in Figure 36B). 
Contrary to the accumulation assay, VAN did not slow down the extrusion of ethidium 
bromide. This finding most likely points to the increased membrane permeability caused 
by VAN, as the reason for increased ethidium bromide accumulation inside the cell, 
which is a dominant process in the accumulation assays (Figure 35), whereas the 
extrusion assay only measures efflux of ethidium bromide (Figure 36). Interestingly, in 
the presence of DOC treatments, the ethidium bromide fluorescence does not decrease to 
the same levels as the control and seem to be followed by re-accumulation. From these 
results, it can be inferred that DOC does inhibit efflux, which is evident by the delay in 
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the extrusion of ethidium bromide seen at the beginning of treatment, and that because of 





Figure 36. Effect of FZ, DOC, and VAN on ethidium bromide efflux 
E. coli K1508 were pre-loaded with ethidium bromide, and the efflux was monitored by measuring 
fluorescence cultures containing FZ, DOC, and VAN alone or in combination, in the (A) presence and (B) 






























































CHAPTER 5 Investigating pathways involved in  
the action and synergy of FZ, DOC, and VAN 
 132 
5.2.6 FZ dose reduction in the combination decreases mutagenicity 
Since FZ has been reported to be a DNA-damaging agent (Olive et al., 1977), it was not 
surprising that the transcriptomics analysis in this study showed FZ-induced upregulation 
of genes involved in the SOS response, the canonical response to DNA damage. The SOS 
response plays a role in increasing the survival of E. coli to nitrofurans by preventing 
irreversible DNA fragmentation (Bryant et al., 1980). However, besides DNA repair, the 
SOS response also triggers error-prone mechanisms that result in increased mutation rate. 
This mutagenicity is one of the reasons the nitrofurans have fallen out of favour (Vass et 
al., 2008). One of the aims of using nitrofuran in a synergistic combination is to take 
advantage of the reduced doses, which could possibly mitigate adverse effects. The 
transcriptional response to the combination did not show the same upregulation of SOS 
response genes as FZ alone, which indicates the absence of severe DNA damage. 
To assess the levels of DNA damage the antibacterials alone and in combination (at the 
same concentrations used in Chapter 4) elicit in E. coli, the mutation frequencies were 
determined by counting the number of bacteria that gain the ability to grow on rifampicin 
plates. Rifampicin is an RNA polymerase inhibitor, and resistance to this antibiotic can 
arise through single base substitutions in the RNA polymerase gene rpoB (Wehrli, 1983). 
E. coli K1508 is rifampicin-susceptible and did not have mutations in rpoB, as indicated 
by the genome sequence. Under nonstress conditions (control), the spontaneous mutation 
frequency of E. coli K1508 is around 7 mutants per 108 cells (Figure 37). Expectedly, 
given FZ’s DNA-damaging effects, this number significantly increased (the mean 
frequency more than doubled) upon FZ treatment. DOC, on the other hand, has also been 
reported to cause DNA damage; however, the DOC concentrations used in this study did 
not result in any significant change in rifampicin mutation frequency. The combination 
and the monotherapies at the concentration used in the combination (FZ 3d, DOC 3d, and 
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VAN 3d) also did not result in a statistically significant change in the mutation frequency 
compared to the control, which confirms that the reduced concentration of FZ in the 
combination does not induce severe DNA damage that triggers the SOS response 
resulting in mutagenicity.  
 
 
Figure 37. Rifampicin resistance mutation frequency in E. coli K1508 treated with 
FZ, DOC, and VAN alone and in combination.  
The mutation frequency of E. coli K1508 cells in the presence of antibacterials determined by counting the 
colonies able to grow on rifampicin (100 g/mL) plates after 24-h incubation. Box plots are derived from 
9-11 biological replicates. Boxes show the interquartile range and the whiskers indicate the minimum and 
maximum values. The mean is indicated by a blue datapoint. Statistical significance (Mann-Whitney U test 
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5.2.7 SOS response is involved in the synergy between FZ and VAN 
The SOS response is a resistance mechanism of bacteria against conditions causing DNA-
damage, such as large lesions and fragmentation. Evidently, removal of the SOS response 
through mutations of lexA, the transcriptional repressor of the SOS response, and recA, 
the sensor and inducer of the SOS response, increases susceptibility of E. coli or 
Salmonella to genotoxic agents and UV radiation (Mount et al., 1972; Mamber et al., 
1993).  
Zhou et al. (2015) have demonstrated the synergistic effect of VAN with NIT and 
trimethoprim, and proposed that VAN must be increasing DNA-damaging effects, 
possibly through oxidative stress, that results in a synergistic interaction. Moreover, a 
closer look at the transcriptomic analysis dataset by O’Rourke et al. (2020) for VAN 
treatment of E. coli with a compromised outer membrane showed downregulation of 11 
genes involved in the SOS response. If these findings were to be validated, this 
downregulation of the SOS response by VAN could amplify the DNA-damaging effect 
of nitrofurans and could explain their synergistic interaction. 
To investigate the involvement of the SOS response in the synergy, a recA mutant of E. 
coli K1508 was constructed by P1 transduction. recA deletion increased the susceptibility 
to FZ by 32-fold relative to the parent (MIC = 0.078 g/mL) in a broth microdilution 
assay. Likewise, this deletion also decreased DOC MIC to 80000 g/mL from more than 
80000 g/mL in the wildtype. VAN MIC, on the other hand, remained unchanged. A 
checkerboard assay was also performed on the recA mutant to investigate the role of 
SOS response in the interaction of FZ, DOC, and VAN. As shown in Figure 38A, the 
FICI of FZ and DOC in the recA mutant increased slightly, but the combination is still 
highly synergistic (FICI = 0.13). In terms of FZ and VAN interaction, deletion of recA 
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resulted in a shift to indifferent interaction (FICI = 1), instead of the synergy observed in 
the wildtype (FICI < 0.5) (Figure 38B).  
 
  
Figure 38. Interactions between FZ and DOC or VAN in the SOS-response-deficient 
mutant ΔrecA 
The isobolograms derived from the checkerboard assays of A) FZ and DOC and B) FZ and VAN. Each 
data point corresponds to the fractional inhibitory concentrations (FICs; ratios of the MIC in combination 
vs. alone). 
 
To investigate whether SOS response also plays a role in the triple combination synergy, 
a three-drug combination checkerboard assay was also performed on K1508 and K1508 
recA mutant. Results show an increase in the FICI of FZ+DOC+VAN in the recA 
mutant (FICI < 0.22) compared to the wildtype (FICI < 0.16), indicating only a slight 
decrease in synergy (Appendix A, Figure A- 5B). Taken together, these findings support 
the hypothesis that the SOS response is an interacting point for the synergy between FZ 
and VAN. In terms of the triple combination synergy, however, the SOS response is 
contributing to the synergy, but, given that deletion of recA still results in a highly 































K1508 (FICI < 0.5) 
 
K1508 recA (FICI = 1) 
K1508 (FICI < 0.09) 
 
K1508 recA (FICI = 0.13) 
CHAPTER 5 Investigating pathways involved in  
the action and synergy of FZ, DOC, and VAN 
 136 
5.3 Discussion 
In this chapter, some insights into the underlying mechanisms of synergy between FZ, 
DOC, and VAN against E. coli were investigated. Deletion of fur gene, encoding the 
master regulator of iron homeostasis, caused a considerable decrease in the synergy 
leading to an indifferent interaction between FZ and DOC. Similarly, deletion of recA, 
which disables the SOS response ability of E. coli, resulted in the loss of synergy between 
FZ and VAN. These two pathways also play a role in the triple combination synergy, 
since both deletion mutations caused a slight decrease in synergy. This small decrease in 
synergy due to the single-gene deletions are likely due to multiple pathways being 
involved in the synergistic triple interaction of FZ, DOC, and VAN. Multiple gene 
deletions will be required to observe a significant loss of synergy of the triple 
combination.  
Fur is the transcriptional repressor of iron uptake genes and is essential for the 
maintenance of iron homeostasis (Troxell et al., 2013). Our transcriptional analysis 
demonstrated that most of the previously identified Fur regulon members (Seo et al., 
2014) are upregulated in E. coli treated with FZ or DOC. In fact, the transcriptional 
response closely resembled that of an E. coli fur deletion mutant (Seo et al., 2014). Three 
possible scenarios can be inferred from this finding: (i) FZ or DOC somehow deplete the 
extracellular iron, causing an iron-depleted environment; (ii) E. coli treated with FZ and 
DOC are exposed to stress conditions that trigger intracellular iron depletion that induce 
the upregulation of iron uptake mechanisms, and downregulation of iron storage and iron-
utilising proteins, in order to replenish the perceived depleted intracellular iron pools and 
re-prioritise iron use to essential proteins; (iii) FZ or DOC may result in direct or indirect 
inactivation of Fur-Fe2+ protein complex. Inactivation of Fur would misleadingly send an 
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iron starvation signal to the cell, inducing a misplaced response that would cause iron 
overload.  
From the ICP-MS analysis, FZ and DOC resulted in the 1.8- and 1.6-fold decrease in total 
intracellular iron levels, respectively (Figure 32A). E. coli grown in iron-depleted media 
has been demonstrated to result in a more significant lowering (14-fold decrease) of 
intracellular iron levels (Abdul-Tehrani et al., 1999). A much less pronounced decrease 
observed here rules out iron depletion in the medium by FZ or DOC. The extent of 
decrease in iron concentrations shown in this study more closely resembled that of E. coli 
fur mutant in iron-replete conditions, which has been shown to decrease intracellular iron 
levels by 2.5-fold compared to wildtype (Abdul-Tehrani et al., 1999). The lowered level 
of intracellular iron seems contradictory to the fact that fur mutants constitutively express 
iron import systems. This contradiction, however, could be resolved by invoking 
mechanisms that prevent iron overload, possibly through iron export (Pi et al., 2017a). 
Alternatively, lowered iron content could reflect lower levels of iron storage proteins 
(Abdul-Tehrani et al., 1999). If so, despite the overall decrease in total intracellular iron 
due to Fur inactivation or in fur mutants, the labile iron pool has been demonstrated to 
increase (Pi et al., 2017b; Keyer et al., 1996). This increase in free iron can explain the 
increased sensitivity of fur mutant to FZ and VAN, as these agents are reported to induce 
ROS production  (Li et al., 2015; Wang et al., 2015), that can be worsened by the iron-
catalysed Fenton reaction.  
The mechanisms by which FZ or DOC inactivate Fur and induce an iron starvation-like 
response are currently unknown. It could be as simple as ROS, such as H2O2, produced 
in response to FZ or DOC directly inactivating Fur protein by oxidising Fe2+ to Fe3+ 
(Varghese et al., 2007). Furthermore, ROS could be damaging the Fe-S clusters, 
providing an additional pathway for oxidising useable Fe2+ to unusable Fe3+ via the 
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Fenton reaction (Imlay, 2006). If so, iron import would be upregulated to supply iron to 
the Fe-S cluster machinery and the labile iron pool. Fur-Fe2+ complex has also been 
shown to be inactivated by nitric oxide (NO) (D'Autreaux et al., 2002). Incidentally, 
nitroheterocyclic drug reduction has been proposed to result in a NO byproduct (Kumar 
et al., 2014), though direct evidence for NO production during nitrofuran activation has 
not yet been demonstrated.  
Since homeostasis regulatory mechanisms of various metals in bacteria are interrelated, 
and excess of some metals, like zinc and nickel, have been shown to perturb iron 
homeostasis (Xu et al., 2019; Washington-Hughes et al., 2019), any disruption to the 
levels of other essential metals was investigated through ICP-MS (Section 5.2.2). FZ 
increased manganese levels by 3-fold (Figure 32). This is in agreement with the reported 
induction of MntH manganese import systems during iron deficiency in the cells. It is 
thought that manganese can replace iron as a cofactor, allowing some enzymes to retain 
function even during iron deficiency (Kehres et al., 2002). Besides low iron, H2O2 stress 
can also induce MntH manganese uptake system to replace the readily oxidisable Fe2+ 
cofactors with a less oxidisable manganese cation, and prevent oxidative protein damage 
(Anjem et al., 2009). Surprisingly, even though DOC induced the OxyR regulon, 
indicating H2O2 stress, at the same time, it caused a decrease in total intracellular 
manganese levels. In addition, the triple-drug combination also resulted in a decrease in 
manganese levels, indicating opposite effects of FZ and DOC on this metal, in which 
DOC effects predominate.  
Another metal that was significantly affected by the antibiotic treatments is copper. DOC 
increased the levels of intracellular copper by 2.5-fold, while the combination resulted in 
a 6.5-fold increase. This significant increase in copper levels could be a result of 
upregulation of copper-dependent proteins NADH dehydrogenase II (ndh) (Rapisarda et 
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al., 2002) and cytochrome bo3 (cyo) (Chepuri et al., 1990). FZ, DOC, and 
FZ+DOC+VAN upregulated these genes to similar levels compared to the control, and if 
this reflects the amount of protein in the cell, it would be expected that all three treatments 
should result in a similar increase of the intracellular copper. Observed differences in the 
intracellular copper levels between DOC-only and the triple-antibacterial combination 
cultures could be due to additional regulation at posttranscriptional level that could result 
in different amounts of these copper-dependent proteins. Interestingly, copper excess is 
known to cause Fe-S cluster degradation and even block Fe-S cluster assembly (Tan et 
al., 2014; Macomber et al., 2009). Furthermore, in Bacillus subtilis and in E. coli, copper 
excess-induced damage was demonstrated to stimulate an iron starvation response 
(Chillappagari et al., 2010; Steunou et al., 2020). From these findings, it appears that 
disturbance in copper homeostasis is another possible cause of Fur inactivation in E. coli 
treated with DOC. 
Another metal that was affected by DOC is magnesium. DOC and FZ+DOC+VAN 
lowered total intracellular magnesium levels by 9-fold and 18-fold, respectively, 
indicating a synergistic effect in the magnesium homeostasis dysregulation. Mg2+ is the 
most abundant divalent cation in bacterial cells. While it plays essential roles in many 
processes, including stabilising macromolecules and as an enzyme cofactor, a substantial 
fraction of Mg2+ in E. coli cells are ribosome-bound and are involved in ribosome 
stabilisation (Goldberg, 1966). The observed low levels of magnesium in DOC is in 
contrast with the upregulation of genes involved in ribosomal proteins and translation 
reported in Chapter 4. It is possible, however, that what causes the translational stress, in 
which E. coli tries to counter by increasing ribosome assembly and translation, is the low 
Mg2+ levels caused by DOC treatment. 
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In Salmonella, insufficient cytosolic Mg2+ induces MgtA and MgtB transporters to import 
Mg2+, and MgtC to lower ATP and inhibit rRNA transcription (Pontes et al., 2016; 
Soncini et al., 1996). Besides lowering the ATP, MgtC was also proposed to influence 
the intracellular levels of (p)ppGpp (Pontes et al., 2016; Pontes et al., 2015), the stringent 
response alarmones that bind RNA polymerase, and ultimately inhibit protein synthesis 
(Artsimovitch et al., 2004; Sanchez-Vazquez et al., 2019). Since all bacterial ribosomes 
are stabilised by Mg2+ and powered by ATP, this mechanism is thought to be highly 
conserved across species. Although E. coli lacks mgtC, this bacterium also inhibits rRNA 
transcription and exhibits lower levels of ATP during Mg2+ limitation, suggesting a 
mechanism similar to that of Salmonella, mediated by a yet unidentified protein (Pontes 
et al., 2016). Since E. coli K1508 is a relA1spoT1 mutant and cannot regulate (p)ppGpp 
levels, this could explain the increase in rRNA transcription even at insufficient 
intracellular Mg2+ concentrations. Consistent with this theory, Salmonella relA spoT 
double null mutant, which is unable to synthesise (p)ppGpp, was reported to have retained 
high ATP levels and exhibited increased rrs (16s rRNA) transcripts compared to wildtype 
under cytosolic Mg2+ limitation (Pontes et al., 2016).  
Checkerboard assays of the ETC mutants of E. coli K1508 and BW25113 showed a slight 
decrease in the synergy between FZ and DOC only for ndh mutant, indicating that the 
action on Ndh is an interacting point of antibacterials’ action that leads to synergy. The 
lack of change in FICI for other mutants cannot rule out the involvement of these ETC 
enzymes in the mechanism of action and synergy of FZ and DOC. This is because the 
respiratory enzymes have overlapping functions (Anraku et al., 1987); thus, deletion in 
one of them could be easily compensated by another. In addition, if the hypothesis that 
the effect on the ETC is a more downstream effect of FZ and DOC, resulting from Fur 
inactivation, downregulation of metabolism, or some other mechanism, then deletion of 
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ETC genes will not have much effect on the synergy, as has been observed here. 
Interestingly, although FZ MIC remained unchanged for all of the ETC mutants, ndh and 
cyoB deletion increased the survival to sub-MIC FZ (Figure 33). ndh and cyo were the 
only genes upregulated by FZ treatment in E. coli, and the increase in resistance when 
these genes are deleted indicates that they are somehow involved in the FZ mechanism 
of action. A possibility is that these enzymes are involved in ROS production as is often 
the case with redox enzymes of the ETC. Deletion of these genes would, therefore, lower 
the burden of oxidative stress caused by FZ, thereby increasing the resistance. 
Another pathway that was hypothesised to contribute to the synergy is the inhibition of 
efflux pumps. We have previously proposed a mechanism of synergy between FZ and 
DOC to be caused by FZ-mediated inhibition of TolC-associated efflux pumps that allows 
accumulation of DOC inside the cells (Le et al., 2020). By measuring oxygen 
consumption, it has been confirmed that FZ and DOC result in an overall inhibitory effect 
on the ETC (Figure 34). Since TolC-dependent efflux pumps and many other efflux 
systems associated with antibiotic resistance are energised by the PMF (Paulsen et al., 
1996), it was posited that inhibition of the ETC, could lead to the dissipation of PMF and 
inhibition of efflux. Using ethidium bromide accumulation and efflux assays (Section 
5.2.5), DOC has been shown to inhibit efflux, while VAN was shown to increase 
membrane permeability. FZ results, on the other hand, were inconclusive since no effect 
was observed in ethidium bromide accumulation, but a very small inhibitory effect was 
seen in ethidium bromide efflux assay. This can be rationalised as follows: since FZ was 
found to induce the expression of efflux pumps (Chapter 4, Section 4.5.10, Figure 29), 
the FZ-induced inhibition of the ETC that possibly results in diminished PMF cannot 
fully inhibit efflux; hence FZ efflux inhibition can only be observed in media without 
glucose that depend more on ETC activity as a source of energy. In this regard, a more 
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direct measurement of PMF should be performed, such as the measurement of the 
membrane potential (ΔΨ) component of the PMF (Benarroch et al., 2020; Suzuki et al., 
2003). 
Lastly, the role of the SOS response in the synergy was investigated. FZ has been reported 
to induce the SOS response, and this study has demonstrated FZ’s ability to increase 
mutagenicity (Figure 37). Taking advantage of the synergy, doses of the components in 
the combination, including FZ, have been reduced, and this has now been confirmed to 
mitigate mutagenicity while preserving the MIC (Figure 37). The SOS response can be 
seen as a resistance mechanism against a variety of DNA-damaging agents (including FZ 
and DOC) that cause major lesions in the bacterial chromosome (Merritt et al., 2009; Ona 
et al., 2009). Since inhibition of resistance is a commonly accepted principle that gives 
way to synergy, it was investigated whether the SOS response is somehow involved in 
the synergy. Deletion of recA eliminated the synergy and resulted in an indifferent 
interaction between FZ and VAN, while only a slight decrease in synergy has been 
observed in FZ+DOC and FZ+DOC+VAN interactions (Section 5.2.7). The mechanism 
by which SOS response plays a role in the mechanism of synergy between FZ and VAN 
could involve inhibitory effect of VAN on SOS induction, as reflected by O’Rourke et 
al. (2020) transcriptome dataset.  
In summary, this study offered some insights into the observed transcriptional response 
of E. coli to FZ, DOC, VAN, or triple combination of these antibacterials. Evidence for 
Fur regulon and SOS pathway as interacting points in the synergy of FZ and DOC, and 
FZ and VAN, respectively, was provided, along with demonstration of the inhibitory 
effect on the ETC that could be contributing to the synergy. In terms of the triple 
combination synergy, multiple other pathways could be involved, in addition to Fur and 
SOS, given that the single-gene deletions lead to a slight decrease in the triple 
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combination synergy. However, since it is highly likely that these drugs interact at 
multiple points in multiple different pathways, multiple gene deletions may be required 
to observe a more significant decrease in the triple combination synergy. 
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6.1 General discussion 
The continuous emergence of multidrug-resistant bacteria and the massive decline in the 
rate of novel antibiotic discovery in recent years have necessitated the exploration of 
alternative strategies to tackle antimicrobial resistance. Effective therapies are especially 
needed for Gram-negative pathogens, as reflected in the WHO priority pathogens list 
(World Health Organization, 2017). To develop a novel therapy, this study employed the 
alternative approach of reviving ‘old’ antibiotics and making some Gram-positive-only 
antibacterials effective against Gram-negative bacteria through a synergistic effect. 
This thesis reports the in vitro synergistic interaction between nitrofurans, DOC, and 
VAN against a wide range of Gram-negative pathogens, including clinically relevant 
multidrug-resistant strains. The choice of this combination was prompted by previous 
discoveries of the pairwise synergies between nitrofuran(s) and VAN or DOC (Le et al., 
2020; Weerasinghe, 2017; Zhou et al., 2015). Although these two-drug combinations 
showed synergy in Gram-negative bacteria, the MICs of VAN and DOC are still high and 
precluded their use as a viable medical treatment option due to toxicity. So in an attempt 
to improve the combination, the interaction of the triple combination was investigated 
and was found to be synergistic, further decreasing the MICs of individual components.  
Gram-negative bacteria, due to their outer membrane and a range of powerful efflux 
pumps, are intrinsically resistant to VAN and DOC (Prieto et al., 2006; Breijyeh et al., 
2020; Thanassi et al., 1997). This is evidenced by their high MICs in Gram-negatives 
compared to Gram-positives (Chapter 3, Table 2 and Table 4). However, due to 
synergistic interaction, the MICs of these agents decrease significantly in combination 
with the Gram-negative active-agent nitrofuran, allowing their use to be expanded beyond 
Gram-positive bacteria. This synergistic interaction is not just advantageous for enabling 
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the use of VAN and DOC; nitrofuran use has been unfavourable due to its mutagenicity 
(Vass et al., 2008). The increase in efficacy of the combination will thereby lower the 
effective doses of each of the components, including nitrofuran, which can mitigate 
adverse effects. In Chapter 4 (Section 4.5.5), the combination was found not to induce the 
SOS response, indicating the lack of severe DNA damage that results in mutagenicity; 
and in Chapter 5 (Section 5.2.6), this mitigation of mutagenicity has been demonstrated 
in E. coli. This finding highlights the advantage of mitigating mutagenicity to decrease 
resistance frequency in bacterial cells and oncogenesis-causing DNA damage in 
eukaryotic cells. 
Besides nitrofuran, VAN also has adverse effects, such as nephrotoxicity, that are partly 
the reason why it is not a first-choice treatment (Filippone et al., 2017). Since the 
combination has synergistic effects against bacterial cells, it is possible that the toxic 
effects of the drugs in mammalian cells will also be synergistic and would be detrimental 
for the development of this combination. Preliminary investigation on the toxic effects 
using an in vitro mammalian cell line model found that the cytotoxic effect of the 
combination is indifferent (Chapter 3, Table 5). Considering only in vitro results showing 
that the efficacy is synergistic and that the toxicity is indifferent, the therapeutic index of 
the combination would be higher than if the drugs were used as monotherapies, and the 
use of the drugs would therefore be more advantageous if used as a combination. 
However, since this was an in vitro assay, its clinical relevance warrants further 
investigation (McKim, 2010).  
Although the combination is not synergistic in Gram-positive bacteria, their interaction 
is at least additive (Chapter 3, Section 3.2.3), and the concentrations of the antibacterials 
in combination that inhibit Gram-negative bacteria are already effective against Gram-
positives. For these reasons, the combination can be used as a broad-spectrum therapy, 
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and potential uses, such as gastrointestinal illness therapy and topical treatment for skin 
and wound infections, were discussed in Chapter 3.  
The finding that nitrofuran, DOC, and VAN does not interact synergistically against 
Gram-positive bacteria alludes to the importance of the outer membrane in the synergistic 
interaction. This can be rationalised by the fact that the outer membrane and the presence 
of efflux pumps prevent the entry and accumulation of VAN and DOC, respectively, 
inside the cells; but when used together with nitrofurans, these resistance mechanisms are 
somehow inhibited allowing the agents to enter the cell and exert their effects. Indeed, 
this interpretation was proposed for the loss or decrease of synergy between FZ and DOC 
when tolC or acrA efflux pump components were deleted (Le et al., 2020).  
Using a transcriptomics approach (Chapter 4), the underlying mechanisms of action and 
synergy of the antibacterials were investigated. The apparent similarity in the 
transcriptional responses induced by FZ and DOC in E. coli is likely the source of their 
synergy. This is in line with studies that found a higher likelihood of synergy occurring 
in drug combinations that induce very similar or very opposite gene perturbations (Bansal 
et al., 2014; Yang et al., 2020). In particular, FZ and DOC induced gene expression 
consistent with Fur protein inactivation that usually occurs during the iron starvation 
response (Seo et al., 2014). Through measurements of the total intracellular iron levels, 
it was ruled out that these drugs cause real iron starvation, for example, through iron 
chelation or sequestration (Jacobs et al., 1970). FZ and DOC more likely cause an iron 
starvation-like response through oxidative stress damage or destabilisation/unfolding of 
iron-containing proteins, interaction with the Fur protein, and in the case of DOC, metal 
homeostasis dysregulation causing copper toxicity to Fe-S clusters. Despite the overall 
decrease of iron content in the cells, it is possible that the inactivation of Fur will lead to 
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an increase in the labile iron pool inside the cell that can increase oxidative damage and 
stress via the Fenton reaction (Keyer et al., 1996).  
The combined effect on Fur protein was confirmed to be a source of synergy between FZ 
and DOC, given that deletion of fur resulted in the shift to indifferent interaction. Fur also 
plays a role in the triple combination synergy, but other interacting points are obviously 
present besides the Fur pathway, since fur deletion only increased the triple combination 
FICI slightly, and the interaction is still synergistic (Chapter 5, Section 5.2.1). 
FZ and DOC also showed gene perturbations usually observed in bacteriostatic 
translation inhibitors, such as downregulation of central carbon metabolism and 
upregulation of ribosomal proteins (Sabina et al., 2003; Lin et al., 2014; O’Rourke et al., 
2020). Protein synthesis inhibition by nitrofurans has been reported before and was 
proposed to be due to non-specific binding to ribosomal proteins (McOsker et al., 1994; 
Yu et al., 1976). However, translation inhibition by DOC has not been demonstrated 
before. Given that Mg2+ content of the cells is dramatically lowered by DOC (Chapter 5, 
Figure 32), a connection between magnesium homeostasis dysregulation by DOC and 
translational stress can be proposed: The decrease in total magnesium levels by DOC will 
decrease the number of functioning ribosomes and inhibit translation in E. coli due to 
activation of the stringent response. However, due to the absence of (p)ppGpp regulation 
in the E. coli K1508 strain used in this work (Chapter 4, Section 4.2), translation control 
based on Mg2+ levels is possibly absent, leading to the unchecked upregulation of 
ribosome assembly even during Mg2+ deficiency. 
FZ and DOC upregulated efflux pump genes  (acrA, acrB), downregulated porins (ompC, 
ompF) (Chapter 4, Section 4.5.10), and induced stress responses that increase the 
tolerance to these agents. In this context, it seems contradictory that the combination is 
synergistic and not antagonistic. A possible explanation is that some of these resistance 
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mechanisms are somehow being inhibited by the combined action of the drugs. A 
proposed pathway in which this might come about is through Fur inactivation or 
downregulation of the central carbon metabolism. Both of these activities will have an 
inhibitory effect on the ETC. Incidentally, most of the ETC genes were shown to be 
downregulated by FZ, DOC, and the combination (Chapter 4, Section 4.5.8). This 
inhibition of aerobic ETC has been confirmed in Chapter 5, where FZ and DOC were 
demonstrated to decrease oxygen consumption (Chapter 5, Figure 34). It was therefore 
posited that FZ and DOC could be causing a dissipation of the PMF, which could inhibit 
the PMF-dependent efflux, leading to synergy. Using ethidium bromide efflux and 
accumulation assay (Chapter 5, Section 5.2.5), apparent inhibition of efflux by DOC was 
demonstrated, along with the increased permeability caused by VAN. FZ, however, does 
not seem to affect the efflux.  
The role of the ETC enzymes in the action and synergy of the antibacterials were also 
investigated using single-gene deletion mutants (Chapter 5, Section 5.2.3). However, a 
limitation of this assay is the redundancy of the ETC enzymes, which have overlapping 
functions (Anraku et al., 1987), and so deletion of one can be compensated by another. 
Expectedly, none of the individual deletion mutants affected the MIC of FZ and DOC, 
and only some caused a slight decrease in synergy. The ETC likely only has a minor 
contribution to the individual action of these drugs, possibly as a source of oxidative 
stress. Alternatively, the contribution of the ETC enzymes is masked due to redundancy. 
Construction of multiple mutations will be required to resolve these two possibilities. 
VAN treatment of E. coli did not induce a considerable change in the overall gene 
expression compared to the control (Chapter 4, Section 4.5.4). Even though only 17 genes 
were significantly differentially expressed, these genes gave insights into the initial 
effects of VAN, which contradicts the commonly accepted notion that Gram-negative 
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bacteria are relatively impermeable to VAN. Majority of the 17 DEGs are members of 
the extracytoplasmic stress responses, particularly the Rcs pathway, which has been 
demonstrated to be induced by peptidoglycan-targeting antibiotics (Laubacher et al., 
2008). Taken together, these findings indicate that VAN can somehow cross the outer 
membrane of E. coli, although only in very small amounts, and inhibit the peptidoglycan 
synthesis. Compromised peptidoglycan can, in turn, affect envelope integrity and 
permeability, and thereby cause the observed increased accumulation of ethidium 
bromide in VAN-containing cultures (Chapter 5, Section 5.2.5).  
From the known mechanisms of action of VAN (peptidoglycan synthesis inhibitor) and 
nitrofurans (DNA damage), there does not seem to be an obvious connection as to why 
these drugs interact synergistically (Zhou et al., 2015). One important mechanism of 
resistance to nitrofurans is the SOS response to DNA damage. Surprisingly, deletion of 
recA, making E. coli unable to mount an SOS response, resulted in the loss of synergy 
between FZ and VAN (Chapter 5, Figure 38B). Data presented here indicate the 
involvement of SOS response in the synergy between FZ and VAN, possibly through 
inhibition of SOS induction by VAN, which can decrease the resistance to the DNA-
damaging effect of FZ. The recA deletion also increased the FICI for the triple 
combination, but again the interaction is still synergistic, supporting the concept of 
multiple interaction points that contribute to the synergy of the triple combination. In this 
regard, multiple gene deletions may be needed to observe a more significant loss of 
synergy of the triple combination.  
6.2 Conclusion 
This thesis presents the synergistic combination of nitrofurans, DOC, and VAN as a 
potential therapy for Gram-negative infections. The synergistic interaction has been 
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characterised in vitro, and the reduced effective doses were demonstrated to mitigate 
nitrofuran’s adverse effects. Pathways perturbed by the antibacterials were identified, and 
from these findings, mechanisms for the action and synergy have been proposed. 
Nitrofurans, DOC, and VAN affected correlated pathways that likely result in the 
suppression of resistance mechanisms and amplification of toxic effects, leading to 
synergy. Lastly, evidence for the involvement of some of the pathways, particularly the 
iron starvation-like response and SOS response, in the synergy of the pairwise and three-
drug combinations were provided, but further work is warranted to fully elucidate the 
mechanism of interaction. It is hoped that the work presented in this thesis, along with 
any future investigations, will lay the groundwork for the development and even 
improvement of this combination into a viable clinical therapy for tackling multidrug-
resistant bacterial infections.  
6.3 Future directions 
Altogether, this thesis provided evidence for the in vitro synergy of FZ, DOC, and VAN 
against a wide range of Gram-negative pathogens and provided insights into the 
mechanism of interaction leading to synergy. Future work is warranted to confirm the 
clinical relevance of our findings and confirm the efficacy and safety of the combination 
through in vivo animal models. Additionally, more work is needed to fully elucidate the 
mechanisms underlying the synergy of the combination.  
Firstly, the mechanism by which FZ and DOC inactivate Fur protein needs to be 
investigated. FZ- and DOC-mediated disruption of Fur interaction with the target 
promoters can be tested using electrophoretic gel mobility assay (EMSA) or DNAse 
protection assays, as previously described (Berg et al., 2020; D'Autreaux et al., 2002). 
Briefly, this consists of incubating the drugs with Fur-Fe2+ protein complex and 
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oligonucleotides or plasmids containing a Furbox (Fur binding site), and looking at 
whether the drugs inhibit binding of Fur to the DNA. Since nitrofuran is a prodrug, the 
assay should also include nitrofuran activating enzyme (NfsA or NfsB) and enzyme 
cofactors. This assay can rule out direct inactivation of Fur protein, leaving only oxidative 
or copper stress-induced iron starvation-like response as culprits. Next, a more direct 
measurement of PMF can be employed, such as measurement of membrane potential 
(Benarroch et al., 2020; Suzuki et al., 2003), to confirm the proposed dissipation or 
decrease of PMF by FZ and DOC. Another area that requires further work is the proposed 
SOS response inhibition by VAN. Using reporter gene systems, SOS gene expression in 
E. coli treated with FZ, VAN, and their combination can be measured to investigate 
whether VAN inhibits SOS induction by FZ.  
Lastly, resistance evolution is an area that is essential to advance the development of this 
triple combination. Evolution of antibiotic resistance to the triple combination can be 
compared to the single antibacterials, to gain insights as to whether the combination 
suppresses, increases, or does not affect the probability of resistance emergence. 
Identification of triple combination-resistance mutations can also help with the 
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Figure A- 1. Interaction of nitrofurans, VAN, and DOC in the growth inhibition of 
E. coli ATCC 25922 
Graphs were obtained using checkerboard analysis, and each data point corresponds to the fractional 
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Figure A- 2. Interaction of FZ, VAN, and Ox gall bile salts in the growth inhibition 
of E. coli ATCC 25922 
Graphs were obtained using checkerboard analysis, and each data point corresponds to the fractional 
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Figure A- 3. Interaction of lipoglycopeptides A) dalbavancin or B) oritavancin with 
FZ, and DOC in the growth inhibition of E. coli ATCC 25922 
Graphs were obtained using checkerboard analysis, and each data point corresponds to the fractional 
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Figure A- 4.  Interaction of FZ, VAN, and DOC in the growth inhibition of E. coli 
K1508 in A) 2xYT and B) cation-adjusted Mueller-Hinton media 
Graphs were obtained using checkerboard analysis, and each data point corresponds to the fractional 
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Figure A- 5. Interaction of FZ, VAN, and DOC in the growth inhibition of E. coli 
K1508 A) fur and B) recA mutants 
Graphs were obtained using checkerboard analysis, and each data point corresponds to the fractional 
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Table A- 1. Variants detected between E. coli MC4100 and K1508 genome 
Position 
(gene) 
MC4100   K1508 
42282 
(IGR) 


























































IGR, intergenic region.  Variant detection using  Pilon v1.23  (Walker et al., 2014) 
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